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Abstract 
This thesis describes expansion of the ability of isothioureas to act as organocatalysts 
in formal [2+2]-, [3+2]- and [4+2]-cycloadditions between carboxylic acids and 
various acceptors via Type I ammonium enolate intermediates.  
Chapter 2 describes the optimisation and investigation of [2+2]-cycloadditions from 
ammonium enolates and N-sulfonylimines as the two components. The development 
of this methodology allows successful access to highly stereodefined β-lactams and, 
following in situ ring-opening, β-aminoesters. The products are obtained from either 
preformed homoanhydrides or directly from carboxylic acids, using open flask 
conditions, from simple, bench-stable starting materials and is scalable. A variety of 
anti-β-lactams (21 examples, 46-68% yield, up to >95:5 dr, 21->99% ee) and β-
aminoesters (9 examples, 44-74% yield, up to >95:5 dr, 68-92% ee) were accessed in 
moderate yield, excellent diastereo- and good enantioselectivity. This represents an 
improved route to anti-β-lactams over previously described ketene and N-triflyl imine 
based methods. 
Chapter 3 subsequently describes studies focussed on the use of ester surrogates in 
the formal [4+2]-cycloaddition reactions of isothiourea generated Type I ammonium 
enolates. Iso-propylphosphonate 163 proved highly effective as the four-component in 
this process, which following the in situ ring-opening of the initial dihydropyranone 
product allowed isolation of a range of novel diester products which were previously 
unobtainable using this methodology. The products were accessed in moderate to 
excellent yields, excellent diastereo- and enantiocontrol (9 examples, 12-63% yield, 
up to >95:5 dr, 67-99% ee) with this process also amenable to a large scale. 
Furthermore, selective reduction and acid-catalysed cyclisation allowed access to δ-
lactone products in good yield with retention of stereocontrol.  
Finally, Chapter 4 describes work on isothiourea-catalysed formal [3+2]-
cycloadditions of oxaziridines and acetic anhydrides gave access to stereodefined 
five-membered oxazolidin-4-one heterocycles. In this case, the use of preformed 
homoanhydrides and an inorganic base was imperitive to avoid reduction of the 
oxaziridine starting material. The oxazolidin-4-one products could be accessed in 
excellent yield and ee however poor dr (13 examples, 63-96% yield, up to 59:41 dr 
anti:syn, up to >99% ee for both diastereoisomers). Following isolation, reduction of 
Abstract 
 
these heterocycles allowed access to enantioenriched diols with little loss in 
stereocontrol. Mechanistic analysis has shown that an improvement in diasterocontrol 
can be obtained by the use of an enantioenriched oxaziridine, demonstrating the 
stereospecificity of this process. 
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Chapter 1: Introduction  
1.1 Asymmetric Synthesis 
The chiral recognition of biological systems has led to the increased significance of 
asymmetric synthesis. As two enantiomers of a chiral compound are often recognised 
as different substances in vivo, they can often produce entirely different biological 
responses. In the best case the undesired enantiomer will be ineffective but it could 
have negative side effects or even exhibit toxicity. A well documented example of this 
is the case of thalidomide, which was prescribed as the racemate for severe morning 
sickness in the 1950’s. In 1961 it was removed from the market following the 
discovery that it was a severe teratogen causing birth defects in thousands of 
children.1 In this case, one of the enantiomers was found to be responsible for this 
detrimental effect and, as the enantiomers interconvert in vivo selling an 
enantiomerically pure drug would be unproductive.2 However, in many other cases, 
the synthesis and administration of only the desired enantiomer of a drug would not 
only potentially reduce costs and increase atom efficiency but also lead to fewer side 
effects and possibly lower required doses. Indeed, the U.S. Food and Drug 
Administration agency treat the presence of an undesired enantiomer as an impurity 
and withhold drug approval unless exclusively one enantiomer is present. Chemical 
and enzymatic resolution alongside the use of chiral auxiliaries are traditional routes 
for the synthesis of enantiomerically pure chiral compounds. However, more recently 
the field of asymmetric catalysis has come to the fore utilising chiral catalysts in sub-
stoichiometric quantities to create enantiomerically pure products. The potential 
economic advantages of this approach has led to the development of this field of 
synthesis and along with metal and biocatalysis, it has been established that small 
organic molecules can be highly selective and efficient catalysts.3 Now considered the 
“third pillar” of asymmetric catalysis,4 organocatalysis is the focus of this thesis.  
1.2 Organocatalysis 
In recent years, the ability of small organic molecules to promote synthetic 
transformations has been investigated extensively. First termed “organocatalysis” by 
MacMillan in 2000,5 this field of chemistry is defined as the acceleration of a 
chemical reaction using sub-stoichiometric amounts of metal-free, low molecular 
Chapter 1: Introduction 
 2 
weight organic molecules as catalysts.6,7 The use of small organic molecules as 
enantioselective catalysts has many advantages over alternative synthetic strategies 
including ease of availability and mild, simple reaction conditions.4 In comparison 
with metal catalysts, which have been invaluable throughout the history of synthetic 
chemistry, they often can enable the development of new chemistry. Also, in some 
cases the development of organocatalytic alternatives to metal-based processes can be 
highly attractive.6  
Early work in this area, prior to the acceptance of organocatalytic methods as useful 
tools in synthetic organic chemistry, began to emerge in the 1960s. Pracejus described 
the first example of a chiral organic molecule catalysing an organic process when o-
acetylquinine 1 (1 mol%) was shown to catalyse the addition of methanol to a ketene 
at low temperature (Scheme 1.1).8 The enantioenriched ester 2 was isolated in 93% 
yield and 74% ee. 
  
Scheme 1.1: Addition of Methanol to a Prochiral Ketene Catalysed by o-Acetylquinine 1 
Following this pioneering study, in 1971 the Hajos-Parrish-Eder-Sauer-Wiechert 
reaction was reported.9 This process employed the naturally occurring amino acid L-
proline 3 to catalyse the intramolecular asymmetric aldol reaction of a triketone 
(Scheme 1.2). In the reaction mechanism, L-proline 3 reacts the starting ketone 4 to 
form enamine 5 as the active species. Proton transfer between the carboxylic acid of 
the enamine nucleophile and the carbonyl electrophile in the proposed intermediate 5 
gives the product precursor 6. Subsequent hydrolysis to release L-proline gives the 
bicyclic diketone product 7 in high yield and with 95% ee at low catalyst loading (3 
mol%).  
O
Ph Me
Ph
OMe
O
Me
2
93% Yield
74% ee
1 (1 mol%)
MeOH (1.1 equiv.)
Toluene
!111  °C
N
N
OC(O)Me
OMe
1
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Scheme 1.2: The Hajos-Parrish-Eder-Sauer-Wiechert Reaction 
Since these early examples of chiral induction, organocatalysis has become 
increasingly important in asymmetric synthesis due to the possibility of forming 
multiple new bonds and stereocentres in a one-pot synthesis with a wide variety of 
activation modes. In 2005, List defined four broad classes of organocatalysis based on 
the character of the substrate-catalyst interaction:3 Brønsted acid, Brønsted base, 
Lewis acid, and Lewis base. These classes will be discussed further in the following 
sections. 
1.2.1 Brønsted Acid Organocatalysis 
Brønsted acid organocatalysis is defined as a process initiated by protonation or 
partial protonation to activate an electrophilic substrate - usually a carbonyl or imine3 
- generating a catalyst/substrate complex and allowing reaction to proceed to generate 
the product (Scheme 1.3). This activation is similar to enzymatic activation where 
hydrogen-bonding to an enzyme’s active site occurs and for this reason, Brønsted acid 
organocatalysis is also known as hydrogen-bonding catalysis. 
Me
O
Me O
O
Me
N
Me O
O
CO2H
O
N O
O
H
Me
O
OH
N O
O
Me
O
O
O
Me
OH 3
L-Proline
N
H
CO2H
4
5
6
7
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Scheme 1.3: General Catalytic Cycle for Brønsted Acid Organocatalysis 
This type of organocatalysis was pioneered by Jacøbsen who reported an 
enantioselective Strecker reaction in 1998 as the first example of Brønsted acid 
catalysis. The unanticipated discovery that Schiff bases, originally designed for use as 
ligands in metal catalysed processes, could independently catalyse the asymmetric 
hydrocyanation reaction of a wide variety of imine substrates initiated this work 
(Scheme 1.4).10 Mechanistic investigations showed it was consistent with a double 
hydrogen-bond activation of the imine by the acidic NH protons of thiourea 8 leading 
to a lowering in the energy of its LUMO and enhancing its electrophilic nature. Since 
this work, chiral alcohols such as BINOL11 and TADDOL12 derivatives have also been 
used as catalysts for similar processes. 
 
Scheme 1.4: Jacøbsen’s Brønsted Acid Catalysed Asymmetric Strecker Reaction 
Subsequent studies from the same group expanded this concept to include the 
Mannich reaction between N-Boc imine 9 and ketene acetal 10 (Scheme 1.5).13 
Access to the β-amino ester was achieved in excellent yield and ee and again it is 
presumed that a double hydrogen-bonding activation allows high reactivity and 
stereoselectivity in this process. 
A-H
A SH
P
S
Acid-Substrate
Ion Pair
Subsequent 
Reaction
Proton Transfer
Release of
Product
A PH
A-H = Brønsted Acid
Catalyst
S = Substrate
P = Product
N
R
i) HCN (2 equiv.)
MeOH
8 (2 mol%)
Toluene, !78 °C
ii) TFAA
N
R CN
N
N
H
N
H
S
H
N
O
t-Bu
8
O
F3C
Up to 92% Yield
Up to 91% ee
Ph
HO
t-Bu OMe
via N
NN
S
H
N
O
t-Bu
Ph
Ar
H H
N
R
R1
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Scheme 1.5: Asymmetric Thiourea Catalysed Mannich-Reaction 
Hydrogen-bonding catalysis has been successfully applied to the synthesis of many 
natural products including that of (–)-epibatidine 11 by Takemoto and co-workers in 
2004 (Scheme 1.6).14 The key step required activation of nitrostyrene 12 for an initial 
asymmetric intermolecular Michael addition catalysed by their thiourea catalyst 13, 
followed by an intramolecular Michael addition which gave the ketoester product 14 
in 75% ee. 
  
Scheme 1.6: Hydrogen-bonding Catalysis in the Synthesis of (–)-Epibatidine 11 
In this case, thiourea 13 acts as as a bifunctional catalyst with Takemoto proposing 
that the thiourea activates the nitro-olefin through a double hydrogen-bonding 
interaction whilst the neighbouring tertiary amine forms a hydrogen-bond to the 
incoming enol, enhancing its nucleophilicity. In this mechanism, the approach of the 
N
Ph
Boc OTBS
Oi-Pr
i) 8 (5 mol%)
Toluene
!40 °C, 48 h
ii) TFA, 2 min Oi-Pr
O
Ph
NH
Boc
95% Yield
97% ee
N
N
H
N
H
X
N
O
Bn
Me t-Bu
HO
t-Bu OMe
X = O, S
9 10
NO2N
Cl MeO O
OO 13 MeO O
OO
N
O OH
N
Cl
O
O
N
O O
N
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MeO
OH
11
(!)-Epibatidine
S
N
H
N
H
CF3
F3C
NMe2
13
H
N
N Cl
14
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nucleophile is also fixed by the chiral catalyst, which accounts for the high levels of 
enantioselectivity observed (Figure 1.1). Other advances in this area have involved 
the use of chiral stronger acids such as BINOL derived phosphoric acids.6 
  
Figure 1.1: Bifunctionality of Takemoto’s Thiourea Catalyst 13 
1.2.2 Brønsted Base Organocatalysis 
A Brønsted base is defined as being as a molecule capable of accepting a proton from 
an acid and therefore in contrast to Brønsted acid catalysis, the Brønsted base catalytic 
cycle is initiated by complete or partial deprotonation of a substrate (Scheme 1.7). 
Typical examples of organic Brønsted base catalysis in asymmetric synthesis are 
hydrocyanation reactions and Michael additions.3  
 
Scheme 1.7: General Brønsted Base Catalytic Cycle 
Onoue et al. described an example of Brønsted base catalysis with use of cyclopeptide 
15 as a catalyst in the addition of hydrogen cyanide to various aldehydes (Scheme 
1.8).15 This process produced cyanohydrins in excellent yield and ee, which could be 
further elaborated to α-hydroxy carboxylic acids, α-hydroxy esters, and β-amino 
alcohols.  
S
NN
CF3
F3C
NMe2H H
O O
N
R
H
O O
EtO OEt
B
P-H
S-H
Base-Substrate
Adduct
Subsequent 
Reaction
Proton Transfer
Release of
Product
SBH
PBH
B = Brønsted Base
Catalyst
S-H = Substrate
P-H = Product
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Scheme 1.8: Brønsted Base Catalysed Addition of Hydrogen Cyanide 
Another example of Brønsted base catalysis was reported by Isobe and co-workers 
describing the Michael reaction of a prochiral glycine derivative t-butyl 
diphenyliminoacetate 16 with acrylates in the presence of a modified guanidine 
catalyst 17 under solvent free conditions (Scheme 1.9).16 Functionalised stereodefined 
amino esters 18 were isolated in high yield with enhanced enantioselectivity for a 
range of substrates. 
  
Scheme 1.9: Isobe’s Brønsted Base Catalysed Michael Reaction 
1.2.3 Lewis Acid Organocatalysis 
Lewis acid catalysts are defined as having a vacant orbital and activate nucleophilic 
substrates through accepting a lone pair of electrons (Scheme 1.10). Many examples 
fall into the class of phase-transfer catalysts in which the reaction of the catalyst and 
substrate facilitates migration from one phase (usually organic) to another (usually 
aqueous) where the reaction occurs. 
 
Scheme 1.10: Lewis Acid Catalysis General Cycle 
The epoxidation of olefins using chiral dioxiranes generated in situ is an important 
example of Lewis Acid organocatalysis. Shi’s example utilises D-fructose derived 
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ketone catalyst 19 with Oxone® as a stoichiometric oxidant to generate the epoxide 
products in excellent ee (Scheme 1.11).17 
  
Scheme 1.11: Lewis Acid Catalysed Epoxidation Reaction 
1.2.4 Lewis Base Organocatalysis 
In 1923, Gilbert N. Lewis proposed the definition of a Lewis base18 as a molecule 
with a lone pair of electrons in its HOMO that can fill the valence shell of a Lewis 
acid (an electron deficient molecule). Lewis base-mediated catalysis represents the 
largest area of organocatalysis (Scheme 1.12). In this mode of catalysis, the Lewis 
base forms an adduct with a Lewis acid substrate via nucleophilic addition. This 
addition changes the reactivity of the substrate, converting it to either an activated 
nucleophile or electrophile3 and therefore increases the rate of reaction with another 
reagent and product formation. The Lewis base is regenerated during this process 
resulting by definition in a catalytic process.19  
  
Scheme 1.12: Lewis Base Organocatalysis 
The Hajos-Parrish-Eder-Sauer-Wichert reaction is an early example of Lewis base 
catalysis (previously discussed in Scheme 1.2) and more specifically, enamine 
catalysis. Lewis base catalysis can be subdivided based upon activation mode into 
enamine, iminium, NHC catalysis and ammonium enolate catalysis amongst others 
(Figure 1.2) and representative examples of these selected reaction modes are 
described in the remainder of this chapter. Asymmetric Lewis base organocatalysis is 
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the main focus of research within the Smith group and therefore of this thesis, 
especially utilising isothiourea catalysts to form ammonium enolate intermediates. 
 
Figure 1.2: Modes of Lewis Base Activation 
1.2.4.1 Iminium Catalysis 
In iminium catalysis, reversible reaction of the Lewis basic amine catalyst with a 
carbonyl substrate forms an activated iminium ion lowering the LUMO.  MacMillan’s 
enantioselective Diels-Alder reaction of α,β-unsaturated aldehydes and ketones, with 
dienes using a chiral imidazolidinone catalyst 27 was the pioneering example of this 
principle in modern organocatalysis (Scheme 1.13).20 Although the 
diastereoselectivity of this reaction was low, the enantioselectivity was excellent, 
giving functionalised cyclohexanes in high yields. 
  
Scheme 1.13: MacMillan’s Enantioselective Diels-Alder Reaction 
This active species has been used to facilitate many asymmetric reactions including 
Knoevenagel condensations,21 Diels-Alder reactions,5 and 1,3-dipolar 
cycloadditions.22  
1.2.4.2 Enamine Catalysis 
Formation of a catalytically generated iminium ion from a nucleophilic amine catalyst 
and a carbonyl compound, followed by deprotonation to form a nucleophilic enamine 
intermediate is the basis of enamine catalysis. This intermediate can then go on to 
react with various electrophiles or alternatively undergo a pericyclic reaction. List and 
co-workers developed enamine catalysis, expanding on the previously described 
Hajos-Parrish reaction, by reporting an intermolecular aldol reaction (Scheme 1.14).23 
They utilised ketone 28 and aldehyde 29 in a L-Proline 3 catalysed process and gave 
access to the crossed aldol product 30 in excellent enantioselectivity. 
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Scheme 1.14: Asymmetric Intermolecular Aldol Reaction 
1.2.4.3 Carbene Catalysis 
Carbene catalysis, particularly N-heterocyclic carbene (NHC) catalysed activation of 
a substrate can occur in a wide variety of reaction manifolds.24 The use of NHCs to 
catalyse the benzoin reaction is well established with Enders and co-workers 
illustrating the use of a t-leucine-derived triazolium NHC 31 to catalyse an 
asymmetric benzoin reaction in 2002 (Scheme 1.15).25 In this reaction, salt 31 is 
deprotonated in situ to reveal the carbene. The reaction then proceeds with the 
carbene adding into an aromatic aldehyde to form the Breslow intermediate 32 via an 
NHC/aldehyde tetrahedral adduct. The Breslow intermediate is nucleophilic and can 
add to a second molecule of aldehyde. Finally, extrusion of the NHC catalyst affords 
the benzoin product 33 in excellent yield and ee. The related carbene catalysed Stetter 
reaction also takes advantage of the reactivity of the Breslow intermediate.26 
  
Scheme 1.15: NHC-Catalysed Asymmetric Benzoin Reaction 
Chiral azolium enolates can be accessed by the reaction of NHCs with ketenes or via 
redox processes with α-functionalised aldehydes or enals.27 Ye and co-workers 
showed in 2008 that NHCs could catalyse the formal [4+2]-cycloaddition of 
disubstituted ketenes and enones via azolium enolate 34 forming the anti-
dihydropyranone product 35 in excellent yield, dr and ee (Scheme 1.16).28 
 Scheme 1.16: NHC-Catalysed Formal [4+2]-Cycloaddtion via Azolium Enolate 34 
O
H
O 3 (20 mol%)
DMSO
rt
O OH
31
97% Yield
96% ee
N
H
CO2H
328 
Excess
N CO2Hvia
29
Ph H
O
Ph
O
Ph
OH
33
83% Yield
90% ee
31 (10 mol%)
KOt-Bu (10 mol%)
THF
rt, 16 h
N
N N
O
t-Bu
Ph
BF4
31
N
N N
O
t-Bu
Ph
Ph OH
32
via
Ph
O
35
79% Yield
>20:1 dr
91% ee
36 (10 mol%)
Cs2CO3 (20 mol%)
THF
0 °C to rt, 24 h
N
N N Ph
BF4
36
via
EtO2C
O
C
EtPh
1.5 equiv.
O
O
PhEtO2C
Et
Ph
Ph
OTBSPh
N
N N PhPh
OTBSPh
O
Et
Ph
34
Chapter 1: Introduction 
 11 
The number of NHC-mediated reactions has vastly increased in recent years and now 
include reactions such as transesterification, activation of esters and conjugate 
additions amongst many others.29 
1.2.4.4 Amidines and Isothioureas as Lewis Base Organocatalysts 
In the last decade, Birman and co-workers have developed a range of catalysts based 
on amidine and isothiourea core structures.30 These catalysts are highly successful in a 
range of processes such as the use of amidine 20 in the kinetic resolution of secondary 
alcohols (Scheme 1.17).31  
  
Scheme 1.17: Birman’s Kinetic Resolution of Secondary Alcohols 
Following the success of amidine 20 in the resolution of secondary alcohols, the 
Birman group undertook investigations to optimise the structure of these catalysts 
(Figure 1.3).32 The addition of a second aromatic ring led to the development of 
amidine 21.33 This was designed to have greater π-stacking with the aromatic alcohol 
substrates. It was found that both the reaction rate and selectivity were improved 
when compared with 20. Birman and co-workers made a further improvement by 
changing to an isothiourea core. It was shown the commercially available isothiourea 
(–)-tetramisole.HCl 22 and its derivative (R)-benzotetramisole 23 were superior in the 
kinetic resolution.34 The use of homobenzotetramisole (HBTM, 24) led to increased 
levels of enantioselectivity35 and then simultaneously but independently, Birman36 and 
Smith37 found that an alkyl substituent at the C(3) position of HBTM (25 and 26) gave 
an increase in catalytic activity when used in two different systems – the kinetic 
resolution of secondary alcohols, and O- to C-carboxyl group transfer of oxazolyl 
carbonates respectively. 
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Figure 1.3: Evolution of Amidine and Isothiourea Catalysts 
1.2.4.5 Ammonium Enolate Catalysis 
Lewis base catalysis has recently been extended to include ammonium enolates as 
intermediates in asymmetric organocatalysis. This important and widespread 
strategy,38 often explored utilising chiral tertiary amine catalysts, provides a chiral 
environment for enolate reactions allowing control of enantioselectivity and often 
result in enhanced reactivity.39 Ammonium enolates can be subdivided and are classed 
as Type I, II or III with the number referring to the number of atoms from the enolate 
oxygen to the ammonium nitrogen (Figure 1.4). Type I enolates are formed directly 
from the reaction of a nucleophilic amine catalyst with a ketene or alternatively, by 
the acylation of a tertiary amine followed by deprotonation by a base. Type II 
ammonium enolates are formed by the SN2 displacement of an α leaving group by an 
amine and Type III are generated by Michael addition of an amine to an acrylate or 
vinyl ketone. The ammonium enolate intermediate can then go on to react with a 
range of electrophiles and their use has been exploited in many areas of 
organocatalysis including β-lactone synthesis, α-halogenation reactions and [4+2]-
cycloaddition type reactions among others.39  
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Figure 1.4: Classes of Ammonium Enolate  
In the synthesis of β-lactones, Type I ammonium enolates are utilised to promote the 
asymmetric dimerization of ketenes. Early work by Pracejus and Sauer40 was 
expanded by Calter into a method for asymmetric dimerisation of methylketene 37 
giving the β-lactone product 38 in high ee (Scheme 1.18).41  Subsequent lithium 
aluminium hydride mediated ring-opening gives access to highly versatile polyketide 
building blocks with preservation of stereochemistry.  
 
Scheme 1.18: The Use of Type I Ammonium Enolates in β-Lactone Synthesis 
Gaunt et al. have shown Type II ammonium enolates can react in an intermolecular 
fashion with electron-deficient olefins to give cyclopropanes in excellent yields and 
ees (Scheme 1.19).42 Initial nucleophilic attack of amine catalyst 40 on the alkyl 
halide 41 at the α-position, followed by deprotonation forms ammonium enolate 42 
(Type II). This activates the substrate which can then undergo Michael addition onto 
the vinyl ketone 43, forming a Type III ammonium enolate species 44. Nucleophilic 
attack of the enolate to release the catalyst forms cyclopropane product 45. 
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Scheme 1.19: Gaunt’s Cyclopropane Formation and Mechanism 
The use of Type III ammonium enolates can be exemplified by the use of tertiary 
amine catalyst 46 in the Morita-Baylis-Hillman reaction (Scheme 1.20).43 It is 
proposed that in this case the catalyst is “bifunctional” with the hydroxyl group being 
important in the observed selectivity, forming a hydrogen bond to the aldehyde 
carbonyl in the proposed transition state 47, orientating it for attack by the ammonium 
enolate. 
  
Scheme 1.20: Type III Ammonium Enolates in a Catalytic Morita-Baylis-Hillman Reaction 
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1.3 Type I Ammonium Enolates: Generation From Carboxylic Acids 
Recent work within the Smith group has focussed on investigating alternatives to the 
use of ketenes in the generation of Type I ammonium enolates. Ketenes can be 
difficult substrates to handle due to their high levels of reactivity, which in turn leads 
to poor long-term stability and often reduced isolated yields. There are also 
limitations in substrate diversity when using ketenes as starting materials with 
disubstituted ketenes being the most common. 44 
Activated carboxylic acids have been shown to be an excellent alternative to ketenes 
in the generation of Type I ammonium enolates. For example, Romo and co-workers 
reported their nucleophile-catalysed aldol lactonisation (NCAL) reaction in which 
carboxylic acid 48 undergoes activation by pyridinium salt 49 and in the presence of 
base and cinchona alkaloid 40 forms Type I ammonium enolate 50. Intramolecular 
aldol reaction and lactonisation then occurs to give lactone 51 with excellent levels of 
stereocontrol (Scheme 1.21).45  
  
Scheme 1.21: Organocatalytic β-Lactone Formation from Aldehyde-Acids. 
In 2010, the Smith group expanded the utility of this form of activation in asymmetric 
inter- and intra-molecular Michael-addition/lactonisation reactions (Scheme 1.22).38 
Using isothiourea catalyst 26 or 22, the formal [4+2]-cycloaddition products can be 
accessed in high yield and enantioselectivities. 
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Scheme 1.22: Isothiourea-Catalysed Asymmetric Inter- and Intramolecular Michael-
Addition/Lactonisations 
In the proposed reaction mechanism for these reactions, activation of carboxylic acid 
53 using pivaloyl chloride forms mixed anhydride 54 (Scheme 1.23). Nucleophilic 
addition of the isothiourea catalyst 26 and subsequent deprotonation gives access to 
the chiral Type I ammonium enolate 55. The ammonium enolate then undergoes 
Michael addition to the double bond of the α,β-unsaturated ketoester 56 to form 
zwitterionic intermediate 57, which can then cyclise with release of the catalyst to 
give lactone product 58. Following the publication of this work, the scope has been 
further expanded to further Michael acceptors including N-tosyl-α,β-unsaturated 
ketimines,46 N-aryl-N-aroyldiazenes47 and trifluoromethylenones.48 
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Scheme 1.23: Proposed Mechanism for the Isothiourea-Catalysed Intermolecular Michael-
Addition/Lactonisation 
Subsequently, Romo has also extended his protocol towards highly enantioselective 
intramolecular desymmetrising aldol-lactonisation reactions, initially using 
isothiourea catalyst HBTM 24 (Scheme 1.24).49 Similarly, this process is initiated by 
activation of keto-acid 59 with tosyl chloride and in the presence of base and the 
isothiourea, forms a Type I ammonium enolate that goes on to form tricyclic β-
lactone 60 in excellent yield and ee. 
  
Scheme 1.24: Romo’s Desymmetrising Aldol/Lactonisation Reaction 
1.4 Aims and Objectives 
This thesis aims to investigate novel applications for Type I ammonium enolates 
generated from isothioureas and carboxylic acids in intermolecular cycloaddition 
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reactions, their use in formal [2+2]- and [3+2] reactions will be discussed. The 
ultimate aim is to create efficient, straight-forward routes to highly stereodefined 
heterocyclic products and their derivatives using bench stable reagents and in open-
flask conditions.  
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Chapter 2: Asymmetric Synthesis of β-Lactams and 
β-Aminoesters using Isothiourea Organocatalysts 
2.1 Introduction 
To expand the scope of previous work within the group, this chapter develops an 
intermolecular formal [2+2]-cycloaddition based on the [4+2]-intermolecular Michael 
addition/lactonisation previously discussed. In looking for suitable partners for the 
[2+2]-cycloaddition, imines were attractive substrates as their use would lead to the 
formation of β-lactams, a widely recognised pharmacophore in both chemistry and 
biology, and therefore of great synthetic interest (Scheme 2.1).1 
 
Scheme 2.1: Proposed Route to β-Lactams via Isothiourea Generated Ammonium Enolates 
2.1.1 β-Lactams 
Consisting of a 4-membered cyclic amide with up to two stereocentres in the lactam 
core, β-lactams are most famously the key structural component in many antibiotics, 
including the penicillins 61 (Figure 2.1). Since Sir Alexander Fleming, Scottish 
scientist and Nobel laureate, discovered the antibiotic behaviour of penicillin in 19282 
and Dorothy Crowfoot-Hodgkin subsequently assigned its structure by X-ray 
crystallography in 1945,3 the β-lactam ring has received extensive biological and 
synthetic investigations.1 They are also key in a wide variety of other drugs for 
example Ezetimibe 62, which is used for the inhibition of cholesterol absorption.4 
This central motif is also prevalent in natural products such as the cephamycins 63, 
another family of antibiotic compounds. A large number of methodologies for the 
synthesis of β-lactams have been developed5 and their use as synthons for the 
synthesis of a wide variety of targets has also been extensively studied.6 
Functionalisation of lactams allows access to heterocycles of various sizes, 
amino(hydroxyl) acid derivatives, β-amino ketones, γ-amino alcohols, and other 
compounds.6,7 
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Figure 2.1: A Range of Molecules Containing the β-Lactam Motif 
The β-lactam ring sets itself apart from other cyclic and acyclic amides with 
differences in their reactivity owing to changes in the rotational barrier of the 
carbonyl C-N bond. In an acyclic amide, this barrier is approximately 16-22 kcal 
mol-1 as a consequence of the strong resonance between the nitrogen atom lone pair 
and the carbonyl π-system.8 In the case of β-lactams, the strain of the four-membered 
ring disrupts this resonance making the carbonyl much more electrophilic. In extreme 
cases the β-lactam can be as reactive as acid chlorides, although in most cases β-
lactams can still be isolated.9 This also alters the IR stretch of the amide carbonyl – 
whereas acyclic amide carbonyls are typically ca. 1660 cm-1, β-lactams show a stretch 
between 1720 and 1815 cm-1.10 
2.1.2 Preparation of β-Lactams 
There are many routes for the construction of β-lactams including cyclisation 
reactions, cycloaddition reactions, organometallic-mediated reactions, and other 
miscellaneous approaches such as ring contraction and radical processes.5 The first 
reported synthesis of a β-lactam through a formal [2+2]-cycloaddition of imines to 
ketenes was reported in 1907 by Staudinger (Scheme 2.2).11 In this reaction, imine 64 
acts as the nucleophile, adding to diphenylketene 65 forming zwitterionic 
intermediate 66 that undergoes ring-closure to give β-lactam product 67.12  
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Scheme 2.2: The Staudinger Reaction 
This synthesis did not receive much attention until the 1940’s, but with the 
elucidation of the structure of the antibiotic penicillin G it has been extensively 
investigated as the basis of many modern routes into β-lactams. Recently these have 
focussed on the development of asymmetric and specifically catalytic methods. 
2.1.2.1 Current Methods for β-Lactam Synthesis 
The Staudinger reaction marked the beginning of synthetic chemistry towards β-
lactams and although many modern methods are based on this approach, there are a 
number of other existing methodologies for β-lactam synthesis. For example, Gilman 
and Speeter first reported the formation of β-lactams via condensation of ethyl α-
bromoacetate 68 and N-phenyl benzaldimine 64 in 1943 as a modification of the 
Reformatsky reaction (Scheme 2.3). 13 
Scheme 2.3: The Gilman-Speeter Reaction 
Although this process works reasonably well and is tolerant of a wide range of 
functional groups, including a range of aryl and alkyl substituents on the nitrogen 
atom, the yields are often reduced by competitive protonation of intermediate 69. 
Grignard addition to the resulting side-product can convert it into the β-lactam via  
deprotonation and cyclisation, but this adds additional steps to the synthesis, 
decreasing the efficiency of this reaction.14 
Alternatively, Ohno et al.15 used triphenylphosphine and Mukaiyama’s 2,2’-
dipyridyldisulfide 70 to convert β-amino acids into β-lactams (Scheme 2.4). This is 
generally applicable to a wide range of β-amino acids with a range of functional 
groups but with varying yields. 
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Scheme 2.4: β-Lactam Formation Using Mukaiyama’s Reagent 70 
Other methods towards β-lactams include photo-induced rearrangements16 and radical 
cyclisations.17 However, owing to the need for the effective synthesis of 
enantioenriched compounds, especially for medicinal chemistry, recent advancements 
have focussed on the development of stereoselective variants of these established 
synthetic methods.10  
2.1.2.2 Methods for Asymmetric β-Lactam Synthesis 
There are two possible stereocentres in the β-lactam core and therefore the possibility 
of up to four stereoisomers. Consequently, controlling the relative and absolute 
configuration during synthesis of these products is important in the context of using 
them as potential pharmaceuticals. In drug molecules different stereoisomers can have 
differing binding to their biological targets and therefore could possibly have entirely 
different pharmacological effects.18 This was the case for Penicillin V, whose 
unnatural enantiomer has less than 1% of the efficacy of the natural enantiomer.19 For 
these reasons, the development of asymmetric routes to enantiopure β-lactams are of 
great importance. 
Much work has been carried out on introducing and controlling stereochemistry 
through adaption of the Staudinger reaction in which stereoinduction through either of 
the two components of the reaction is possible. Inducing asymmetry through the 
imine component can be achieved by utilizing an imine derived from either an 
enantiomerically enriched aldehyde20 or the amine.21 For example, Gunda used an 
enantioenriched N-protecting group on the imine to give the syn-β-lactam product in 
high diastereoselectivity but in only modest yield (Scheme 2.5).  In addition, this 
method required two steps to synthesise the enantiopure imine and a further two steps 
to remove the N-protecting group if required. 
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Scheme 2.5: Gunda’s Chiral Auxiliary Approach to β-Lactam Synthesis 
Alternatively, Evans et al. demonstrated that the use of a stereodirecting group on the 
ketene could also be effective (Scheme 2.6).22 Homochiral (4S)-
phenyloxazolidylacetyl chloride 71 was used as a ketene precursor, with base being 
used to generate the ketene in situ. Following reaction with imine 72 and cleavage of 
both the chiral oxazolidinone and N-protecting groups in one step, β-lactam 73 was 
isolated in excellent yield and diastereoselectivity. The requisite oxazolidinone could 
be accessed in two steps from the commercially available amino acid (S)-
phenylglycine in good overall yield (62%) and the facile, one-step removal is a 
benefit of this chemistry. 
 
Scheme 2.6: Evans’s Chiral Auxiliary Approach to β-Lactam Synthesis 
However, both of these examples rely on chiral auxiliaries that whilst effective, are 
required in stoichiometric quantities with added costs and require extra steps for their 
introduction and removal.10 It is for this reason that catalytic, asymmetric syntheses of 
the β-lactam ring have been of increasing interest in recent years. 
2.1.2.3 Catalytic Asymmetric Synthesis of β-Lactams 
One of the first asymmetric synthesis of β-lactams in conjunction with catalysis was a 
metal-catalysed carbonylation reaction that produces β-lactam rings by the insertion 
of carbon monoxide into C-N bonds. Expanding on their 1981 work on the 
carbonylation of azirines,23 Alper et al. reported the metal-catalysed carbonylation of 
aziridines to yield β-lactams (Scheme 2.7).24 Using an enantiopure aziridine starting 
material, 5 mol% of a rhodium (I) catalyst under 20 atm CO pressure at 90 ˚C yielded 
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exclusive insertion of the carbon monoxide into the aryl-substituted C-N bond with 
complete retention of configuration and quantitative yields.  
 
Scheme 2.7: Rhodium Catalysed Carbonylation to β-Lactams 
This was later expanded to an asymmetric variant using racemic aziridines in a kinetic 
resolution (Scheme 2.8).24b Excess chiral additive L-menthol 74 was employed with a 
chloro(1,5-cycloctadiene)rhodium(I) dimer 75 as the catalyst to give the (S)-β-lactam 
in excellent optical yield. This gave access to optically enriched β-lactams using an 
inexpensive, commercially available chiral additive, although owing to the use of 
excess equivalents this could be seen as less efficient than later methods. 
 
Scheme 2.8: Kinetic Resolution of Aziridine to give β-Lactams in High Optical Purity 
An alternative approach to β-lactam asymmetric synthesis is the intramolecular C-H 
insertion reaction. This process was first reported by Corey and Felix in 196525 and 
later developed into an asymmetric process by Doyle and co-workers (Scheme 2.9).26 
Using conformationally constrained diazoacetylazacycloalkanes to allow competitive 
formation of β-lactams over γ-lactams, chiral dirhodium(II) carboxamate catalyst 76 
gave the desired β-lactam products in good yields and excellent enantioselectivity 
whilst using low catalyst loadings (2 mol%).  
 
Scheme 2.9: Rhodium Catalysed Asymmetric C-H Insertion Reaction 
In 1972, Kinugasa and Hashimoto reported the synthesis of syn-β-lactams in the 
reaction between a copper(I) acetylide and a nitrone.27 This original Kinugasa reaction 
used preformed stoichiometric copper acetylide, with the mechanism first proposed 
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by Ding and Irwin in 1976 (Scheme 2.10).28 It is postulated that [3+2]-cycloaddition 
of the nitrone and copper acetylide initiates the reaction and following formation of 
ketene and cyclisation, the β-lactam product is formed. Ding had evidence to support 
this mechanism including experiments varying the groups on both the nitrone and 
acetylide, which led to products with the predicted substitution patterns, whilst 
reaction in the presence of 18O labelled water produced no 18O-labelled products. This 
indicated that the oxygen in the product was derived from the nitrone.   
 
Scheme 2.10: Kinugasa Reaction 
The Kinugasa reaction is amenable to catalysis with the first catalytic modification 
described by Miura in 1993 and later extended to incorporate chiral ligands.29  
However, this reaction is highly sensitive to both the ligand used and the substitution 
on the nitrone, with the product distribution between β-lactams, azaenynes, imines 
and carboxylic acids varying and the methodology generally suffers from low 
enantioselectivities.51a In 2002, Fu and co-workers developed the first successful 
diastereo- and enatioselective catalytic variant in which a variety of nitrones and 
terminal alkynes were coupled to make syn-β-lactams using 1-2.4 mol% of CuCl and 
a C2-symmetric planar-chiral bis(azaferrocene) ligand 77 (Scheme 2.11).30 This 
successful method incorporated a wide scope of nitrones and alkynes with good 
isolated yields and high ees and drs. 
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Scheme 2.11: Fu’s Enantioselective Kinugasa Reaction 
2.1.2.4 Organocatalytic Asymmetric Synthesis of β-Lactams 
By far the most successful methods for the asymmetric synthesis of β-lactams to date 
have been based on an organocatalytic umpolung Staudinger approach with 
nucleophilic addition of a ketene-derived enolate to the imine.10 Pioneered by Lectka 
in 2000,31 examples of asymmetric β-lactam formation have been shown 
independently by Fu and Lectka using enantioenriched amines and N-heterocyclic 
carbenes as organocatalysts. 
Lectka et al. showed that cinchona alkaloid benzoylquinine 78 (BQ) or 
benzoylquinidine (BQd) could catalyse the addition of a range of mono- and 
disubstituted ketenes (with the very reactive monosubstituted ketenes formed in situ 
from acid chlorides 79) to electron-deficient N-tosylimino ester 80. This gives the 
syn-β-lactam product 81 in excellent enantio- and diastereoselectivities but usually 
with moderate yields (Scheme 2.12).32 A non-nucleophilic base was required to form 
the ketene in order to avoid a base catalysed racemic background reaction. In this 
case, proton sponge 82 was the superior base and, whilst not being able to form the 
ketene itself, could act as a thermodynamic sink allowing the more kinetically active 
BQ or BQd to deprotonate the ketene precursor and shuttle the proton to the proton 
sponge that precipitates as the hydrochloride salt. This leaves the BQ free to catalyse 
the desired reaction.  
 
Scheme 2.12: Asymmetric Organocatalytic Synthesis of β-Lactams Using a Cinchona Alkaloid 
Catalyst 
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The proposed mechanism involves initial attack of the amine catalyst 78 on the 
carbonyl of the ketene to form the ammonium enolate, followed by formal [2+2]-
cycloaddition with the imine acceptor 80 to generate 83. Release of the catalyst 
produces the β-lactam product 81 (Scheme 2.13). 
 
Scheme 2.13: Proposed Mechanism for the Organocatalytic Asymmetric Staudinger Reaction 
This work was later extended by Lectka to incorporate solid-phase chemistry with the 
catalyst held on a solid-support resin.33 This method gave the β-lactam products in 
comparable yields (65%) and high ee (>99%) following recrystallisation. The 
catalyst-packed columns could be used up to 20 times without sacrificing yield or ee. 
The yields of the original system were then improved (up to 95%) with the use of a 
bifunctional catalyst system with 10 mol% In(OTf)3 as a co-catalyst to further activate 
the imine (Scheme 2.14).34 These methods, whilst practical and allowing access to the 
syn-β-lactams in high levels of stereoselectivity, were very limited as the scope of the 
imine is confined almost exclusively to the highly reactive tosyl imino ethyl ester 
80.10 
 
Scheme 2.14: Improved Yields with Use of Indium Triflate Co-catalyst 
In 2001, Fu showed that a planar-chiral 4-(pyrrolidino)pyridine (PPY) derivative 84 
was also a highly efficient catalyst for the umpolung Staudinger reaction (Scheme 
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2.15a).35 In the reaction of both symmetrical and unsymmetrical preformed aryl and 
alkyl ketenes with a wide range of N-tosyl imines, the trisubstituted β-lactams could 
be accessed in up to 94:6 dr (syn:anti) and up to 98% ee. A drawback of this method 
is that it is limited to disubstituted ketenes. Mechanistically, this is believed to 
proceed in a similar manner to the Lectka method. Interestingly, when Fu investigated 
varying substituents on the imine nitrogen atom, it was found that by changing the 
nitrogen protecting substituent from tosyl to triflate the diastereoselectivity of the 
reaction was reversed to favour the anti-product, again with good dr and ee (Scheme 
2.15b).36 Unfortunately, the high cost of the synthesis of these imines limits the 
commercial viability of this route to anti-β-lactams. 
 
Scheme 2.15: Fu’s Reversal of Diastereoselectivity Using N-Trifyl Imines 
It is proposed that the diastereoselectivity is altered owing to a change in mechanism. 
It has been suggested that with a N-triflyl substituent the catalyst preferentially attacks 
the imine to form zwitterionic intermediate 85 (Scheme 2.16). The anionic nitrogen 
atom can then add to the carbonyl of the ketene 86 and, following enolate cyclisation, 
generate β-lactam 87 in high diastereo- and enantioselectivities. However, this is 
purely speculative with no evidence to support this mechanism other than the change 
in observed diastereoselectivity. 
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Scheme 2.16: Proposed Mechanism to Account for the Change in Diastereoselectivity  
In 2008, it was shown by the Smith group that NHCs can also be used as 
organocatalysts in the Staudinger reaction (Scheme 2.17).1 They promote the formal 
[2+2]-cycloaddition of diphenyl ketenes with N-tosyl imines to give the β-lactam 
products in excellent yields and when using chiral NHCs modest ees (55-75%) that 
could be improved by recrystallisation. 
 
Scheme 2.17: Asymmetric Formation of β-Lactams using N-Heterocyclic Carbenes as 
Organocatalysts 
Independently in 2008, Ye published a similar route to β-lactams using NHCs as 
organocatalysts in the reaction of disubstituted ketenes and N-Boc-substituted imines 
to form syn-β-lactams (Scheme 2.18).37 Although the yields were moderate (53-78%), 
the ees and drs were generally excellent. This route also gave access to the free β-
lactam as the Boc group can be removed by TFA without loss of enantiopurity. 
However, both this and the previous example from the Smith group are limited to 
disubstituted ketenes. 
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Scheme 2.18: Ye’s Approach to Organocatalytic Asymmetric Formation of β-Lactams 
In the proposed mechanism for these examples (Scheme 2.19), the NHC 91, generated 
by deprotonation of the corresponding salt 90, adds to the carbonyl of the ketene 92 
forming zwitterionic intermediate 93. The enolate then attacks imine 94 to give 
intermediate 95, which following intramolecular cyclisation and release of the 
carbene affords β-lactam product 96.  
 
Scheme 2.19: Proposed Mechanism for the use of NHCs as Organocatalysts in the Asymmetric 
Formation of β-Lactams 
More recently, Kerrigan reported a method that favours the generation of anti-β-
lactams from disubstituted ketenes, N-tosylaryl imines and a nucleophilic phosphine 
catalyst 97 (Scheme 2.20).38 The β-lactams are formed in modest to excellent yields 
(51-99%) and ees (44-98%), and typically excellent drs (anti:syn 9:1). A major 
advantage of this route over Fu’s is the use of the less expensive N-tosyl instead of N-
triflyl imines. 
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Scheme 2.20: Kerrigan’s Approach to β-Lactam Synthesis 
1.1 Aims and Objectives 
Although many routes to β-lactams have been reported, organocatalytic methods 
based on the Staudinger reaction currently rely on the use of ketene starting materials. 
Although synthetically useful compounds, ketenes are notoriously difficult to work 
with owing to their high reactivity, poor long-term stability and inconvenient 
preparation. Therefore we felt there was scope for a new method based on the 
ammonium enolate chemistry developed within the Smith group as an alternative 
Staudinger approach. 
It was postulated that direct replacement of the α,β-unsaturated keto-esters used as 
four components in asymmetric Michael additions with an imine two component 
would lead to β-lactam formation (Scheme 2.21). There is scope for variation of the 
catalyst (including changes in the ring size and functionalisation), the acid (variation 
of the aryl group to introduce more steric bulk, electron-donating and withdrawing 
groups or heteroatoms) and the imine (varying the R-group and the N-protecting 
group). 
It was hoped that the anti-product would predominate as opposed to the syn-products 
observed previously through the method reported by Lectka. If this were the case, it 
would give a more convenient and cheaper approach to these highly desired products 
without the use of expensive N-triflyl imines employed by Fu or the difficult to 
handle ketene starting materials.39 
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Scheme 2.21: Postulated Mechanism for Formation of β-Lactams via Ammonium Enolates 
2.2 Results and Discussion 
2.2.1 Initial Optimisation of Reaction to β-Lactams 
2.2.1.1 Model Reaction 
Initial studies focussed on trialling the use of imines under the standard conditions 
previously optimised within the group for the intermolecular Michael 
addition/lactonisation reactions using pivaloyl chloride as the carboxylic acid 
activating agent.40 Phenylacetic acid 98 and p-bromo-N-tosyl imine 99 were used for 
the initial screen using racemic tetramisole 22 as the catalyst. We were pleased to 
observe the formation of essentially one diastereoisomer (dr >95:5) of the expected β-
lactam product 100 in a 49% yield (Scheme 2.22). Under the same reaction conditions 
achiral DHPB 101 could be used, giving a slightly higher yield of 67% yield of 100 
with the dr remaining the same. 
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Scheme 2.22: Formation of β-Lactam 100 Using an Isothiourea Catalyst 
2.2.1.2 Determination of Stereochemistry 
Much study into the coupling constants between the C(3) and C(4) protons of the β-
lactam ring has been carried out. Akagi et al., reported the coupling constants of the 
syn and anti diphenyl β-lactams as 3JH-H= 6 and 3 Hz, respectively (Figure 2.2).41 This 
pattern is a general phenomenon and is widely used to assign the relative 
stereochemistry in β-lactams. 
 
Figure 2.2: Reported Coupling Constants in β-Lactam Rings 
For example, Gunda et al. used the analogy to these coupling constants to assign their 
β-lactam products as predominantly the syn-diastereoisomer (3J = 5.6 Hz) (Figure 2.3) 
and this was later confirmed by nOe analysis.42  
 
Figure 2.3: Gunda’s β-Lactam Product 
The same analogy was used to assign the major diastereoisomer of β-lactam 100 as 
the anti product (3J = 3 Hz) (Figure 2.4) and was also applied to all further products. 
Following this, nOe analysis showed no transfer of spin from HA and HB confirming 
the anti stereochemistry of this β-lactam. 
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Figure 2.4: Assignment of Our Major Diastereoisomer 
2.2.1.3 Chiral Catalyst Screen 
The range of chiral isothiourea catalysts available to us, (−)-tetramisole.HCl 22, 
(2S,3R)-HBTM-2.1 26 and (R)-BTM 23 were then screened under the initial reaction 
conditions (Table 2.1). All reactions gave high diastereoselectivity for the anti-
product although with modest ees.  
During the course of our studies into the reactivity of this process a test reaction was 
carried out to investigate the possibility of a racemic background reaction. Under 
standard reaction conditions with omission of the isothiourea catalyst, formation of 
the product was observed in relatively good yield (entry 4). The implication is that the 
in situ formed mixed anhydride is sufficiently reactive enough to cyclise with the 
imine promoted by the base present in the reaction.  
A change in procedure was devised in which the mixed anhydride would be formed in 
the absence of the imine. Following addition of the chiral isothiourea catalyst and 
base, allowing formation of the chiral ammonium enolate in catalytic amounts, the 
imine would be added and cyclisation would form the β-lactam, hopefully avoiding 
high levels of the racemic background reaction occurring. Under this new procedure, 
with (−)-tetramisole.HCl 22 as the catalyst, the ee of product 100 was slightly 
increased from 57% to 60% (entry 5). 
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Entry Catalyst Yield (%)a Pivalic Anhydride 
(%)a 
dr 
(anti:syn)b 
ee (%)c 
1 (–)-Tetramisole.HCl 22 37 5 >95:5 57 
2 (2S,3R)-HBTM-2.1 26 89 4 >95:5 57 (ent) 
3 (R)-BTM 23 67 7 >95:5 66 (ent) 
4 None 39 3 >95:5 N/A 
5 (–)-Tetramisole.HCl 22 67 6 >95:5 60 
a As a mixture of β-lactam and pivalic anhydride. b Determined by inspection of 1H NMR spectrum of 
crude. c Obtained by chiral HPLC analysis. 
Table 2.1: Chiral Isothiourea Catalyst Screen 
However, a major concern with our development of this methodology at this stage 
were variable yields. Although in all cases the quoted yields contain a majority of the 
β-lactam product, they also all contained varying amounts of pivalic anhydride that 
could not be readily separated by chromatography. Considering our proposed 
mechanism, the pivalic anhydride 102 by-product may arise in situ in two ways 
(Scheme 2.23). Following generation of the mixed anhydride 103 and subsequent 
reaction with the Lewis base catalyst, the carboxylate leaving group 104 could react 
with excess pivaloyl chloride 105 to form homoanhydride 102 (Scheme 2.23a). 
Alternatively, the homoanhydride can be formed via reaction of the same anionic 
leaving group 104 with the mixed anhydride 103 (Scheme 2.23b).  
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Scheme 2.23: Proposed Mechanisms for Generation of Homoanhydride 102 
Despite numerous attempts, a suitable purification method could not be found and this 
contaminant was unable to be removed from the product. It was therefore concluded 
that it would necessary to screen alternative activating agents for this process. 
2.2.1.4 Screening of Activating Agents 
4-Methoxybenzoic anhydride and tosyl chloride were chosen as possible alternatives 
to pivaloyl chloride and were screened under the previous racemic reaction conditions 
(Table 2.2). When using 4-methoxybenzoic anhydride, no conversion into the product 
was observed (entry 2). Tosyl chloride was more successful, forming the desired β-
lactam product, again in excellent dr (entry 3) and although the isolated yield 
remained the same as with pivaloyl chloride, the actual yield of β-lactam product was 
increased as it could now be successfully purified. Therefore, tosyl chloride was 
selected as our activating agent of choice in further studies.  
 
Entry Activating Agent Yield (%) dr (anti:syn)b 
1 Pivaloyl chloride 67a >95:5 
2 4-Methoxybenzoic 
anhydride 
NR N/A 
3 Tosyl chloride 68 >95:5 
a As a mixture of β-lactam and pivalic anhydride. b Determined by inspection of 1H NMR spectrum of 
crude. 
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Table 2.2: Screening of Activating Agents 
A further advantage of changing the activating agent to tosyl chloride was an 
enhanced enantioselectivity of the reaction compared with pivaloyl chloride (Table 
2.3). These results allowed us to select (R)-BTM 23 and tosyl chloride as the optimum 
catalyst and activating agent respectively, with this combination giving β-lactam 100 
in 77% yield , >95:5 dr and 85% ee (entry 4). 
 
Entry Catalyst Activating 
Agent 
t (h) Yield (%) dr 
(anti:syn)b 
ee (%)b 
1 (2S,3R)-HBTM-2.1 26 PivCl 2.5 89a >95:5 57 
2 (2S,3R)-HBTM-2.1 26 TsCl 4.5 32 >95:5 72 
3 (R)-BTM 23 PivCl 2.5 67a >95:5 66 
4 (R)-BTM 23 TsCl 3.5 77 >95:5 85 
a As a mixture of β-lactam and pivalic anhydride. b Determined by inspection of 1H NMR spectrum of 
crude. c Obtained by chiral HPLC analysis 
Table 2.3: Variation of ee with Activating Agent 
2.2.1.5 Screening Solvent and Temperature 
Following identification of the optimum catalyst and activating agent for β-lactam 
formation, a solvent screen was carried out to observe any effects on the yield or ee 
(Table 2.4). In previous work from the group, improvements had been seen when 
using THF as the solvent,43 however in this case it led to a reduction in both yield and 
ee (entry 2). It was proposed that reducing the temperature would further inhibit the 
racemic background reaction and so screening at lower temperatures was carried out. 
Although the ee at 0 ˚C was very high (93%, entry 3), the product was contaminated 
with an unknown by-product. Further analysis revealed that this was also present in 
the crude products from the racemic series when catalysed with DHPB 101, although 
only a minor component. So far, analysis has not been able to confirm the structure of 
Ph
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Ts
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Br
i) Activating Agent (1.5 equiv.)
i-Pr2NEt (1.5 equiv.)
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0 °C, 5 min
ii) Catalyst (20 mol%)
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t, rt
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this product. Interestingly, lowering the temperature further to −10 ˚C, the ee was 
seen to decrease (80%, entry 4). Further lowering the temperature led to a greatly 
extended reaction times with full conversion never being achieved and so the product 
was not isolated (entry 5). 
 
Entry Solvent Temperature 
(˚C) 
t (h) Yield (%) dr 
(anti:syn)a 
ee (%)b 
1 CH2Cl2 rt 2 77 >95:5 85 
2 THF rt 2 57 >95:5 59 
3 CH2Cl2 0 5 58 >95:5 93 
4 CH2Cl2 −10 18 17 >95:5 80 
5 CH2Cl2 −30 40 ND >95:5 N/A 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis 
Table 2.4: Solvent and Temperature Screen 
2.2.2 Variation of Acid  
With the optimum conditions in hand, a variety of aryl acetic acids were screened in 
the newly developed process (Table 2.5). The corresponding β-lactams were isolated 
in modest to good yield (42-77% yield), excellent diastereoselectivity and in high 
enantioselectivity (79-88% ee). As yet this effect is unexplained however it is possible 
that the mixed anhydride is more reactive in this case and so there could be more 
competition from a racemic background reaction. o-Tolylacetic acid showed a slightly 
reduced diastereoselectivity (entry 4), with the minor diastereoisomer having a much 
lower ee. It is thought this also may be owing to less discrimination between the faces 
of the ammonium enolate. Additionally, an non-aryl example, (thiophenyl)acetic acid 
could also be used in this protocol, generating 105 with moderate diastereo- and 
enantiocontrol (entry 6). This procedure, although producing the β-lactam products in 
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t, T
9998 100
Chapter 2: Asymmetric Synthesis of β-Lactams and β-Aminoesters 
41 
excellent dr and ee, often suffered variable product yields that were not representative 
of reaction conversion. We propose that instability of the β-lactam products towards 
chromatographic purification is the cause of this.  
 
Entry Compound R Yield (%) dr (anti:syn)a ee (%, anti/syn)b 
1 100 Phenyl 77 >95:5 85 
2 101 p-Tolyl 42 >95:5 87 
3 102 m-Tolyl 53 >95:5 81 
4 103 o-Tolyl 70c 90:10 81/47 
5 104 p-Methoxyphenyl 67 >95:5 83 
6 105 S-Phenyl 42c 85:15 61/62 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis. c 
Combined yield to partially separable diastereoisomers. 
Table 2.5: Variation of Acid Component 
2.2.3 Derivatisations 
Following the discovery that the β-lactam products formed from our protocol were 
unsuitable for column chromatography and other purification methods proved 
ineffective, derivatisations to convert the product into stable, isolable substrates were 
investigated with the hope that they would be easier to obtain (Scheme 2.24). 
Treatment of the β-lactam products with methanol alone afforded none of the 
expected β-amino ester product. However, the addition of sodium azide led to full 
consumption of the β-lactam after one hour, with β-aminoester 106 consistently 
isolated in 42-46% yield with excellent dr (>95:5). Other methods to derivatise the β-
lactam were attempted including: reductive ring-opening using lithium aluminium 
hydride; removal of the N-tosyl group using sodium/naphthalene; and ring-opening 
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i) TsCl (1.5 equiv.)
i-Pr2NEt (1.5 equiv.)
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0 °C, 5 min
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5 h, rt
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using benzylamine. However, all of these methods led to a mixture of products from 
which the desired products were unable to be isolated.  
Therefore, our next step was to optimise the ring-opening using sodium azide and 
methanol. This derivatisation was convenient and could be carried out in situ with no 
intermediate work up (yield with work up 42%, without 46%). 
  
Scheme 2.24: Derivatisation Routes Investigated 
2.2.4 Optimisation of Reaction to β-Aminoesters 
2.2.4.1 Chiral Catalyst Screen 
Literature precedent for the kinetic resolution of β-lactams by isothiourea catalysts led 
us to be mindful that the catalyst could be involved in the ring-opening step of our 
process.44 Therefore, the chiral catalyst screen was repeated for the β-amino ester 
forming procedure (Table 2.6). All catalysts screened gave excellent dr (>95:5), 
although the yields were much lower than the racemic reaction. The ee was good in 
all cases with (2S,3R)-HBTM-2.1 26 giving the highest ee of 83% (entry 3). Although 
this was a different optimum catalyst to the β-lactam forming reactions, it was chosen 
for all further investigations. 
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Entry Catalyst Yield (%) dr (anti:syn)a ee (%)b 
1 DHPB 101 42-46 >95:5 N/A 
2 (–)-Tetramisole.HCl 22 16 >95:5 70 (ent) 
3 (2S,3R)-HBTM-2.1 26 24 >95:5 83 
4 (R)-BTM 23 30 >95:5 74 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis. 
Table 2.6: Chiral Catalyst Screen for Formation of β-Aminoesters 
2.2.4.2 Screen of Ring-Opening Conditions 
Following further investigation of the literature, other ring-opening methods were 
investigated to see if the yield could be further improved (Table 2.7). If the ring-
opening was carried out using only a catalytic amount of sodium azide (10%) in 
methanol, the yield increased from 24 to 66% using catalyst 26 (entry 2).  However, 
sodium methoxide in methanol not only increased the yield to 40% but also the ee 
from 83% to 96%, the reason for which is unclear (entry 3).  
Cooling the reaction mixture to 0 °C had no impact on the enantioselectivity of the 
reaction and cooling further led to no improvement with a much extended reaction 
time (entries 4 and 5). Following the success of the reactions with sodium methoxide 
in methanol, formation of methoxide in situ from n-butyllithium was investigated 
(entry 6). This led to a further increase in yield to 62% with 93% ee, a superior result 
to that with catalytic sodium azide, so this method was used for all further examples. 
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Entry Ring Opening Method t (h) T (°C) Yield (%) dr (anti:syn)a ee (%)b 
1 NaN3/MeOH 1 rt 24 >95:5 83 
2 NaN3 (10 mol%)/MeOH 4 rt 66 >95:5 85 
3 NaOMe/MeOH 2 rt 40 >95:5 96 
4 NaOMe/MeOH 4 0 53 >95:5 96 
5 NaOMe/MeOH 24 –30 43 >95:5 95 
6 n-BuLi/MeOH 1 –78 to rt 62 >95:5 93 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis 
Table 2.7: Investigation into Ring Opening Methods 
2.2.4.3 Investigation into Enantioselectivity of the Ring-Opening Step 
It was observed during the catalyst screen that there was a slight enhancement in the 
ee of β-amino esters when compared with the β-lactams isolated under the same 
conditions (Scheme 2.25). When using isothiourea (2S,3R)-HBTM-2.1 26, the ee had 
increased from 72% of the β-lactam to 96% of the β-amino ester. This was thought to 
be outwith measurement error and given that the kinetic resolution of syn-β-lactams 
using isothioureas was reported in the literature, there was speculation that the 
isothiourea catalyst maybe involved in the ring-opening step.44 
 
Scheme 2.25: Comparison of Isolated ees of β-Lactam and β-Aminoester 
To investigate this further, two reactions were carried out, one in which the β-lactam 
would be formed with the achiral catalyst, DHPB 101 and then following a work-up, 
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the ring-opening would be carried out in the presence of the chiral catalyst (2S,3R)-
HBTM-2.1 26 and a second with asymmetric β-lactam formation and ring-opening in 
the presence of the achiral catalyst (Scheme 2.26). 
In the first reaction, if no catalyst were involved in the ring-opening step, we would 
expect to form the racemic β-amino ester. However, a modest ee of 16% was obtained 
from the final product (Scheme 2.28a). In the second reaction, the previously isolated 
β-lactam was found to have an ee of 72%, which was conserved when the ring 
opening was carried out in the presence of achiral DHPB 101 (Scheme 2.28b). Under 
our standard reaction conditions, the ee of the isolated aminoester is 10% higher than 
the β-lactam. These results support the theory that the ring-opening is also 
enantioselective, however, later investigations found that the ee enhancement was not 
general and so perhaps this phenomenon is not as significant as first thought. 
Scheme 2.26: Kinetic Resolution of Ring-Opening 
2.2.4.4 Catalyst Loading 
Following optimisation of the yield at 20 mol% of catalyst 26, the catalyst loading 
was reduced to investigate its impact on yield and the enantioselectivity of the 
reaction (Table 2.8). The loading could be reduced to 5 mol% with no significant 
impact, the yield remained moderate at 65% and the ee was excellent at 92%. 
However, the time for the β-lactam forming step had to be increased from one hour to 
2.5 hours to allow full consumption of starting material (entry 3). Further decreasing 
of the catalyst loading to 1 mol% was not productive as there was a slight drop in ee 
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to 85% and the starting material was only 85% consumed after 2.5 hours (measured 
by 1H NMR, entry 4). 
 
Entry Catalyst 
Loading 
(mol%) 
Time (h) Yield (%) dr (anti:syn)a ee (%)b 
1 20 1 60-62 >95:5 89-93 
2 10 2 53 >95:5 95 
3 5 2.5 50 >95:5 >99 
4 1 2.5 44 >95:5 85 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis 
Table 2.8: Reduction of Catalyst Loading 
2.2.4.5 Screening of Activating Agent 
To conclude a thorough optimisation of the ring-opening procedure, other activating 
agents were screened for the β-lactam formation (Table 2.9). Benzoyl chloride gave a 
comparable ee of 91% however the yield was only 45% (entry 2). Although pivaloyl 
chloride gave a comparable yield to reactions with tosyl chloride, the ee of the 
product was only 78% (entry 3). It was decided to cool the reaction using pivolyl 
chloride during the β-lactam formation step to investigate whether the ee could be 
improved while maintaining the good yield. There was a significant increase in the ee 
of the product from 78% to 92% when reducing the temperature to 0 °C, however the 
yield was reduced to 34% (entry 4) and the 1H NMR spectrum of the crude material of 
the reaction at 0 °C revealed that there had not been full consumption of the imine. 
Additional reduction of the temperature led to no further increase in ee. In fact, at –30 
°C the ee decreased to 76% indicating that the catalysed process was also 
considerably slower at this temperature allowing competition from the racemic 
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background reaction (entry 6). Therefore, tosyl chloride was kept as the optimum 
activating agent. 
 
Entry Activating 
Agent 
T (°C) t (h) Yield 
(%) 
dr (anti:syn)a ee 
(%)b 
1 TsCl rt 1 62 >95:5 93 
2 BzCl rt 1 45 >95:5 91 
3 PivCl rt 1 65 >95:5 78 
4 PivCl 0 5 34 >95:5 92 
5 PivCl –10 18 36 >95:5 90 
6 PivCl –30 18 31 >95:5 76 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis. 
Table 2.9: Investigation into Activating Agent 
2.2.5 Variation of the Carboxylic Acid Component 
Using the final optimised conditions, the acetic acid component was varied to explore 
the scope of the reaction. Steric tolerance around the aromatic ring, electron-donating 
and -withdrawing substituents were all investigated along with the addition of 
heteroaromatic groups.  
In general, the addition of steric bulk was well tolerated (Table 2.10). Some loss of 
diastereoselectivity was seen with a substituent in the ortho position (entries 4 and 5) 
although the enantioselectivity was not dramatically affected. 
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Entry Compound R Yield (%) dr (anti:syn)a ee (%)b 
1 106 Phenyl 50 >95:5 >99 
2 107 p-Tolyl 46 >95:5 86 
3 108 m-Tolyl 40 >95:5 74 
4 109 o-Tolyl 61 90:10 76 
5 110 1-Naphthyl 46 90:10 82 
6 111 2-Naphthyl 68 >95:5 85 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis. 
Table 2.10: Steric Investigation of Acid Variation 
Further investigations revealed electron-donating and withdrawing substituents were 
well tolerated (Table 2.11, entries 5 and 7) with no loss of diastereo- or 
enantiocontrol. However, when a strongly electron-withdrawing acid was used (entry 
8) the reaction was slow and less than 5% conversion was seen into the β-lactam 
overnight. It is thought that this is owing to the decreased nucleophilicity of the 
ammonium enolate. 
Hetereoaromatic groups and (phenylthio)acetic acid (entries 1, 2, 3 and 10) were also 
tolerated in the reaction conditions and gave product in yields consistent with other 
examples, however the diastereoselectivity and especially the enantioselectivity was 
much lower. Pleasingly, the reaction could also be carried out on a gram scale, with 
1.3 g (41% yield) of β-amino ester 106 synthesised in 85% ee. 
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Entry Compound R Yield (%) dr (anti:syn)a ee (%)b 
1 112 2-Thiophene 46 85:15 21 
2 113 3-Thiophene 50 91:9 ND 
3 114 1-Methyl-3-indole 55 56:44 23 
4 115 p-Bromophenyl 43 >95:5 98 
5 116 p-Methoxyphenyl 42 >95:5 76 
6 117 p-Chlorophenyl 68 >95:5 78 
7 118 p-Fluorophenyl 56 >95:5 76 
8 119 p-
Trifluoromethylphenyl 
<5% conversion overnight 
9 120 Diphenyl 44 >95:5 73 
10 121 S-Phenyl 71 75:25 57 (syn: 57) 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis. 
Table 2.11: Further Acid Variation 
2.2.6 Variation of the Imine 
Next, a range of imines were synthesised and investigated under the standard reaction 
conditions to further expand the scope of the reaction (Table 2.12). 
Use of phenyl imine (entry 2) gave consistent results with a yield of 49% and an ee of 
80%. However, electron-donating groups on the aryl substituent or nitrogen 
protecting groups were seen to have a detrimental effect on the reaction with less than 
5% conversion into the β-lactam observed at extended reaction times (18 h, entries 3 
and 10). This is presumably owing to deactivation of the imine to nucleophilic attack 
R
OH
O
N
Ts
Br
i) TsCl (1.5 equiv.)
i-Pr2NEt (1.5 equiv.)
CH2Cl2
0 °C, 5 min
ii) (2S,3R)-HBTM-2.1 26
(5 mol%)
i-Pr2NEt (1.5 equiv.)
5 h, rt
iii) n-BuLi, MeOH
1 h, !78 °C to rt
99
MeO
O
R
NHTs
Br
Chapter 2: Asymmetric Synthesis of β-Lactams and β-Aminoesters 
50 
by the ammonium enolate. A furyl group on the imine was also tolerated (entry 4) 
although with some drop in the diastereo- and enantiocontrol. 
 
Entry Compound R Ar Yield 
(%) 
dr 
(anti:syn)a 
ee (%)b 
1 106 Tosyl p-Bromophenyl 50 >95:5 >99 
2 122 Tosyl Phenyl 49 >95:5 80 
3 123 Tosyl p-Methoxyphenyl <5% conversion overnight 
4 124 Tosyl Furyl 55 80:20 70 
5 125 Tosyl p-Trifluoromethylphenyl 49 92:8 44 
6c 125 Tosyl p-Trifluoromethylphenyl 36 92:8 52 
7 126 Tosyl 1-Naphthyl 61 75:25 56 
8 127 Tosyl 2-Naphthyl 55 >95:5 95 
9 128 Nosyl Phenyl 54 >95:5 80 
10 129 Boc Phenyl <5% conversion overnight 
11 130 PMP Phenyl <5% conversion overnight 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis. PMP = 
p-methoxyphenyl. c Reaction carried out at 0 ˚C. 
Table 2.12: Variation of the Imine Component 
Changing the electronics of the imine seemed to have a much greater effect on the 
outcome of the reaction than variation of the acid. Using an electron-withdrawing 
group on the aryl ring (p-trifluoromethyl) gave the product in only moderate yield 
with a significant decrease in dr and ee (entry 5). This is thought to be owing to the 
increased electrophilicity of the carbonyl increasing the rate of the racemic 
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background reaction with respect to the catalysed reaction. Decreasing the 
temperature of the ring-forming step to 0 °C led to a slight increase in ee, which lends 
some support to this theory (entry 6). Increasing steric bulk was tolerated in good 
yield (entry 7) but, as seen with the acid variation, increased sterics in the ortho-
position led to a decrease in the dr and ee of the β-amino ester product. Pleasingly, 
there was no change in selectivity seen when changing from a N-tosyl to a N-nosyl 
protecting group (entry 9) however, changing to either a N-Boc or N-PMP protecting 
group again shut down the reaction (entry 10 and 11). 
The absolute configuration of β-amino ester 106 was determined using X-ray 
crystallography as (2S,3R) (Figure 2.5).  
 
Figure 2.5: X-Ray Crystal Structure of β-Aminoester 106 
By correlation the absolute configuration of β-lactam 100 must also be (2S,3R) 
(Scheme 2.27). This further confirms the anti stereochemistry of the major 
diastereomer assigned through coupling constant analysis. 
  
Scheme 2.27: Assignment of Absolute Configuration of β-Lactam 100 
2.2.7 Recrystallisation of β-Amino Ester Products 
Following comparison of the β-amino ester ees with those previously obtained for the 
isolated β-lactams, it was noted that only the examples using phenylacetic acid or p-
bromophenylacetic acid with the N-tosyl protected p-bromophenyl imine showed an 
increase in ee. It was postulated that these products may be more crystalline than the 
others and therefore some racemic product was crystallising during column 
chromatography giving an enantioenriched product.45 
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To investigate this, the ee of the crude product from the reaction of phenylacetic acid 
and the N-tosyl-protected p-bromophenyl imine followed by ring-opening was 
obtained and found to be 80% ee. This is consistent with the ee of the previously 
isolated β-lactam and also the other β-aminoesters synthesised. 
To investigate whether the ee could be enhanced in general, a selection of β-amino 
esters were synthesised on a larger scale, isolated via column chromatography and 
then recrystallised (Table 2.13). The ee was increased in three cases (entries 1, 3 and 
4) and mostly without too much loss in yield during the recrystallization. In the case 
of the p-chlorophenylacetic β-amino ester, the ee of the recrystallised material was 
only 20% (entry 2). On analysis of the filtrate, it was found to have an ee of 81% ee. 
This implies that in this case, the racemic compound is more crystalline than the 
major enantiomer. Whereas the N-nosyl-protected β-aminoester 128 resulted in no 
improvement in the ee (entry 5). However the ability to recrystallize the β-amino ester 
products for enhancement of ee does appear to be a general trend for the tosyl 
protected β-aminoesters. 
 
Entry R Ar Ar1 Column 
Yield 
(%) 
Recrystallisation 
Yield (%) 
ee (previous 
ee, %)a 
1 Ts o-Tolyl p-Bromophenyl 58 42 96 (76) 
2 Ts p-Chlorophenyl p-Bromophenyl 40 13 20 (78) 
3 Ts Phenyl Phenyl 54 26 93 (80) 
4 Ts 2-Naphthyl p-Bromophenyl 58 41 >99 (85) 
5 Ns Phenyl Phenyl 45 35 76 (76) 
a Obtained by chiral HPLC analysis. 
Table 2.13: Improvements in ee Following Recrystallisations 
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2.2.8 Proposed Pre-Transition State Assemblies 
The conformation of the ammonium enolate is key to understanding the 
stereoselectivity of the reaction. Treating the acyl ammonium species 131 with base 
(Scheme 2.28), deprotonation must occur when the σC-H orbital is approximately 
perpendicular to the carbonyl group to allow electron flow into the oxygen π* orbital. 
When drawn in a Newman-type projection with the large aryl group orientated away 
from the steric bulk of the catalyst, deprotonation forms (Z)-ammonium enolate 55.  
  
Scheme 2.28: Proposed Conformation of the Ammonium Enolate 
There is also evidence that further stabilisation and conformational control in this 
ammonium enolate could be possible through a 1,5 S-O interaction. This 
intramolecular non-bonded interaction has been observed in a large number of 
organosulfur compounds. Nagao et al. showed by X-ray crystallographic analysis that 
in the favoured conformer of 132 (conformer B), the distance between the sulfur and 
the oxygen atom (2.646 Å) is smaller than the sum of their Van der Waals radii (3.32 
Å) and therefore proposed a stabilising S-O interaction (Figure 2.6). They suggested 
this was owing to an overlap of the carbonyl non-bonding orbital with the σ* orbital of 
the C-S bond.46  
  
Figure 2.6: Evidence of a 1-5 S-O Interaction  
Additionally, Birman noted in his work on the design of amidine derivatives as 
acylation catalysts that introduction of a sulfur atom results in a vast increase in 
catalytic activity, which he attributed to the non-bonded S-O interaction stabilising N-
acylated intermediates.47 Futhermore, Romo accredited the selectivity of his NCAL 
process to the same non-bonding interaction.48 
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Recent work within the Smith group investigating the mechanism of anhydrides as 
α,β-unsaturated acyl ammonium precursors led to the isolation of acyl ammonium 
species 133 (Scheme 2.29).49 X-ray crystallography confirmed the structure and 
supported the previously hypothesised stabilising non-bonding S-O interaction by 
showing syn geometry between the carbonyl oxygen and the isothiourea sulfur atom 
with the O-S distance (2.479 Å) being significantly shorter than that of the calculated 
Van der Waal’s distance (3.620 Å). In this system, 133 could also be used as a pre-
catalyst in the reaction, indicating that it is an intermediate in the reaction.  
  
Scheme 2.29: Isolation of Acyl Ammonium Species 133 
Using this information, a transition state can be proposed that is consistent with the 
observed anti product (assuming it is formed under kinetic control). It is postulated 
that when the imine approaches enolate 55, locked in position by the S-O interaction, 
it would approach anti to the stereodirecting group of the catalyst and that the very 
bulky N-protecting group will be furthest from the aryl group of the carboxylic acid 
(Figure 2.7). Addition of the enolate to the imine Re-face followed by cyclisation of 
this proposed transition state would result in the aryl groups being on opposite faces 
of the β-lactam and the observed anti-β-lactam being formed. 
 
Figure 2.7: Proposed Transition State 
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2.3 Reaction from the Preformed Homoanhydride 
While an effective procedure for the formation of a range of anti-β-amino esters with 
excellent diastereocontrol and good to excellent enantiocontrol has been described, a 
process that allows reproducible access to the corresponding β-lactam was still 
desired. Previous work within the group has shown that preformed homoanhydrides 
can be used as alternative starting materials for related isothiourea catalysed 
cyclisations (Scheme 2.30).50  
 
Scheme 2.30: Preformed Homoanhydrides as Starting Materials for Isothiourea-Catalysed 
Cyclisations Followed by a Ring-Opening Reaction 
In this case, it was hoped that simplifying the reaction conditions by removing the 
need for in situ acid activation would lead to minimal by-products and ultimately aid 
purification, allowing for isolation of analytically pure, stereodefined anti-β-lactams. 
2.3.1 Optimisation of Reaction from Preformed Anhydride 
Initial work was carried out by project student Hugues Prevet to optimise the process 
for formation of β-lactams from a preformed anhydride. Treatment of benzoic 
anhydride and 134 with (2S,3R)-HBTM-2.1 26 (5 mol%) and i-Pr2NEt (1.5 equiv.) led 
to formation of the β-lactam 100 that could be consistently isolated as the major 
reaction product, albeit in low yield (30%).  
Dropwise addition of an increased quantity of anhydride (1.5 equivalents over 45 
minutes) at a lower reaction temperature (−78 °C) was required in order to eliminate 
competitive addition of the ammonium enolate to the homoanhydride. This improved 
the yield to 74% with excellent diastereoselectivity and good enantioselectivity, 
which following recrystallisation could be isolated in 90% ee (Scheme 2.31).  
Importantly, as opposed to the original procedure from the arylacetic acid, the use of a 
preformed homoanhydride allowed isolation of the β-lactam heterocycle in 
reproducible yields. 
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Scheme 2.31: Optimised Conditions for Formation of β-lactams from Preformed 
Homoanhydrides 
2.3.2 Variation of the Imine 
A moderate selection of aryl imines were screened under the newly developed 
conditions and were also tolerated in similar yield (47-60% yield) and 
enantioselectivity (68-92% ee) but in slightly reduced diastereoselectivity (up to 93:7 
dr) (Table 2.14). Similarly to the reaction directly from the carboxylic acid, strongly 
electron-withdrawing substituents were tolerated although with reduced ee (entry 3) 
and aldimines with electron-donating groups showed no activity (entry 4). Extended 
aromatic systems with increased steric bulk were tolerated (entry 5) albeit with 
reduced dr. Attempted use of an alkyl imine gave complete loss of diastereocontrol 
(entry 6). 
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Entry Compound R R1 Yield 
(%) 
dr 
(anti:syn)a 
ee 
(%)b 
1 100 p-Bromophenyl Tosyl 74 >95:5 79 
2 135 Phenyl Tosyl 60 90:10 82 
3 136 p-
Trifluoromethylphenyl 
Tosyl 47 93:7 68 
4 137 p-Methoxyphenyl Tosyl NR N/A N/A 
5 138 2-Naphthyl Tosyl 56 85:15 92 
(syn 
54) 
6 139 Isopropyl Tosyl ND 50:50c ND 
7 140 Phenyl Nosyl 51 90:10 86 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis. c Could 
not be isolated and therefore not fully characterised. 
Table 2.14: Imine Variation 
Analogous to the β-amino esters, β-lactam formation was performed on a large scale, 
purified by column chromatography and then the products were recrystallised to 
investigate if this had a positive effect on the final ee (Table 2.15). In both cases, the 
ee could be significantly enhanced to greater than 90% ee. 
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Entry Ar1 R Column Yield 
(%) 
Recryst Yield 
(%) 
Recryst ee 
(%) 
(previous ee)a 
1 p-
Bromophenyl 
Tosyl 74 56 90 (79) 
2 Phenyl Tosyl 60 34 >99 (82) 
a Obtained by chiral HPLC analysis. 
Table 2.15: Enhancement of ee by Recrystallisation 
2.3.3 Variation of the Anhydride 
Modification of the anhydride portion provided β-lactams with good to excellent dr 
and good enantiocontrol incorporating a range of aryl and heteroaryl substitution 
(Table 2.16). Again, in comparison with reactions directly from the acetic acids, the 
yields were more consistent, although the dr dropped. The ee of the products was 
consistent with previously isolated β-lactams from the acid.  
 
Entry Compound Ar Yield (%) dr (anti:syn)a ee (%)b 
1 141 p-Bromophenyl 74 >95:5 79 
2 104 p-Methoxyphenyl 72 >95:5 70 
3 142 3-Thiophene 47 93:7 68 
4 143 2-Naphthyl 44 90:10 83 
a Determined by inspection of 1H NMR spectrum of crude.  b Obtained by chiral HPLC analysis 
Table 2.16: Variation of Homoanhydride 
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Additionally, removal of the N-tosyl substituent of the parent β-lactam was possible 
by treatment with SmI2 to give 144 without racemisation (Scheme 2.32). 
 
Scheme 2.32: Detosylation Reaction 
2.3.4 Control Studies 
As slightly reduced diastereocontrol was observed in formation of the β-lactam 
products from pre-made arylacetic anhydrides as opposed to directly from the 
carboxylic acid, a sample of (3S,4R)-3,4-diphenyl-1-tosylazetidin-2-one 135 was 
retreated to the reaction conditions for one hour. Following this, the dr was found to 
have improved from 90:10 to 93:7 implying that epimerisation occurs over time. 
There is precedent in the literature that syn-β-lactams can be readily converted into 
the more thermodynamically stable anti-isomers by a straightforward base-catalysed 
isomerisation.51 As reaction from the homoanhydrides requires a shorter time and 
lower temperature than from the acid, this could explain the lower dr as the rate for 
epimerisation may be reduced. 
This observation prompted us to investigate the possibility of in situ product 
epimerisation leading to enhanced diastereocontrol. To test this hypothesis, the 
diastereoselectivity of the reaction was analysed at intervals (Scheme 2.33a) with the 
reaction carried out at −78 ˚C in order to slow down the rate. At modest levels of 
conversion (<20%) a dr of 85:15 was observed, however, after further reaction time, 
enhanced diastereocontrol was observed (dr >95:5), consistent with in situ 
epimerisation. To further confirm our theory, an isolated example of β-lactam 138 (dr 
anti:syn 21:79; anti 90% ee; syn 52% ee) was retreated with i-Pr2NEt (1.5 equiv.) and 
(2S,3R)-HBTM-2.1 26 (5 mol%) in CH2Cl2, generating (ent)-anti-138 (>95:5 dr, 32% 
ee) in quantitative yield (Scheme 2.33b).52 This is consistent with the syn-
diastereoisomer having preferentially the (3S,4S)-configuration, and with in situ 
epimerisation generating ent-138 preferentially. Under identical experimental 
conditions, a sample of anti-138 (>95:5 dr, 90% ee) showed no change in dr or ee, 
consistent with no epimerisation of the anti-β-lactam under the reaction conditions.  
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Scheme 2.33: Diastereoselectivity Investigations 
2.4 Conclusions  
The chemical synthesis of the β-lactam core structure continues to be a very 
significant field of research.10 This chapter has discussed our developments in this 
area, which demonstrate that isothioureas can efficiently catalyse an umpolung 
Staudinger type reaction in high diastereo- and enantioselective to form the anti-β-
lactam products from homoanhydrides. An in situ ring-opening allows access to the 
equally synthetically interesting β-amino ester products directly from arylacetic acids 
with good to excellent enantioselectivity (up to >99% ee). This synthetic route is of 
particular interest as it involves easy to prepare or commercially available, bench-
stable starting materials and the reaction is carried out under mild conditions without 
the need for anhydrous solvent. 
Further work in this area from within the group has shown 3-alkenoic acids to also be 
effective ammonium enolate precursors that, when coupled with imine partners, form 
alternatively substituted anti-β-lactam products in good dr and excellent ee (Scheme 
2.34). As with work described in this thesis, the syn-β-lactam products could be 
readily converted into the anti-product under basic conditions. 
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Scheme 2.34: Use of Alkenoic Acids for β-Lactam Formation 
This work could potentially lead to future applications such as to a synthetic target for 
example the cholesterol absorption inhibitor AZD4121.53 The key intermediate is 
formed via a Staudinger reaction between a chiral carboxylic acid and an imine. 
However a mixture of diastereoisomers of the β-lactam is obtained and a resolution 
must be carried out (Scheme 2.35). As our process has thus far proved highly 
diastereoselective, it is thought that using our catalytic process instead of the standard 
Staudinger reaction may remove the need for this resolution. However further 
optimization of our process would be required as thus far, carboxylic acids containing 
a sulfur atom have resulted in disappointing ees. 
Scheme 2.35: Staudinger Reaction en route to AZD4121 
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Chapter 3: Asymmetric Isothiourea-mediated 
Organocatalytic Formation of Diesters via Ammonium 
Enolates from Ester Surrogates 
3.1 Introduction 
In an effort to expand the scope of previous work within the group, we were 
interested in developing alternative intermolecular formal [4+2]-cycloadditions based 
on the intermolecular Michael-addition/lactonisation previously discussed. The use of 
α,β-unsaturated esters and amides as Michael acceptors in such processes remains a 
significant synthetic challenge owing to the decreased electrophilicity of these species 
(Scheme 3.1a). For example, whilst α-keto-β,γ-unsaturated esters work well in this 
methodology,1 methyl cinnamate does not. Alternative ester surrogates were sought 
which were reactive towards the ammonium enolates generated from isothioureas but 
also contained a leaving group, which could be displaced on ring-opening by an 
alcohol (Scheme 3.1b). These acceptors could then be used as alternatives to esters in 
this catalysis leading to the same ring-opened diester products after treatment with 
alcohols. 
Scheme 3.1: (a) Direct Use of Esters in Isothiourea Catalysed Michael-Addition/Lactonisation 
Reactions are Unsuccessful (b) Strategy to Overcome This 
3.1.1 Esters Surrogates as Michael Acceptors 
Various acceptors have proved amenable in the ammonium enolate formal [4+2]-
cycloaddition chemistry developed within the group, including α-keto-β,γ-unsaturated 
esters,1 N-tosyl-α,β-unsaturated ketimines,2 N-aryl-N-aroyldiazenes3 and 
trifluoromethylenones.4 However, simple α,β-unsaturated esters and amides have not 
been employed successfully owing to their inherent decreased reactivity.  
Ar
OH
O
R
O i) Activation
ii) Isothiourea
Catalysed
Michael-addition
lactonisation
O
O
OMe
Ar
R
OMe MeO
O
OMe
O
Ar
RMeOH 
Ring-Opening
Ar
OH
O
R
O i) Activation
ii) Isothiourea
Catalysed
Michael-addition
lactonisation
O
O
LG
Ar
R
LG MeO
O
OMe
O
Ar
RMeOH 
Ring-Opening
a)
b)
Chapter 3: Asymmetric Formation of Diesters from Ester Surrogates 
66 
Within the literature, strategies to overcome the typical modest reactivity of α,β-
unsaturated esters problem use ester surrogates such as N-acylpyrroles 145,5 2-
acylimidazoles 1466 and activated imides 147,7 and in asymmetric catalysis the use of 
trichloromethylketones 148 and α,β-unsaturated phosphonates 149 has been forged 
(Figure 3.1).8,9,10 Trichloromethylketones 148 and phosphonates 149 will be further 
discussed as the basis of this chapter. 
 
Figure 3.1: α ,β-Unsaturated Ester Equivalents 
3.1.1.1 Trichloromethylketones as Ester Surrogates 
The versatility of trichloromethylketones has previously been shown in their use as 
carboxylic acid, ester and amide equivalents in haloform-type reactions owing to the 
leaving group ability of the CCl3 group.11 It has also been previously reported that 
α,β-unsaturated trichloromethyl ketones can be used as ester and amide equivalents of 
Michael acceptors.12,13 For example, Zhao and co-workers reported an asymmetric 
epoxidation of α,β-unsaturated trichloromethylenone using prolinol catalyst 150 
(Scheme 3.2).12 Following isolation of the epoxide, esters and amides could be 
obtained by displacement of the CCl3 group. 
 
Scheme 3.2: Zhao’s Use of Trichloromethylketones as Ester Mimics 
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More recently, Wang et al. utilised α,β-unsaturated trichloromethylketones in their 
squaramide catalysed asymmetric Michael-addition of α,β-unsaturated γ-
butyrolactams (Scheme 3.3).13 Methanolysis of the CCl3 group without loss of 
stereoselectivity demonstrated the utility of their methodology. 
Scheme 3.3: Wang’s Use of Trichlormethylketones as Ester Surrogates 
3.1.1.2 α-Ketophosphonates as Ester Surrogates 
α-Ketophosphonates as ester equivalents were first reported by Evans et al. in 
1998.6,8,9,14 They utilised ketophosphonate 152 in a stereoselective Lewis acid 
catalysed hetero Diels-Alder reaction with vinyl ethers (Scheme 3.4). The copper (II) 
bis(oxazoline) 153 catalyst formed intermediate 154 in which coordination of both the 
carbonyl and phosphonate oxygens to the copper sufficiently activated them for 
reaction, forming 155 in excellent yield, dr and ee. Treatment of the product with 
acidic methanol gave the aldehyde ester 156. 
 
Scheme 3.4: First Example of α-Ketophosphonates as Ester Surrogates 
Jørgensen later demonstrated an asymmetric thiourea catalysed addition of oxazolone, 
amongst other nucleophiles, to α-ketophosphonates (Scheme 3.5).10 In situ 
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methanolysis of the ketophosphonate ester equivalent gave access to a range of 
optically active ester conjugate adducts in excellent enantioselectivity and yield. This 
process was believed to proceed through activation of the oxazolone by deprotonation 
along with coordination of the thiourea 157 to the α-ketophosphonate. DBU catalysed 
addition of a second nucleophile leads to formation of the desired ester product. 
 
Scheme 3.5: Jørgensen’s Demonstration of α-Ketophosphonates as Ester Surrogates 
During these investigations, Jørgensen outlined a set of three characteristics he 
believed a successful ester surrogate should possess: enhanced activation of the 
substrate towards nucleophilic attack; improved coordination to the chiral catalyst; 
and easy replacement of the group, preferably in situ.  
3.2 Aims and Objectives 
As part of our on-going research into isothiourea catalysed ammonium enolate 
chemistry, we wished to investigate the use of trichloromethylketones and α-
ketophosphonates as ester equivalents to give access to stereodefined diester products 
(Scheme 3.6). Further derivatisation of these products would be investigated in order 
to demonstrate the synthetic utility of this methodology. 
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Scheme 3.6: Use of Trichloromethylketones (a) or α-Ketophosphonates (b) as Ester Surrogates in 
Isothiourea Catalysed Ammonium Enolate Chemistry 
3.3 Results and Discussion 
3.3.1 Previous Work on [4+2]-cycloadditions of α-Ketophosphonates Within 
the Smith Group 
Previous work carried out by Reuben Holmes and Stuart Leckie led to optimisation of 
the synthesis of the α-ketophosphonate acceptors. Preparation through a modified 
version of the method published by Spilling,15 whereby cinnamaldehyde 158 and 
dimethylphosphite 159 were stirred under Michaelis-Arbuzov conditions with 
triethylamine at room temperature, gave the allylic alcohol 160 (Scheme 3.7). 
Oxidation of 160 under Parikh-Doering conditions as described by Evans16 gave the 
crude α-ketophosphonate 161. An observed disadvantage of these acceptors was 
difficulty of purification – both silica column chromatography and distillation led to 
degradation of the α-ketophosphonate. In order to avoid the need for purification, the 
intermediate alcohol was triturated with ether allowing the final compound to be used 
without further purification. 
 
Scheme 3.7: Synthesis of a-Ketophosphonate Acceptors 
Following optimisation of the starting material synthesis, the enantioselective 
Michael-addition/lactonisation using arylacetic acids was explored (Scheme 3.8). In 
situ activation of the carboxylic acid 98 to the mixed anhydride was carried out using 
pivaloyl chloride and Hünig’s base at 0 °C for 20 minutes. The reaction mixture was 
then cooled to –78 °C and (2S,3R)-HBTM-2.1 26, the α-ketophosphonate and further 
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Hünig’s base were added before stirring at –78 °C overnight. This allowed access to 
the dihydropyranone product 162 in high disatereo- and enantioselectivity and good 
yields. However, isolation of the products was difficult owing to their instability 
especially to silica column chromatography – a problem noted with many similar δ-
lactones produced within the group.1,2,3,4 
 
Scheme 3.8: Reaction of α ,β-Ketophosphonates to Dihydropyranones 
As the ultimate aim of this work was to use these α-phosphonates as masked esters in 
our reaction, in situ alcholoysis was investigated and optimised (Scheme 3.9). 
Pleasingly, the desired diester products were accessed in excellent yields, dr and ee 
with the absolute configuration confirmed by X-ray crystallography.  
 
 
Scheme 3.9: In Situ Methanolysis of Dihydropyranones to the Desired Diester Products 
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Further to this work, my research started with a short investigation into the optimised 
conditions (Table 3.1). Solvent had not previously been varied from dichloromethane 
although THF had been shown to give improved stereoselectivities at room 
temperature in a similar process using N-tosyl-α,β-unsaturated ketimines as 
acceptors.2 Although changing the solvent to THF gave improved enantioselectivity at 
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room temperature (entry 2, dr 89:11, 97% ee compared with previous result of dr 
88:12, 86% ee), owing to solubility problems the reaction could not proceed to full 
conversion and a low yield of 41% was obtained (entry 2). Combinations of solvents 
(CH2Cl2/THF) were tried but the reactions failed to reach completion even with 
extended reaction times.  
 
Entry Solvent Yield (%) (conversion)a dr (anti:syn)b ee (%)c 
1d CH2Cl2 51 88:12 86 
2 THF 41 (50) 89:11 97 
3 THF:CH2Cl2 (3:1) (78) 89:11 ND 
4 THF: CH2Cl2 (1:1) (80) 89:11 ND 
a Isolated yield of single diastereoisomer, conversion calculated by analysis of 1H NMR spectrum of 
crude. b Determined by analysis of 1H NMR spectrum of crude. c Determined by chiral HPLC analysis. 
d Work carried out by Reuben Holmes 
Table 3.1: Solvent Screen 
During the initial catalyst screen (Table 3.2), (2S,3R)-HBTM-2.1 26 had been 
identified as the optimum catalyst (entry 1) with superior enantioselectivity over 
HBTM  24 and (–)=tetramisole.HCl 22 (entries 2 and 3). However, (R)-
benzotetramisole 23 had not been tested in this process. Under the same reaction 
conditions benzotetramisole gave a lower isolated yield and reduced 
enantioselectivity (entry 4), therefore (2S,3R)-HBTM-2.1 26 was used as the optimum 
asymmetric catalyst. 
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Entry Catalyst Yield (%)a dr (anti:syn)b ee (%)c 
1d (2S,3R)-HBTM-2.1 26 51 88:12 86 
2d HBTM 24 76 88:12 65  
3d (−)-Tetramisole.HCl 22 66 84:16 60 (ent) 
4 (R)-BTM 23 42 74:26 56 
a Isolated yield of single diastereoisomer, conversion calculated by analysis of 1H NMR spectrum of 
crude. b Determined by analysis of 1H NMR spectrum of crude. c Determined by chiral HPLC analysis. 
d Work carried out by Reuben Holmes 
Table 3.2: Screen of Asymmetric Isothiourea Catalysts 
However, the long-term stability of the employed dimethoxy ketophosphonates was 
problematic with degradation occurring very quickly even when stored under an inert 
atmosphere at low temperature and this was a considerable drawback of this 
methodology. The starting material significantly degraded over a 3-4 week period and 
resulted in loss of ultimate yield of our cycloaddition reactions, even when using 
excess acceptor. Owing to this, an investigation into alternative acceptor substrates 
was carried out. 
3.3.3 Iso-Propylphosphonate 
It was noted that iso-propylphosphonate 163 was easier to prepare than its methoxy 
counterpart as it was able to be purified by silica gel chromatography. This α-
ketophosphonate could be stored for several months in the fridge under argon without 
degradation. This indicates that this phosphonate is more stable and indeed we were 
able to make it on a large scale (40 mmol, Scheme 3.10) with purification by column 
chromatography.  
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Scheme 3.10: Large Scale Synthesis of α-Ketophosphonate 163 
An initial reaction under the previously optimised reaction conditions revealed that 
the iso-propylphosphonate 163 also underwent displacement by methanol to give 
access to the diester product 164 in excellent diastereo- and enantioselectivity 
(Scheme 3.11), although in a slightly reduced overall yield. 
 
Scheme 3.11: α-Ketophosphonate 163 in Diester Formation 
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The scope of the reaction was investigated using the preferred di-iso-
propylphosphonate 163 by variation of the arylacetic acid. A range of diester products 
were synthesised and isolated in generally good yield, diastereo- and excellent 
enantioselectivities (Table 3.3). 
In the case of the α-ketophosphonate acceptors, ortho-substituted acids had not 
previously been investigated. A short investigation into this was carried out using o-
tolyl acetic acid (entry 2) and the dr appeared to be very poor (56:44) however the 
products were not isolated and so not fully characterised. 
Electron-donating and withdrawing groups were tolerated however with a small 
decrease in the dr in the case of p-fluorophenylacetic acid (entry 4). Notably the 
substrate scope included heteroarylacetic acids although with varying 
stereoselectivities with these acids. Diesters 168 and 169 were both isolated in 
moderate yields and lower ee (entries 5 and 6) however 3-thiophenylacetic acid was 
well tolerated with 170 isolated in excellent yield, dr and ee (entry 7). 
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Entry Compound Ar Yield (%)a dr 
(anti:syn)b 
ee (%)c 
1 164 Phenyl 49 90:10 99 
2 165 o-Tolyl ND  
(45% conversion) 
56:44 ND 
3 166 p-Methoxyphenyl 73 >95:5 >99 
4 167 p-Fluorophenyl 77 85:15 99 
5 168 N-Methyl-3-indolyl 62 86:14 88 
6 169 2-Thiophene 51 >95:5 67 
7 170 3-Thiophene 86 >95:5 >99 
All reactions carried out on a 0.4 mmol scale. a Isolated yield of single diastereoisomer, conversion 
calculated by analysis of 1H NMR spectrum of crude. b Determined by analysis of 1H NMR spectrum 
of crude. c Determined by chiral HPLC analysis.  
Table 3.3: Variation of Arylacetic acid with Iso-Propylphosphonate 163 
This methodology was shown to be amenable to scale synthesis with reaction on 2 
mmol of 98 carried out and the diester 164 was isolated in excellent yield, dr and ee 
(Scheme 3.12). 
 
Scheme 3.12: Large-Scale Synthesis of 164 
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with the iso-propylketophosphonate acceptor 163 (Table 3.4). Pleasingly, these acids 
were also tolerated in this system with excellent yields, diastereo- and 
enatioselectivity except for in the case of styrylacetic acid. Here, a decrease in the dr 
from >95:5 to 90:10 was observed following column chromatography and also a 
much lower ee than other examples was obtained (entry 2). The reasons for this are 
currently unknown. 
 
Entry Compound R Yield (%)a dr (anti:syn)b ee (%)c 
1 171 
 
74 >95:5 >99 
2 172  77 >95:5
e 27 
3 173 
 
76 >95:5 >99 
a Isolated yield of single diastereoisomer, conversion calculated by analysis of 1H NMR spectrum of 
crude. b Determined by analysis of 1H NMR spectrum of crude. c Determined by chiral HPLC analysis. 
e dr 90:10 following silica gel column chromatography. 
Table 3.4: Screen of Alkenylacetic acids 
3.3.3.2 Product Derivatisations 
To further demonstrate the utility of this protocol, a series of synthetic 
transformations of the diester products were investigated. Previous work by Stuart 
Leckie showed that following isolation of the diester product 164, it was possible to 
reduce both esters to give the diol 174 using lithium aluminium hydride or to 
selectively reduce the less sterically crowded ester using DIBAL-H to give alcohol 
175, both with no erosion of the dr or ee (Scheme 3.13). 
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Scheme 3.13: Reductions of Diester Product 164 
Following isolation of alcohol 175, subsequent acid-catalysed cyclisation gave access 
to lactone 176 without the need for purification and again with no effect on the dr or 
ee (Scheme 3.14). 
 
Scheme 3.14: Acid-Catalysed Cyclisation of Alcohol 175 to Give New Lactone Scaffold 
With an aim to prove this was a general process, several diesters with a variety of 
substitution patterns were treated under these reaction conditions. Generally, it was 
found that this method worked well, with the stereochemistry conserved in all cases. 
Also, the reaction could be carried out from the diester without the need to purify the 
intermediate alcohol. However, the alkenyl examples 180 and 181 were only isolated 
in low yield using this protocol which potentially could be improved by purification 
of the intermediate (Table 3.5). 
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Entry Compound R Yield (%)a dr (anti:syn)b ee (%)c 
1 176 Phenyl 54 >95:5 98 
2 177 p-Methoxyphenyl 49 >95:5 >99 
3 178 p-Fluorophenyl 63 >95:5 >99 
4 179 2-Thiophenyl 30 >95:5 70 
5 180 
 
12 >95:5 99 
6 181 
 
29 >95:5 98 
a Isolated yield of single diastereoisomer, conversion calculated by analysis of 1H NMR spectrum of 
crude. b Determined by analysis of 1H NMR spectrum of crude. c Determined by chiral HPLC analysis. 
e dr 90:10 following silica gel column chromatography. 
Table 3.5: Scope of Selective Reduction and Lactonisation 
3.3.4 Previous Work on [4+2]-cycloadditions of Trichloromethylketones Within 
the Smith Group 
Previous work carried out by Agathe D’Hollander, Carmen Simal and James Squires 
led to optimisation of the synthesis of the trichloromethylketone acceptors and their 
enantioselective lactonisation (Scheme 3.15). Following ring-opening with methanol, 
the same diester products formed from the α-ketophosphonates were observed, 
indicating that trichloromethylketones can also act as ester surrogates in this process. 
In this case, the trichloromethylketones had an added advantage over the α-
ketophosphonates in that they were bench stable for over a year. 
Scheme 3.15: Trichloroketones as Ester Surrogates 
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The scope of trichloromethylketones in our Michael-addition/lactonisation reaction 
was extensively investigated with 15 examples synthesised in up to 74% yield, 91:9 
dr and >99% ee. The nucleophile for ring-opening was also varied and shown to be 
successful (Scheme 3.16). 
Scheme 3.16: Variation of Ring-Opening Nucleophile 
3.3.5 Expansion of This Work to Alkenyl Acids 
Following the success of alkenyl acids in other processes from our group, an example 
was carried out with the trichloromethylketone acceptor (Scheme 3.17). The reaction 
proceeded well with the diester product being isolated in good yield and with 
excellent diastereo- and enantioselectivity. 
 
Scheme 3.17: Example of Alkenyl Acid in Trichloromethylketone Chemistry  
3.4 Conclusions  
In conclusion, the use of α,β-unsaturated ketophosphonates as masked ester 
equivalents in Michael addition/lactonisation reactions with a range of acetic acids 
has been demonstrated. Difficulty with the purity of the methoxy phosphonate 
acceptor was overcome by using isopropyl phosphonate as it was amenable to column 
chromatography and found to be much more stable. A number of diester products 
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have been isolated from the newly developed reaction in excellent stereoselectivities. 
Subsequently, the synthetic utility of these diesters was then demonstrated through 
reduction to the diol and selective reduction to the ester-alcohol, which, following 
acid-catalysed cyclisation, gives access to new disubstituted lactone products without 
loss of stereocontrol. 
Trichloromethylketones were also found to be useful ester equivalents under similar 
conditions and in this case have the advantage of being bench stable for over a year. 
Although initially optimised conditions required dry conditions, continuation of this 
work by other members of the group has identified conditions under which anhydrous 
solvent is not required (Scheme 3.18).17 
 
Scheme 3.18: Final Optimised Conditions for Diester Synthesis from Trichloromethylketones 
Interestingly, recent work has established that using lower equivalents of the 
nucleophile for ring-opening of the trichlorolactone led to isolation of the monoester 
where displacement of the trichloromethyl group had not taken place. This led to the 
possibility of forming differentially protected dicarbonyl derivatives through the 
sequential addition of two distinct nucleophiles. This theory was proven through the 
reaction between phenylacetic acid and trichloromethylketone, which was first ring-
opened with three equivalents of isopropylamine. Upon the disappearance of the 
initial dihydropyranone product by TLC analysis, addition of a large excess of 
methanol and catalytic DMAP (20 mol%) led to formation of γ-ester amide 182, 
which was isolated in 42% yield over the one-pot 3-step reaction sequence as a single 
diastereoisomer in 99% ee (Scheme 3.19). 
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Scheme 3.19: Sequential Addition of Two Nuclephiles to Form γ-Ester Amide 182 
In the future it is hoped this methodology could be applied to the synthesis of a 
potential bioactive target molecule. Pulveravens A and B have both been shown to 
have micromolar activity against carcinogen induced precancerous lesion formation 
(Figure 3.2).18 They contain a similar substitution pattern as accessed from our 
methodology and so could be an interesting target for this work. 
 
Figure 3.2: Pulveraven A and B 
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Chapter 4: An Isothiourea Catalysed Formal [3+2]-
Cycloaddition Towards Oxazolidin-4-ones 
4.1 Introduction 
4.1.1 Expansion of Isothiourea Ammonium Enolate Chemistry to Formal 
[3+2]-Cycloadditions 
Continuing from previous work in this thesis describing work towards novel [2+2]- 
and [4+2]-cycloadditions, we now wished to expand this to formal [3+2]-
cycloadditions. In the quest to synthesise a range of enantiomerically pure 
heterocyclic compounds, formal [3+2]-cycloadditions would provide an excellent 
approach towards five-membered ring systems of various connectivities and 
substitution patterns.1 Previous work within the Smith group on ammonium enolate 
chemistry with various electrophilic partners has proven successful and it was 
postulated that an oxaziridine would make a good substrate for initial studies into the 
expansion of this work into [3+2] reactions (Scheme 4.1). 
Scheme 4.1: Premise for Expansion of Ammonium Enolate Chemistry to Incorporate Five-
Membered Ring Formation 
4.1.2 Oxaziridines 
Oxaziridines, three-membered heterocycles containing an oxygen, nitrogen and 
carbon atom, were first reported in 19562 with Emmons’s observation that certain 
aldimines were readily oxidised using peracetic acid. All analytical and experimental 
data indicated the formation of an oxygen-nitrogen-carbon ring, now known as an 
oxaziridine (Scheme 4.2). Their reactivity was similar in many respects to organic 
peroxides, with an active oxygen atom that allowed assaying by iodometric 
procedures - analysis by the oxidation of hydrogen iodide into iodine2 - and initial 
research into their properties focussed on their use as oxidising agents.3 Oxiaziridines 
have increased stability compared to analogous dioxiranes and peroxometal 
complexes, allowing improved ease of preparation and storage.4 
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Scheme 4.2: Oxidation of Imine into Oxaziridine by Peracetic Acid 
Oxaziridines can be classified by their N-substituent and varying this has a significant 
effect on their reactivity. In general, oxaziridines with small groups on the nitrogen 
atom (H, Me) act as aminating agents, whilst those with larger or electron-
withdrawing groups acting as oxidising agents.5 N-Alkyl, N-H, N-acyl, N-
phosphinoyl, N-silyl and N-sulfonyloxaziridines have all been reported, however N-
sulfonyloxaziridines are the most extensively used class after first being reported in 
the late 1970’s by Davis and co-workers.6 Their stability, ease of synthesis and 
superior oxidising ability over other classes facilitates their preparation and use in 
synthesis.5 N-Sulfonyloxaziridines are characterised by a highly electrophilic oxygen 
atom and were first shown to selectively oxidise sufides and disulfides into the 
corresponding sulfoxides and thiolsulfinates (Scheme 4.3).6 This process was 
observed to be virtually instantaneous and highly selective for sulfoxide synthesis 
without formation of the corresponding sulfone. 
 
Scheme 4.3: Oxidation of Sulfides and Disulfides by N-Sulfonyloxaziridines 
In 1984, Davis and co-workers expanded this process to use oxaziridine 183 for the 
direct hydroxylation of enolates (Scheme 4.4).7 Efficient methods for the α-
hydroxylation of carbonyl compounds are of great synthetic interest owing to the 
presence of this structural motif in many biologically active natural products8 and is 
perhaps the most widely utilised reaction of oxaziridines.5 Davis observed that the 
base used to form the enolate (and therefore the enolate counterion) was important 
and an imino-aldol side-product 184 was formed using lithium enolates but not 
observed using sodium enolates. He proposed this was due to a difference in the 
equilibrium between 185 and 186. With a lithium counterion, this equilibrium lay 
more to the right allowing enolate 186 to react directly with imine by-product 187 to 
form imino-aldol product 184. 
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Scheme 4.4: Direct Hydroxylation of Enolates by N-Sulfonyloxaziridines 
Further work in this field has included oxidation of olefins into epoxides,7 
triphenylphosphines into their oxides,9 hydrogen iodide into iodine and chloride ions 
into chlorine,10 organometallics into alcohols,11 and amines into amine oxides.3  
4.1.3 Oxaziridines in Asymmetric Synthesis 
An interesting feature of oxaziridines is their inherent stereochemistry.2 The 
stereogenicity of the nitrogen atom and its considerable barrier to inversion allows the 
synthesis of enantiopure oxaziridines. The barrier to inversion at nitrogen was 
determined to be 25-32 kcalmol-1 for N-alkyl oxaziridines,12 although this varies 
depending on the N-substituent. The transition state for thermal epimerisation also has 
increased ring strain, which provides a further barrier to nitrogen inversion.13 
Davis noted that this property could allow for stereospecific transfer of heteroatoms if 
the starting oxaziridine was of high enantiopurity. In 1979, Davis reported the use of 
camphor derived oxaziridine 188 as an enantioenriched oxidising agent providing an 
alternative to chiral peroxy acids.14 Synthesis of oxaziridine 188 employed a two-step 
procedure (Scheme 4.5), with the first step requiring heating of (−)-camphor-10-
sulfonamide with the diethyl acetals of the requisite nitrobenzaldehydes. Oxidation by 
m-CPBA in the presence of sodium bicarbonate gave the oxaziridines as mixtures of 
diastereoisomers (66:33). Following several recrystallisations, the diastereomeric ratio 
was improved to 84:16 and this mixture was used for further experiments. 
Scheme 4.5: Synthesis of Chiral Oxaziridines 
The first synthetically useful approach to reagent-controlled asymmetric oxidation 
using chiral N-sulfonyloxaziridines utilised oxaziridine 189, formed by the selective 
oxidation of camphor sulfonic acid derived imine 190 (Scheme 4.6).15 These 
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synthetically useful compounds are readily available on kilogram scale as single 
stereoisomers. As a result of their widespread utility, varients of these compounds are 
currently commercially available from Sigma Aldrich.16 
 
Scheme 4.6: Synthesis of Davis’s Chiral Camphor-Derived Oxaziridine 189 
Davis and co-workers applied (camphorylsulfonyl)oxaziridine 189 to the α-oxidation 
of ketones. For example, treating ketone 191 with NaHMDS followed by oxaziridine 
189 gives α-hydroxyketone 192 in 84% yield with excellent levels of stereocontrol 
(Scheme 4.7).15  
 
Scheme 4.7: Davis’s Asymmetric Hydroxylation of Ketones 
This process has been used to insert α-hydroxyl groups in many total syntheses of 
biologically important natural products17 including (−)-acutumine 193,18 (−)-
jiadifenolide19 194 and tetracycline AB enone 195, a key precursor to tetracycline 
antibiotics (Scheme 4.8a),20 and also in two syntheses of Taxol® including Wender’s 
synthesis in 1997 (Scheme 4.8b). 21 
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Alternative methods for the α-oxidation of carbonyls include using Vedejs’s 
oxodiperoxymolybdenum(pyridine)-(hexamethylphosphoric triamide) (MoOPH) 196 
reagent as the electrophilic oxygen source with camphor derived starting materials 
(Scheme 4.9a),22 or using Evans’s chiral auxiliary with a racemic N-
sulfonyloxaziridine 183 as the electrophile (Scheme 4.9b).23 Whilst both these 
methods give good selectivities they both make use of a chiral auxiliary, a well-
documented disadvantage of which is the need to prepare and then remove the 
auxiliary thereby adding extra steps to the synthetic sequence.  
 
Scheme 4.9: Alternative Methods for α-Hydroxylation 
4.1.4 Oxaziridines in Asymmetric Catalysis 
As the historic route for asymmetric oxidation by oxaziridines generally requires 
either a stoichiometric amount of a chiral oxaziridine or a chiral auxiliary,24 recently 
there has been a quest to develop a catalytic asymmetric version of Davis’s 
oxaziridine oxidation reaction, especially for asymmetric α-hydroxylation reactions. 
Catalytic processes involving oxaziridines were again first investigated by Davis et al. 
who published a process requiring catalytic amounts of oxaziridine and a 
stoichiometric re-oxidant in 1988 (Scheme 4.10).25 The oxidation of sulfides into 
sulfoxides using a catalytic amount of 197 followed by re-oxidation of the 
sulfonylimine 198 to the oxaziridine was described. m-CPBA could not be used as a 
re-oxidant as under the reaction conditions it would oxidise the desired sulfides into 
sulfones, however, buffered peroxymonosulfate (Oxone®) was suitable and gave no 
background oxidation. 
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Scheme 4.10: Oxidation of Sulfides into Sulfoxides Using Catalytic Oxaziridine 
In 2003, Yamamoto et al. described the first catalytic enantioselective introduction of 
an oxy group at the α-position of a ketone enolate using nitrosobenzene as an 
oxaziridine alternative (Scheme 4.11).26 Using an (R)-BINAP-silver complex, the α-
hydroxy compounds could be isolated in up to 97% ee after N-O bond cleavage using 
CuSO4, with high regioselectivity for the O-adduct over the N-adduct. 
 
Scheme 4.11: Nitrosobenzene as an Oxaziridine Alternative for α-Hydroxylation 
The use of oxaziridines for the asymmetric hydroxylation of β-ketoesters was 
reported by Togni and co-workers in 2004 (Scheme 4.12).27 This was the first direct 
asymmetric transition-metal-catalysed α-hydroxylation reported. Using a chiral Lewis 
acid titanium (IV) TADDOLate complex 199 as the catalyst and 2-(phenylsulfonyl)-
3-(4-nitrophenyl)oxaziridine 200 as the oxidising agent, products containing a 
quaternary stereocentre could be isolated in high yields and enantioselectivities. The 
proposed mechanism involved coordination of the titanium catalyst to the dicarbonyl 
compound to form a chiral enolate 201, which is epoxidised by the oxaziridine with 
subsequent ring-opening giving the observed product. 
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Scheme 4.12: Hydroxylation of β-Ketoesters using Titanium (IV) TADDOLate Complex 199 
Recently, organocatalytic examples of α-hydroxylation have come to the forefront. 
Lewis base catalysts have been shown to catalyse formal [3+2]-cycloaddition 
reactions of N-sulfonyloxaziridines via N-O bond cleavage, giving access to 
oxazolidin-4-one products. In 2010, Ye et al. reported the formal [3+2] cycloaddition 
of a ketene and an oxaziridine catalysed by NHC 203 (Scheme 4.13).24 These 
products are masked α-hydroxy carbonyl compounds and Ye demonstrated that 
reduction of these compounds with LiAlH4 gives access to the enantioenriched diol 
204. Notably, when 1.2 equivalents of racemic oxaziridine was used, the optically 
active oxaziridine could be recovered in reasonable yield and good to excellent 
enantiopurity. 
 
Scheme 4.13: Ye’s Synthesis of Oxazolidin-4-ones and Optically Active Diols 
This formal cycloaddition reaction is proposed to proceed through addition of the 
Lewis base catalyst to the ketene substrate, forming zwitterionic enolate intermediate 
205 (Scheme 4.14). Subsequent oxidation by the oxaziridine gives intermediate 206 
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and imine 207 which undergo a nucleophilic addition to zwitterionic complex 208. 
Following collapse of this intermediate, the final cycloadduct 209 is formed and the 
Lewis base catalyst regenerated. 
 
Scheme 4.14: Proposed Reaction Mechanism for Ye’s [3+2]-Cycloaddition 
This method was not suitable for monsubstituted ketenes generated in situ from acyl 
chlorides however, using cinchona alkaloid catalyst TMS-quinidine 210, the 
disubstituted syn-products could be accessed in moderate to good yields and high 
enantioselectivities (Scheme 4.15).24,28  
 
Scheme 4.15: Formation of Oxazolidin-4-ones from Monosubstituted Ketenes  
In 2013, Lui and Feng reported a similar route to oxazolidin-4-ones via the 
oxyamination of azlactones using oxaziridine 211 catalysed by chiral bis-guanidinium 
salt 212 (Scheme 4.16).29 The products were formed in excellent diastereo- and 
enantioselectivity and the process also results in the kinetic resolution of a range of 
oxaziridines. 
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Scheme 4.16: Oxazolidin-4-ones via Oxyamination of Azlactones 
Also in 2013, Zou et al. reported that the use of a TADDOL-like chiral guanidine 213 
for the α-hydroxylation of β-ketoesters forms products with excellent yields and 
enantioselectivities (Scheme 4.17).30 N-Tosyloxaziridine 211 was selected as the 
source of electrophilic oxygen as it was much more selective than other sources 
screened. 
Scheme 4.17: TADDOL-like Chiral Guanidine 213 for α-Hydroxylation of β-Ketoesters 
4.2 Aim 
Expanding our work on isothiourea based chiral ammonium enolates in 
organocatalysis, it was postulated that these intermediates could be used as an 
alternative to ketene derived enolates in a similar system to that of Ye.24,28 Using 
isothioureas as our Lewis base catalysts to generate ammonium enolates in situ from 
activated carboxylic acids and oxaziridines as electrophiles, we hoped to gain access 
to enantioenriched oxazolidin-4-ones. A secondary aim was to probe the mechanistic 
influence of the use of enantioenriched oxaziridines in this system. 
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4.3 Results and Discussion 
4.3.1 Previous Work on [3+2]-Cycloadditions Within the Smith Group 
Initial studies carried out by Louis Morrill identified oxaziridines as suitable partners 
for formal [3+2]-cycloadditions with isothiourea generated ammonium enolates 
(Scheme 4.18). The oxazolidin-4-one product 214 was isolated in 64% yield with 
good diastereoselectivity (86:14 anti:syn) and excellent ee (both diastereoisomers 
>99% ee), however the product containined 6% of an imine contaminant 215 and also 
trace levels of β-lactam 135. X-ray crystallography of a racemic sample allowed 
assignment of the relative configuration of the major diastereoisomer as anti, however 
a crystal of the asymmetric sample could not be obtained precluding determination of 
the absolute configuration by this method. The absolute configuration of both 
enantiomers was assigned by methods discussed later in this chapter. 
Scheme 4.18: Isothiourea-Catalysed Oxazolidin-4-one Formation 
The observation of imine in the product distribution led to the hypothesis that this was 
the product of an alternative pathway outwith the isothiourea catalysed [3+2]-
cycloaddition via oxaziridine degradation. Furthermore, as the imine co-eluted with 
the product during column chromatography, isolation of clean oxazolidin-4-one 214 
was not possible.  
4.3.2 Reaction Optimisation  
4.3.2.1 Initial Scope Screen 
In continuing this project, our initial work focussed on variation of the aryl unit within 
the oxaziridine in order to see if this gave any effect on the formation of the imine 
side-product. In dichloromethane at room temperature to phenylacetic acid 98, N-
sulfonyloxaziridine, pivaloyl chloride and Hünig’s base were added and the reaction 
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mixture stirred at room temperature for five minutes. Following cooling to –78 °C, 
(2S,3R)-HBTM-2.1 26 (10 mol%) and further Hünig’s base were added and the 
reaction mixture stirred for 1 hour before quenching with 1M hydrochloric acid. A 
number of N-tosyloxaziridines were screened including the o-chlorophenyl example 
Ye favoured for his chemistry (Table 4.1).24,28 
 
Entry Compound Ar β-Lactam
a 
(%) 
Imine 
(%)a 
Yield 
(%)b 
dr 
(anti:syn)c 
ee  
(%, anti/syn)d 
1 214 Phenyl 5 13 60 69:31 >99/>99 
2 216 o-Chloro 
phenyl 
9 13 20 74:26 96/>99 
3 217 p-Bromo 
phenyl 
0 48 21 78:12 94/>99 
4 218 2-
Naphthyl 
0 6 0 N/A N/A 
a Percentage of material relative to product from inspection of 1H NMR spectrum of crude. b As a 
mixture of diastereomers including imine contaminent. c Determined by inspection of 1H NMR 
spectrum of crude. d Obtained by chiral HPLC analysis 
Table 4.1: Variation of Oxaziridine 
The results varied considerably in the amounts of imine and β-lactam present. This 
was unsurprising as it has been reported that small structural changes in the 
oxaziridine can affect their reactivity vastly and, in the case of a more reactive 
oxaziridine, this could lead to an increase in any background reaction.5  
Use of o-chlorophenyl oxaziridine 219 (entry 2) allowed us to directly compare the 1H 
NMR spectrum of our product with that of Ye’s. Evaluation of the chemical shift of 
the C(2) proton of Ye’s product 216 showed their major syn-oxazolidin-4-one to be at 
5.34 ppm and their minor anti-oxazolidinone to be at 5.38 ppm (Figure 4.1). The 
signal for our major diastereoisomer was at 5.38 ppm further confirming its 
assignment as the anti product. 
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Figure 4.1: Assignment of Diastereoisomers via Chemical Shift 
p-Bromophenyl oxaziridine 220 (entry 3) showed low conversion to the desired 
oxazolidin-4-one product with 48% of the undesired imine instead being formed, 
whereas, the 2-naphthyl substituted oxaziridine 221 (entry 4) had very limited 
solubility in dichloromethane and no desired product was observed, with only a small 
amount of imine and starting material observed in the 1H NMR spectrum of the crude 
material. This reaction was repeated in tetrahydrofuran in which the oxaziridine 
dissolved  fully, however the results of the reaction were again disappointing with 
only degradation of the oxaziridine observed. 
As none of the alternative oxaziridines gave any improvement in the outcome of the 
reaction, further investigations were undertaken to optimise the reaction for the 
synthesis of the desired oxazolidinone products. 
4.3.2.2 Lowering of Catalyst Loading 
It was postulated that the catalyst 26 could be oxidised by the oxaziridine in a side 
reaction and that lowering the catalyst loading would lead to less imine side-product. 
A brief catalyst loading investigation was carried out in order to hopefully minimise 
imine formation and make the reaction more economical (Table 4.2). 
Interestingly, at lower catalyst loadings the dr was seen to increase, although this also 
increased the levels of imine observed. When using 2 mol% of isothiourea catalyst 
(entry 3), 28% of β-lactam side-product was present in the crude reaction mixture. 
When using 1 mol% of catalyst (entry 4) there was no conversion into product with 
only degradation of the oxaziridine into imine observed. This implies that the catalyst 
is not involved in the pathway for imine formation and in fact higher levels of catalyst 
allows oxazolidinone formation to be competitive with imine formation. 
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Entry mol % Iminea (%) Yield (%)b dr (anti:syn)c ee (%, anti/syn)d 
1 10 13 60 69:31 >99/>99 
2 5 16 62 73:27 44/ND 
3 2 50 ND 83:17 ND 
4 1 68 ND ND ND 
a Percentage of material relative to product from inspection of 1H NMR spectrum of crude. b As a 
mixture of diastereomers. c Determined by inspection of 1H NMR spectrum of crude. d Obtained by 
chiral HPLC analysis 
Table 4.2: Catalyst Loading Screen 
At 5 mol% catalyst loading (entry 2), similar levels of imine and product were seen as 
at 10 mol% (entry 1) however there was a small amount of imine left in the purified 
sample.  Disappointingly the ee decreased dramatically from >99% to 44% upon 
decreased catalyst loading and so 10 mol% was therefore kept as the optimum catalyst 
loading. 
4.3.2.3 Attempted Removal of Imine 
Alternative purification techniques to column chromatography for removal of the 
unwanted imine side-product were investigated. A reductive work up with sodium 
borohydride, which would convert the imine into an amine and hopefully allow easier 
purification proved unsuccessful in practise as it also caused degradation of the 
oxazolidin-4-one product. 
Trituration of the product following column chromatography yielded only the major 
diastereoisomer, but in low yields and so was again discounted. 
Further lowering of the temperature of the reaction to −100 ˚C with a dry ice/Et2O 
bath in an attempt to stop the side reaction led to very low conversion into the desired 
product (24%, dr 80:20 anti:syn) and a large proportion of imine and aldehyde side 
products (37% and 13% respectively) were obtained.  
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4.3.2.4 Side Reaction Investigations 
At this point, an evaluation of all results collected highlighted that the degradation of 
the oxaziridine starting material was the major problem when developing this 
chemistry as any contamination of the crude product with greater than 5% of imine 
resulted in the inability to successfully purify the product. In addition, if the imine 
was formed in a large proportion prior to oxidation of the enolate, competitive β-
lactam formation ensued and this had a detrimental effect on the yield of the desired 
product. Additionally, the presence of imine and formation of β-lactam led us to 
propose that the imine was being formed independently of the desired reaction. 
In order to investigate imine formation, we considered possible pathways for its 
formation through analysis of combinations of the reaction components. A 1H NMR 
sample of Hünig’s base in deuterated dichloromethane was treated with oxaziridine 
211 and the sample re-analysed by 1H NMR spectroscopy. The results show 
formation of the N-oxide of the base in less than one hour at room temperature, along 
with formation of imine 215 (Figure 4.2).31 Evaluation of the literature highlighted the 
ability for oxaziridines to act as strong oxidising agents not just for enolates7 but also 
amines into amine oxides.3 That the base was so readily oxidised was a major 
breakthrough in understanding the reaction process and showed we needed to re-
evaluate our reaction conditions. 
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Figure 4.2: Oxidation of Hünig’s Base by the Oxaziridine 211 
In addition, our use of a potentially oxidisable isothiourea catalyst allows another path 
to imine formation to be proposed – through catalyst oxidation by the oxaziridine 
acceptor. A similar 1H NMR experiment to that with Hünig’s base was carried out 
with the isothiourea catalyst (2S,3R)-HBTM-2.1 26 (Scheme 4.19). After one hour, 
one equivalent of oxaziridine 211 and one equivalent of catalyst showed no change. 
However, over an extended period (>18 hours) the appearance of imine and a shift of 
the isothiourea’s chemical shifts indicated that oxidation had occurred although the 
product was not isolated. This evidence along with the high levels of 
enantioselectivity observed in [3+2]-cycloaddition indicates that this pathway would 
not be highly competitive and we therefore dismissed this as a route to imine 
formation in our reaction timescale. 
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Scheme 4.19: Oxidation of (2S,3R)-HBTM-2.1 26 by the Oxaziridine 
Following these investigations, a second base screen was carried out with 2,6-lutidine 
and cesium carbonate being used in CH2Cl2 at −78 ˚C. With 2,6-lutidine we hoped the 
N-oxide would be less readily formed and although initial results seemed promising 
with no imine present in samples taken after one hour, after 2.5 hours 8% of imine 
was present (Scheme 4.20a). Full conversion of the oxaziridine was not achieved even 
when left overnight and an exceptionally high level of imine was observed (46%). 
Although cesium carbonate had initially been dismissed due to poor levels of 
solubility in THF at low temperatures, it had not yet been evaluated in 
dichloromethane at −78 ˚C. This reaction was seen to proceed with good conversion 
over one hour (71%) however around 10% of imine was also present. After 2.5 hours 
there was little change (Scheme 4.20b) and after leaving overnight, multiple products 
were observed. 
 
Scheme 4.20: 2,6-Lutidine and Caesium Carbonate Base Screen 
These results were disappointing and indicated there must be a further route to imine 
formation that had yet to be investigated. As oxaziridines have been shown to oxidise 
chloride ions into chlorine,10 the use of pivaloyl chloride as an activating agent in this 
process was questioned, as following activation, chloride ions would be formed and 
need a quenching pathway. This seemed to be an obvious route for competitive 
reaction of the oxaziridine and formation of imine that we wished to avoid. We 
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therefore chose to examine the use of homoanhydrides in this reaction, which as 
shown in previous work in the group, can also be used as ammonium enolate 
precursors whilst removing the need for the preactivation step (Scheme 4.21).32 
The use of homoanhydrides proved very effective and we were able to minimise the 
presence of β-lactam and imine completely. Using 1.5 equivalents of the 
homoanhydride 134 under the previous conditions in dichloromethane with cesium 
carbonate as the base gave the product 214 in poor dr (57:43, anti:syn) but excellent 
yield and ee. These were used as the optimum conditions for further investigations 
into the scope of the reaction.  
 
Scheme 4.21: Homoanhydride 134 as Starting Material for Oxazolidin-4-one 214 Formation 
4.3.3 Investigation into the Scope of the Reaction 
4.3.3.1 Variation of the Oxaziridine 
With the optimum conditions in hand, the scope of the reaction was investigated by 
first varying the oxaziridine component. As before, the aromatic group was varied, 
and also the N-protecting group was changed to a nosyl group to give a small number 
of examples (Table 4.3).  
In all cases the yield was high (73-83%) but the dr was poor. The ees of both product 
diastereoisomers were good, although a lot of variation was seen between examples. 
Surprisingly, in the case of the o-chlorophenyl oxaziridine 219 (Entry 2), the ee was 
seen to be much reduced whereas the reaction directly from the acid had showed high 
levels of enantiocontrol. As this process should go through the same postulated 
intermediate, the change in ee is likely to be due to an enhanced racemic background 
reaction when reacting from a pre-formed homoanhydride. 
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Entry Compound Ar P Yield (%) 
dr 
(anti:syn)c 
ee 
(%, anti/syn)d 
1 214 Phenyl Ts 83a 57:43 97/97 
2 215 o-Chlorophenyl Ts 78b 55:45 78/79 
3 216 p-Bromophenyl Ts 82b 55:45 81/90 
4 222 Phenyl Ns 73b 59:41 85/80 
a As a mixture of diastereomers. b Combined yield of partially separable diastereomers. c Determined by 
inspection of 1H NMR spectrum of crude. d Obtained by chiral HPLC analysis 
Table 4.3: Variation of the Oxaziridine 
4.3.3.2 Variation of the Anhydride  
Investigation of the scope of this chemistry continued with variation of the anhydride 
component. A range of homoanhydrides were synthesised and used in the optimum 
reaction conditions (Table 4.4). In most cases the results are consistent, with products 
formed in excellent yields, low diastereomeric ratios but excellent ees.  
In the case of 2-naphthylanhydride 223 (entry 4) the yield was significantly lower 
than  other examples, however this was owing to isolation issues and not low reaction 
conversion. Ortho-substituents were well tolerated with o-tolylacetic anhydride 224 
giving the product in excellent yields, with both diastereoisomers formed in >99% ee 
(entry 5). The 3-thiopheneacetic anhydride 225 (entry 8) was tolerated with the 
product being isolated in excellent yield, however the ees of both diastereoisomers 
were seen to be 10% lower than other examples. This is consistent with previous 
examples of isothiourea generated ammonium enolate chemistry from 3-
thiopheneacetic acid derivatives (see previous chapters) and is thought to be owing to 
disruption of the favourable interaction between the oxygen non-bonding orbital and 
the C-S σ* orbital, or electrostatic interaction, within the catalyst ammonium enolate.  
Pleasingly, an alkenyl example provided product 234 in excellent yield and ee (entry 
9), however p-trifluorophenylacetic anhydride 226 (entry 10) gave a low ee of only 
43% for the anti-diastereoisomer. It is proposed that this highly activated anhydride 
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undergoes a rapid racemic background reaction that is in competition with the 
isothiourea catalysed pathway, hence giving a good yield of the product but with 
reduced ee. 
 
Entry Compound R Yield (%) 
dr 
(anti:syn)c 
ee 
(%, anti/syn)d 
1 214 Phenyl 83a 57:43 97/97 
2 227 p-Fluorophenyl 73a 54:46 99/>99 
3 228 p-Methoxyphenyl 89a 55:45 97/94 
4 229 2-Naphthyl 48a 53:47 93/90 
5 230 o-Tolyl 96b 53:47 >99/>99 
6 231 m-Tolyl 79b 51:49 92/94 
7 232 p-Tolyl 88a 53:47 97/>99 
8 233 3-Thiophene 79b 59:41 87/81 
9 234  63
b 54:46 97/97 
10 235 
p-
Trifluoromethylphenyl 
68a 49:51 43/36 
a As a mixture of diastereomers. b Combined yield of partially separable diastereomers. c Determined by 
inspection of 1H NMR spectrum of crude. d Obtained by chiral HPLC analysis 
Table 4.4: Variation of the Anhydride 
4.3.4 Scale Up 
To further show the utility of this reaction, two examples were carried out in 
increased scale (Scheme 4.22) in an attempt to access gram quantities of the product. 
Using phenylacetic anhydride on 3 mmol scale, the yield of product 214 decreased 
considerably, although there was not much change in the diastereo- or 
enantioselectivity of the reaction (Scheme 4.22a). The low yield was attributed to the 
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fact that the reaction did not reach full conversion in the reaction time (after 16 hours 
the conversion was only 72%) and therefore future reactions on a large scale would be 
left for an extended reaction time. With the alkenyl anhydride 236 (6.5 mmol), the 
reaction was carried out using a cryostat allowing the reaction temperature to be 
maintained at –78 ˚C for 24 hours upon which time the reaction was complete by TLC 
(Scheme 4.22b). The oxazolidin-4-one product 234 was isolated in excellent ee with 
comparable yield to the smaller scale example, although the dr was slightly worse. 
 
Scheme 4.22: Large Scale Synthesis of Oxazolidin-4-ones 214 and 234 
In total, twelve oxazolidin-4-one examples were synthesised, many of which were 
novel compounds. The reaction exhibits a wide level of scope tolerated within both 
the oxaziridine and acetic anhydride substituents, including electron-donating and 
withdrawing groups, steric bulk around the aromatic ring, heterocyclic, and alkenyl 
examples. 
4.3.5 Derivatisation of Products 
With the scope of the reaction having been thoroughly investigated, our attention 
turned to derivatisation of the oxazolidin-4-one products in order to demonstrate the 
utility of the reaction in organic synthesis. 
Firstly, reduction of oxazolidin-4-one 214 (dr 71:29 anti:syn) with LiAlH4 in order to 
access diol 237 (Scheme 4.23) was investigated. Pleasingly, the diol was formed and 
isolated in 35% yield and maintained high levels of enantioenrichment (90% ee) – 
indicating that the C(5) stereochemistry is the same in both diastereoisomers. 
Although the ee was slightly lower than that expected, this did allow us to assign the 
absolute configuration of our products via comparison of the [α]D to literature values 
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([α]D –50, c 0.1; literature of (R) diol –38, c 1).24 Therefore, the configuration of the 
major anti-diastereoisomer of our oxazolidin-4-one is (2R,5R) and the minor syn-
diastereoisomer is (2S,5R). 
 
 
Scheme 4.23: Reduction of Oxazolidin-4-one to Enantioenriched Diol and Assingment of 
Stereochemistry 
The reduction was repeated using 234 as the starting material to investigate whether it 
was a general process (Scheme 4.24). Again a small decrease in ee was observed, 
however with the pendant alkene still intact, this interesting diol 238 could allow a 
pathway into many other synthetically interesting products in hopefully high 
stereoselectivities. 
 
Scheme 4.24: Reduction of Oxazolidin-4-one 234 
A second derivatisation of interest was the removal of the N-protecting group. As 
seen in our previous work on β-lactams, samarium iodide allows mild removal of N-
tosyl groups without degradation of the starting material or product. In this case, it 
was again found to be the most reliable method after first having no success with 
either sodium/naphthalene,33 magnesium/titanium isopropoxide,34 or TBAF methods.35 
The product 239 was isolated in good yield though only the anti diastereoisomer 
could be obtained, and with some small loss in ee observed (Scheme 4.25). 
 
Scheme 4.25: Samarium Iodide Removal of N-Tosyl Group 
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4.3.6 Stereoselectivity Investigations 
In order to investigate the variations seen in diastereoselectivity between reactions 
with the in situ activated acid and the pre-activated homoanhydride, a study into the 
matched/mismatched effect between the chiral ammonium enolate and the two 
enantiomers of the racemic oxaziridine was undertaken. It was therefore necessary to 
synthesise an enantioenriched oxaziridine. This was accomplished using the method 
reported by Jørgensen in 2011 using the commercially available hydroquinidine 240, 
which had been shown during their optimisation to give good levels of 
stereoinduction.36 Oxidation of the imine 215 by m-CPBA in the presence of 240 gave 
the (R)-oxaziridine 211 in moderate yields and 70% ee (Scheme 4.26). 
 
Scheme 4.26: Synthesis of Enantioenriched Oxaziridine (R)-211 
Initial studies, under the standard conditions, used homoanhydride 134 with the 
enantioenriched oxaziridine (R)-211 in the presence of (2S,3R)-HBTM-2.1 26 
(Scheme 4.27). After two hours the reaction was quenched to show the level of 
stereoinduction. At 34% conversion (by 1H NMR spectroscopy) the ee determined by 
chiral HPLC remained high at >99%, however, interestingly the dr was now excellent 
at >95:5. The high dr suggests that the reaction mechanism occurs without scrambling 
of the oxaziridine configuration at the carbon stereocentre and that this was a matched 
case with the ammonium enolate reacting preferentially with the major enantiomer of 
the oxaziridine. This was further supported by the ee of the recovered oxaziridine 
being lower (52%) than the starting ee (70%). 
 
Scheme 4.27: Reaction of Homoanhydride with Enantioenriched Oxaziridine in Presence of 
Enantiomerically Pure Catalyst 
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In the mis-matched case with the opposite enantiomer of the catalyst, (2R,3S)-HBTM-
2.1 26, the opposite major enantiomer of each diastereoisomer was formed as dictated 
by catalyst stereochemistry. The reaction dr was observed to swing slightly in favour 
of the syn-diastereoisomer and the ees observed were lower (Scheme 4.28). The drop 
in ee from >99% to 87-89% could be explained by this catalytic pathway being less 
favoured and therefore a competitive racemic background reaction is possible. The ee 
of recovered oxaziridine increases which supports the hypothesis that the minor 
enantiomer of the oxaziridine is reacting preferentially in this case. 
 
Scheme 4.28: Reaction of Homoanhydride with Enantioenriched Oxaziridine in Presence of 
Enantiomerically Pure Catalyst in a Mis-matched Case 
A reaction was then carried out using the enantioenriched oxaziridine (R)-211 and the 
achiral isothiourea DHPB 101 to investigate the level of substrate control on the 
reaction (Scheme 4.29). In this case, product 214 was formed in a moderate ee (78 %) 
under substrate control. As the product ee effectively matches that of the starting 
oxaziridine, this supports that the C(2) stereogenic centre is maintained from the 
oxaziridine without scrambling of the stereochemistry. Through chiral HPLC 
analysis, we can identify that the major enantiomer of the syn diastereoisomer is 
(2R,5S), the opposite to that usually observed. This supports that the C(5) stereogenic 
centre is formed under catalyst control – and in this case there is no control from the 
achiral isothiourea forming a mixture of diastereoisomers at this position.  
Scheme 4.29: Reaction of Homoanhydride with Enantioenriched Oxaziridine in Presence of 
Achiral Catalyst  
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complete conversion there would be subsequent reaction of the “mis-matched” case. 
This would explain the near 1:1 dr observed as each enantiomer of the oxaziridine 
would eventually react completely.  
To investigate these hypotheses, reactions were carried out where samples were taken 
at intervals in an attempt to observe any change in dr or ee. In the first experiment, 
benzoic anhydride 134 was reacted with racemic oxaziridine using (2S,3R)-HBTM-
2.1 26 and the dr was monitored by 1H NMR spectroscopy over time (Table 4.5). It 
was expected that the dr would start high, as in the 50:50 mix of the two enantiomers 
of the oxaziridine the ammonium enolate would react preferentially with its matched 
partner before this effect was overcome by the presence of a higher relative 
concentration of the “mis-matched” enantiomer. This product distribution was 
observed, with high dr at the start of the reaction (<1 min dr: 70:30) and lower dr at 
the end of the reaction (at completion the dr was 53:47). The ee of the anti 
diasteroisomer was high throughout showing that the oxaziridine had little effect on 
the ee and this was under catalyst control. Purification by preparative tlc allowed 
determination of the ee in some cases and as expected, a small resolution of the 
oxaziridine 211 was seen over the course of the reaction with isolated samples having 
an ee of 10%. 
  
Chapter 4: Isothiourea Catalysed Formal [3+2]-Cycloaddition Towards Oxazolidin-4-ones 
106 
 
Entry Time Conversion (%)a dr (anti:syn)a 
214 ee  
(%, anti/syn) b 211 ee (%)
b 
1 <1 min 15 70:30 ND ND 
2 5 min 15 72:28 ND ND 
3 15 min 27 68:32 >99/ND 10 
4 30 min 32 66:34 ND ND 
5 1 hour 27 68:32 >99/>99 10 
6 2 hours 33 68:32 ND ND 
7 4 hours 74 57:43 >99/>99 ND 
8 16 hours 100 53:47 >99/>99 N/A 
a Determined by inspection of 1H NMR spectrum of crude. b Obtained by chiral HPLC analysis 
following preparative tlc. 
Table 4.5: Monitoring of Diastereoselectivity and Enantioselectivity Over Time 
In a second reaction, the homoanhydride 134 was reacted again with the 
enantioenriched oxaziridine, although this time the reaction was allowed to proceed to 
completion (Scheme 4.30). It was expected that at completion, the dr would match the 
er of the starting oxaziridine; this was found to be the case with the dr of the reaction 
being 85:15 corresponding to an er of 85:15 (70% ee) of oxaziridine 211. 
 
Scheme 4.30: Repeat of Matched Case with Reaction Completed 
In the case of the reaction directly from the carboxylic acid, an improved dr is 
observed. From the mechanistic information gathered thus far, it is proposed that this 
could be due to two possible side reactions. Firstly, the matched case reacting at a 
relatively higher rate and in turn, competitive oxidation of the base and chloride ions 
is being carried out preferentially with the slower reacting enantiomer of the 
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oxaziridine (owing to an increase in its relative concentration), or secondly because of 
low conversion of the reaction.  
4.3.7 Proposed Reaction Mechanism and Stereochemical Rationale 
The proposed mechanism of the reaction proceeds via the N-acylation of the catalyst 
by the homoanhydride and deprotonation to give the ammonium enolate 241, which 
has been previously discussed (Scheme 4.31). The stabilising S-O 
interaction/electrostatic interaction previously described again locks the enolate 
conformation and oxidation can only occur on the Re face. Ye and co-workers36 then 
propose oxidation by oxaziridine 211 to form an epoxide and imine, although we 
prefer an α-oxidation to give intermediate 242 followed by lactamisation to form the 
oxazoldin-4-one product 214 and regenerate the catalyst. 
 
Scheme 4.31: Proposed General Mechanism for Oxazolidin-4-one Formation 
The reaction mechanism shows the stereochemistry at the C(5) position of the 
oxazolidin-4-one is set by the facial selectivity due to the isothiourea catalyst’s 
substituents. This accounts for the high enantioselectivities observed. When using an 
enantioenriched oxaziridine, substrate control can come into play at the C(2) 
stereocentre. Assuming the configuration is maintained in intermediate 242 following 
oxidation, lactamisation would occur to give just one diastereoisomer. However, 
under our standard reaction conditions, the racemic oxaziridine allows no control of 
N
N
SPh
N
N
SPh
Ph
O
O
Ph
O
N
O
Ts
Ph
Cs2CO3
O
NTs
O
Ph Ph
N-Acylation
26
Ammonium Enolate
241
Lactamisation
O
Ph
N
N
SPh
O
Ph
N
N
SPh
O
Ph
O
Ph
HN
242
H
H Acyl Ammonium
134
214
211
Chapter 4: Isothiourea Catalysed Formal [3+2]-Cycloaddition Towards Oxazolidin-4-ones 
108 
the C(2) centre which accounts for the near 50:50 dr observed in all cases, at high 
conversion. 
4.3.8 Conclusions 
This chapter has discussed the development of a highly enantioselective route to 
oxazolidin-4-ones with excellent yields though low drs, which in turn, gives access to 
synthetically useful diols in ee. This work further expands the chemistry of 
oxaziridines, which are convenient, bench-stable and neutral sources of electrophilic 
oxygen5 and our own work on the uses of isothiourea generated chiral ammonium 
enolates. Further work in this area would focus on improvement of the 
diastereoselectivity of the reaction. It was postulated that this could be achieved by 
the use of enantiopure oxaziridine starting materials, as shown by the positive results 
in test reactions using an oxaziridine of high enantioselectivity and this work has now 
been carried out by another group member, Charlene Fallan, with great success 
(Scheme 4.32). This work could ultimately allow access to both enantiomers of the 
diol products when using the correct combinations of catalyst and oxaziridine, taking 
advantage of matched effects. 
 
Scheme 4.32: Potential Use of Enantiopure Oxaziridine (R)-211 to Form Products in High 
Diastereo- and Enantiocontrol 
Alternatively, the use of an excess of oxaziridine with modest ee could be 
investigated. At completion, with the catalyst only selecting for its matched pair, 
would return the product in excellent yields, dr and ee. Another possibility would be 
to investigate the use of excess racemic oxaziridine; in this case the matched effect 
may be strong enough to allow high levels of diastereoselectivity of the oxazolidin-4-
one product (Scheme 4.33). 
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Scheme 4.33: Use of Excess Racemic Oxaziridine to Force High Levels of Diastereoselectivity 
Further investigation of other N-oxaziridines could also allow access to other products 
as oxaziridines have high sensitivity to the steric and electronic properties of their 
substituents, which can allow different chemoselectivities.5 For example, N-
unsubstituted or N-acyl substituted oxaziridines have been found to have extensive 
use as electrophilic sources of nitrogen and so may allow us access to enantioenriched 
α-aminated products (Scheme 4.34).  
  
Scheme 4.34: Use of Alternative Oxaziridines for Different Substitution Patterns 
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Chapter 5: Conclusions 
This thesis has documented expansion of the use of isothiourea and carboxylic acid 
generated Type I ammonium enolates in asymmetric synthesis. Further to published 
methodologies from the Smith group on their use in intermolecular formal [4+2]-
cycloaddition reactions, this work has been expanded to include [2+2]- and [3+2]-
cycloadditions. 
Firstly, asymmetric formal [2+2]-cycloaddition of isothiourea generated Type I 
ammonium enolates and N-sulfonylimines was reported. This methodology allows 
successful access to highly stereodefined β-lactams and β-aminoesters, either from 
preformed homoanhydrides or directly from carboxylic acids respectively. The protocol 
is carried out using open flask conditions, from simple, bench-stable starting materials 
and is also scalable. A variety of anti-β-lactams and β-aminoesters were accessed in 
moderate yield, excellent diastereo- and good enantioselectivity (Scheme 5.1). 
Recrystallisation can allow improvement of the enantioselectivity to excellent levels and 
represents an improved route to anti-β-lactams over the previous ketene and N-triflyl 
imine based methods reported. 
 
Scheme 5.1: Summary of β-Lactam and β-Aminoester Synthesis 
Subsequent studies focussed on the use of ester surrogates in the formal [4+2]-
cycloaddition reactions of isothiourea generated Type I ammonium enolates to gain 
access to diester products which were previously unobtainable using this methodology. 
The use of iso-propylphosphonate 163 in this chemistry proved highly effective in this 
process, following in situ ring-opening of the initial dihydropyranone product isolation 
of the desired diester products was achieved in moderate to excellent yields and with 
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excellent diastereo- and enantiocontrol (Scheme 5.2). Furthermore, selective reduction 
and acid-catalysed cyclisation allowed access to δ-lactone products in good yield with 
retention of stereocontrol. This process is also amenable to large scale and further work 
in this area has also shown the use of α,β-unsaturated trichloroketones in the synthesis 
of identical diester products.  
 
Scheme 5.2: Summary of Work on α-Ketophosphonates as Ester Surrogates 
Finally, it was shown that isothiourea-catalysed formal [3+2]-cycloadditions of 
oxaziridines and acetic anhydrides gave access to five-membered oxazolidin-4-one 
heterocycles. In this case, the use of preformed homoanhydrides and an inorganic base 
was imperative to avoid reduction of the oxaziridine starting material. The oxazolidin-4-
one products could be accessed in excellent yield and ee however poor dr (Scheme 5.3). 
Investigations using an enantioenriched oxaziridine with two opposite enantiomers of 
the isothiourea catalyst, into the “matched” and “mis-matched” cases allowed insight 
into the mechanistic influence of the oxaziridine. This indicated that use of a racemic 
oxaziridine accounted for the poor diastereoselectivity of the reaction and further work 
has revealed that when using an enantioenriched oxaziridine in a “matched” case, the 
diastereoselectivity is much improved (93:7 from an oxaziridine of 94% ee). Synthesis 
of the oxazolidin-4-one products was amenable to a large scale and following isolation, 
reduction allowed access to enantioenriched diols with little loss in stereocontrol.  
 
Scheme 5.3: Formal [3+2]-Cycloaddition Reaction Using Oxaziridine Starting Material 
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Prior to the beginning of this thesis, although carboxylic acid starting materials had been 
shown to be useful ammonium enolate precursors by Romo and co-workers, and 
isothioureas had been used in the catalytic generation of ammonium enolates by the 
Smith group, however the scope of these reactions were limited to mainly [4+2]-
cycloaddition processes. The work described within this thesis adds to the existing 
research within the ammonium enolate literature with the development of inter-
molecular [2+2]- and [3+2]-cycloaddition reactions. The use of isothioureas in this work 
has further shown their use as nucleophilic Lewis base organocatalysts for the generation 
Type I ammonium enolates capable of transferring excellent levels of stereocontrol. 
Further research is currently underway within the Smith group to investigate the 
potential for these ammonium enolates in a range of organocatalytic processes. 
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Chapter 6: Experimental 
6.1 General Information 
Reactions involving moisture sensitive reagents were carried out under an argon 
atmosphere using standard vacuum line techniques in addition to dry solvents. All 
glassware used was flame dried and cooled under vacuum. 
For moisture sensitive reactions, solvents (THF, CH2Cl2, toluene, hexane and Et2O) 
were obtained anhydrous and purified by an alumina column (Mbraun SPS-800). 
Petrol is defined as petroleum ether 40-60 °C. All other solvents and commercial 
reagents were used as supplied without further purification unless stated otherwise. 
Room temperature (rt) refers to 20-25 °C. Temperatures of 0 °C and −78 °C were 
obtained using ice/water and CO2(s)/acetone baths respectively. Temperatures of 0 °C 
to −50 °C for overnight reactions were obtained using an immersion cooler (HAAKE 
EK 90). Reflux conditions were obtained using an oil bath equipped with a contact 
thermometer. In vacuo refers to the use of a Büchi Rotavapor R-2000 rotary 
evaporator with a Vacubrand CVC2 vacuum controller or a Heidolph Laborota 4001 
rotary evaporator with a vacuum controller.  
Analytical thin layer chromatography was performed on pre-coated aluminium plates 
(Kieselgel 60 F254 silica). TLC visualisation was carried out with ultraviolet light (254 
nm), followed by staining with a 1% aqueous KMnO4 solution. Flash column 
chromatography was performed on Kieselgel 60 silica in the solvent system stated. 
1H, 13C and 19F nuclear magnetic resonance (NMR) spectra were acquired on either a 
Bruker Avance 300 (300 MHz, 1H, 75 MHz 13C{1H}, 282 MHz 19F{1H}), Bruker 
Avance II 400 (400 MHz, 1H, 100 MHz 13C{1H}, 376 MHz 19F{1H}) or a Bruker 
Avance II 400 (500 MHz, 1H, 125 MHz 13C{1H}, 470 MHz 19F{1H}) spectrometer at 
ambient temperature in the deuterated solvent stated. All chemical shifts are quoted in 
parts per million (ppm) relative to the residual solvent as the internal standard. All 
coupling constants, J, are quoted in Hz. Multiplicities are indicated by: s (singlet), d 
(doublet), t (triplet), q (quartet), sept (septet), ABq (AB quartet), sept (septet), oct 
(octet), m (multiplet), dd (doublet of doublets), ddd (doublet of doublet of doublets, dt 
(doublet of triplets), dq (doublet of quartets) and td (triplet of doublets). The 
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abbreviation Ar is used to denote aromatic, Ph to denote phenyl, Bn to denote benzyl, 
br to denote broad and app to denote apparent. NMR peak assignments were 
confirmed using 2D 1H correlated spectroscopy (COSY), 2D 1H nuclear Overhauser 
effect spectroscopy (NOESY), 2D 1H−13C heteronuclear multiple-bond correlation 
spectroscopy (HMBC), and 2D 1H−13C heteronuclear single quantum coherence 
(HSQC) where necessary. 
Infrared spectra (νmax/cm-1) were recorded on either a Perkin-Elmer Spectrum GX FT-
IR spectrometer using either thin films on NaCl plates or KBr discs or a Shimadzu 
IRAffinity-1 using a Pike attenuated total reflectance (ATR) accessory. Only the 
characteristic peaks are quoted.  
Melting points were recorded on an Electrothermal 9100 melting point apparatus and 
are uncorrected. Dec refers to decomposition. 
HPLC analyses were obtained on two separate machines; a Gilson HPLC consisting 
of a Gilson 305 pump, Gilson 306 pump, Gilson 811C dynamic mixer, Gilson 805 
manometric module, Gilson 401C dilutor, Gilson 213XL sample injector and sample 
detection was performed with a Gilson 118 UV/vis detector while the temperature 
was assumed to be 23 °C; a Shimadzu HPLC consisting of a DGU-20A5 degasser, 
LC-20AT liquid chromatograph, SIL-20AHT autosampler, CMB-20A 
communications bus module, SPD-M20A diode array detector and a CTO-20A 
column oven which allowed the temperature to be set from 25-40 °C. Separation was 
achieved using DAICEL CHIRALCEL OD-H and OJ-H columns or DAICEL 
CHIRALPAK AD-H, AS-H, IA, IB, IC and ID columns. All chiral HPLC traces were 
compared to the authentic racemic spectrum prepared in analogous fashion. 
Mass spectrometry (m/z) data were acquired by electrospray ionisation (ESI), 
chemical ionisation (CI), electron impact (EI), atmospheric solids analysis probe 
(ASAP), atmospheric pressure chemical ionization (APCI) or nanospray ionisation 
(NSI) either at the University of St Andrews or the EPSRC National Mass 
Spectrometry Service Centre, Swansea. At the University of St Andrews, low and 
high resolution ESI MS were carried out on a Micromass LCT spectrometer. At the 
EPSRC National Mass Spectrometry Service Centre, low resolution NSI MS was 
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carried out on a Micromass Quattro II spectrometer and high resolution NSI MS on a 
Thermofisher LTQ Orbitrap XL spectrometer. 
Optical rotations were measured on a Perkin Elmer Precisely/Model-341 polarimeter 
operating at the sodium D line with a 100 mm path cell at rt. 
6.2 Experimental for Chapter 2  
6.2.1 Isothiourea Catalysts 
 
DHPB 101, (2R,3S)-HBTM-2.1 26 and (±)-HBTM-2.1 26 were made within the 
group according to literature procedures.1,2 (–)-Tetramisole.HCl 22 is commercially 
available 
 
6.2.1.1 Synthesis of (2S,3R)-HBTM-2.1 26 
26 was prepared using the procedure described by Smith et al. as described in the 
following section.3  
t-Butyl benzylidenecarbamate 243 
 
t-Butyl(phenyl(phenylsulfonyl)methyl)carbamate (20.0 g, 57.57 mmol) was added to 
a solution of potassium carbonate (47.8 g, 346.0 mmol) and sodium sulfate (60.0 g, 
422.0 mmol) in THF (500 mL). The reaction mixture was refluxed for 15 h before 
allowing to cool to room temperature, filtering and concentrating the filtrate in vacuo 
to afford 243, a yellow oil (9.8 g, 47.7 mmol, 83% yield) with all data was in 
accordance with the literature.3 1H NMR (300 MHz, CDCl3) δH:  1.54 (9H, s, C(CH3)), 
7.53-7.58 (2H, m ArH), 7.61-7.77 (1H, m, ArH), 7.92-7.95 (2H, m, ArH), 8.80 (1H, s, 
CH).  
N
N
SPh
(2S,3R) HBTM 2.1 26
N
N
S
Ph
(R)-Benzotetramisole 23
N
N
S
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N
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t-Butyl (1S,2S)-2-formyl-3-methyl-1-phenylbutylcarbamate 244 
 
t-Butyl (1S,2S)-2-formyl-3-methyl-1-phenylbutylcarbamate 243 (5.0 g, 24.4 mmol) 
was dissolved in acetonitrile (250 mL) and isovaleraldeyhyde (5.23 mL, 49.8 mmol) 
was added. The reaction was cooled to 0 ˚C and (S)-proline (0.56 g, 4.7 mmol) was 
added before stirring for 18 h before addition of distilled water (80 mL). The solution 
was allowed to warm to room temperature whilst stirring vigorously before adding 
diethyl ether (100 mL) and extracting the aqueous layer (3 × Et2O). The organic 
extracts were combined, washed with brine, dried (MgSO4), filtered and concentrated 
in vacuo to give the crude product, which was triturated with hexane to afford 244 as 
a white fluffy solid (5.9 g, 20.3 mmol, 83% yield) with all data was in accordance 
with the literature.3 mp 130-132 ˚C {lit.3 mp 141-142 ˚C}; –54.0 (c 1.0, CHCl3) 
{lit.3 –68.0 (c 1.0, CHCl3)}; 1H NMR (300 MHz, CDCl3) δH:  0.93 (3H, d, J 6.8, 
CH3), 1.05 (3H, d, J 6.9, CH3), 1.33 (9H, s, C(CH3)3), 1.97-2.07, (1H, m, C(3)H), 
2.37-2.44 (1H, m, C(2)H), 4.83-5.09 (2H, m, C(1)H and NH), 7.11-7.26 (5H, m, 
ArH), 9.41 (1H, d, J 4.2, C(O)H).  
 
t-Butyl (1S,2S)-2-(hydroxylmethyl)-3-methyl-1-phenylbutyl carbamate 245 
 
To a solution of 244 (5.40 g, 18.55 mmol) in methanol (160 mL), sodium borohydride 
(1.05 g, 27.83 mmol) was added and the reaction mixture stirred at room temperature 
for 2 h. Saturated aqueous sodium bicarbonate (50 mL) was added and the methanol 
was removed in vacuo. The aqueous layer was extracted with dichloromethane (3× 25 
mL), the organic layers combined, dried (MgSO4) and concentrated in vacuo to give 
245 (4.6 g, 15.9 mmol, 86%), a white solid with all data was in accordance with the 
H
ONH
Boc
244
[!]D20
[!]D20
OH
NH
Boc
244
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literature.3 mp 101-110 ˚C {lit.3 mp 106-108 ˚C}; –25.6 (c 1.0, CHCl3) {lit.3 
–26.7 (c 0.7, CHCl3)}; 1H NMR (300 MHz, CDCl3) δH: 0.85 (3H, d, J 6.9 Hz, 
CH3), 0.99 (3H, d, J 6.8 Hz, CH3), 1.41 (9H, s, C(CH3)3), 1.73 (1H, m, CH(CH3)2), 
1.86 (1H, m, CHi-Pr), 3.50 (1H, m, CHAHBOH), 3.65-3.68 (1H, m, CHAHBOH), 5.00-
5.04 (1H, m, CHNH), 5.47 (1H, br s, NH), 7.27-7.37 (5H, m, ArH).  
 
(1S)-2-((2S)-Amino(phenyl)methyl)-3-methylbutan-1-ol hydrochloride 246 
 
245 (4.6g, 15.9 mmol) was added to a solution of 4 M HCl in dioxane (49.7 mL, 198.8 
mmol) and stirred at room temperature for 4 h. The reaction was concentrated in 
vacuo to give 246 as an off-white solid (3.5 g, 15.4 mmol, 97%) with all data was in 
accordance with the literature.3 mp 185-190 ˚C; {lit.3 mp 168-170 ˚C} –23.8 (c 
1.0, MeOH); {lit.3 –22.9 (c 0.98, MeOH)}; 1H NMR (300 MHz, CDCl3) δH: 0.48 
(3H, d, J 6.8, CH3), 1.13 (3H, d, J 6.8, CH3), 1.18 (1H, app. oct, J 6.8, CH(CH3)2), 
1.61-1.69 (1H, m, CHi-Pr), 3.13 (1H, dd, J 10.4, 9.9, CHAHBOH), 3.40 (1H, dd, J 
10.6, 4.5, CHAHBOH), 4.21 (1H, d, J 4.3, CHNH), 7.09-7.18 (5H, m, ArH).  
 
(3S,4R)-3-iso-Propyl-4-phenyl-3,4-dihydro-2H-pyrimido[2,1-b] benzothiazole 247 
 
A sealed vial was charged with 246 (400 mg, 1.75 mmol), Hunig’s base (1.16 mL, 
6.65 mmol) and purged with nitrogen. The mixture was heated to 135 °C and 2-
chlorobenzothiazole (0.24 mL, 1.84 mmol) was added. The reaction was stirred at 135 
°C for 3 days then allowed to cool to room temperature. The resulting mixture was 
applied directly to a silica column for purification (98:2, dichloromethane:ethanol) to 
[!]D20
[!]D20
OH
NH3 Cl
246
[!]D20
[!]D20
OH
HN S
N
247
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yield 247 as a yellow oil (0.41 g, 1.26 mmol, 73%) with all data was in accordance 
with the literature.3 –52.7 (c 1.0, CHCl3); {lit.3  –54.8 (c 0.5, CHCl3)}; 1H 
NMR (300 MHz, CDCl3) δH: 0.85 (3H, t, J 6.9, CH3), 1.07 (3H, d, J 6.8, CH3), 1.75-
1.84 (1H, m, CH(CH3)2), 2.05-2.10 (1H, m, CHi-Pr), 3.57-3.69 (1H, m, CHAHBOH), 
3.75-3.79 (1H, m, CHAHBOH), 5.02 (1H, m, CHNH), 7.04-7.29 (5H, m, ArH), 7.32-
7.51 (4H, m, ArH).  
 
(3R,4S)-4-Phenyl-3-iso-Propyl-3,4-dihydro-2H-pyrimido[2,1-b] benzothiazole 26 
 
Thionyl chloride (0.48 mL, 6.64 mmol) was added to 247 (1.03 g, 3.16 mmol) in 
toluene (20 mL) and the reaction heated at reflux for 3 h until complete (aliquots 
monitored by 1H NMR). The reaction was cooled and quenched with methanol (20 
mL), concentrated, basified with 10% NaOH solution and extracted with 
dichloromethane (3 × 10 mL). The combined organic layers were washed with brine, 
dried (MgSO4) and concentrated to give 26 as a light brown solid (0.71 g, 2.29 mmol, 
73%) with all data was in accordance with the literature.3 Chiral HPLC analysis, 
Chiralcel AD-H (80:20 Hexane:IPA, flow rate 1.0 mL min-1, 254 nm, rt) tR major 
(2S,3R) 17.6 min, tR minor (2R,3S) 30.7 min, >99% ee; mp 145-151 ˚C, {lit.3 mp 136-
138 ˚C}; +332.4 (c 1.0, CHCl3); {lit.3  +288.4 (c 0.5, CHCl3)}; 1H NMR 
(300 MHz, CDCl3) δH: 0.93 (3H, d, J 6.6, CH3), 1.19 (3H, d, J 5.9, CH3), 1.37-1.45 
(1H, m, CH(CH3)2), 1.56-1.63 (1H, m, CHi-Pr), 2.10-2.19 (1H, m, CHAHB), 3.62-3.71 
(1H, m, CHAHB), 4.24-4.29 (1H, m, CHPh), 7.05-7.21 (4H, m, ArH), 7.32-7.71 (5H, 
m, ArH).  
 
6.2.1.2 Synthesis of (R)-Benzotetramisole 23 
23 was prepared following the procedure by Birman et al. as described in the 
following section.1  
 
[!]D20 [!]D20
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(R)-N-(Thiazolyl-2)-2-hydroxy-1-phenylethylamine 248 
 
2-chlorobenzothiazole (1 mL, 8.08 mmol), (R)-(+)-phenylglycinol (1.11 g, 8.08 
mmol) and i-Pr2NEt (2.11 mL, 12.1 mmol) were added to a sealed tube, flushed with 
nitrogen and heated at 130 °C for 19 h. After cooling, the reaction mixture was 
treated with dichloromethane (5 mL) and left at room temperature to dissolve over 3 
h. The diluted reaction mixture was applied directly to a silica column and purified 
(96:4 CH2Cl2:IPA) to give 248 as an off-white solid (2.15 g, 7.9 mmol, 99 %) with 
all data was in accordance with the literature.1 mp 158-162 ˚C {lit.1 mp 159-160 ˚C}; 
+97.4 (c 1.0, MeOH); {lit.1 +98.7 (c 0.99, MeOH)}; 1H NMR (300 MHz, 
CD3OD) δH: 3.75-3.85 (2H, m), 4.99 (1H, dd, J 7.1, 5.2), 7.02 (1H, t, J 7.1), 7.20-
7.48 (7H, m), 7.56 (1H, d, J 8.1).  
 
(R)-Benzotetramisole 23 
 
248 (5.87 g, 21.71 mmol) was dissolved in anhydrous dichloromethane (200 mL) 
cooled to 0 °C and treated with triethylamine (9.08 mL, 65.13 mmol) and mesyl 
chloride (2.52 mL, 32.57 mmol). The mixture was stirred for 1 h and then warmed to 
room temperature. Methanol (2.5 mL) and then triethylamine (30.3 mL, 217.1 
mmol) was added and the mixture refluxed overnight. The mixture was cooled to 
room temperature, washed with water and dried over Na2SO4 before removing the 
solvent in vacuo. The crude product was purified by silica chromatography (94:5:1 
Hexane:IPA:NEt3) to give a yellow solid which following recrystallization 
(Et2O:hexane) gave 23 as a white solid (3.55 g, 14.1 mmol, 65%) with all data was 
in accordance with the literature.1 mp 91-95 ˚C {lit.1 mp 94.5-95.0 ˚C}; +251.1 
(c 1.0 in CH3OH) {lit.1 +256.7 (c 1.00 in CH3OH)}; 1H NMR (300 MHz, 
N
S
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Ph
248
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CDCl3) δH: 3.72 (1H, dd, J 8.9, 8.2), 4.28 (1H, dd, J 10.1, 8.9), 5.66 (1H, dd, J 10.3, 
8.1), 6.79 (1H, m), 7.00 (1H, m), 7.23 (1H, m), 7.30-7.39 (6H, m).  
 
6.2.2 General Experimental Procedures 
6.2.2.1 General Procedure A: Formation of N-Sulfonyl Imines 
N-Sulfonylimines were prepared according to the procedure described by Proctor in 
1981.4 Boron trifluoride diethyletherate (0.016 equiv.) was added to a refluxing 
solution of the aldehyde (1.0 equiv.) and appropriate sulfonamide (1.0 equiv.) in 
toluene (150 mL) using Dean-Stark apparatus. The mixture was refluxed overnight 
until the theoretical amount of water had been collected. The solution was then cooled 
and washed with 2 M NaOH solution and water. The organic layer was separated, 
dried (MgSO4) and the solvent was removed in vacuo. The resulting solid was 
purified by recrystallization. 
6.2.2.2 General Procedure B: Synthesis of Homoanhydride Starting Materials 
To a solution of the appropriate carboxylic acid (1 equiv.) in toluene (0.3 M), DCC 
(0.50-0.55 equiv.) was added and the solution stirred at room temperature for 15 min. 
The suspension was filtered and concentrated in vacuo to give the crude product, 
which was used without further purification. 
6.2.2.3 General Procedure C: Asymmetric Formal [2+2]-Cycloaddition of 
Arylacetic Acids and N-Sulfonylimines 
To a stirred solution of the appropriate carboxylic acid (1 equiv.) in dichloromethane 
(~1 mL/0.2 mmol) at 0 °C, tosyl chloride (1.5 equiv.) and i-Pr2NEt (1.5 equiv.) were 
added. The solution was stirred at 0 °C for 20 min. The isothiourea catalyst (20 
mol%) and the imine (1 equiv.) were added followed by i-Pr2NEt (1.5 equiv.). The 
solution was then stirred at room temperature for 5 h, quenched using 1M HCl (~1 
mL/0.2 mmol), extracted (3 × EtOAc), the combined organic layers were dried 
(MgSO4) and concentrated in vacuo to give the crude product which was purified by 
column chromatography in the stated conditions to give the β-lactam product. 
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6.2.2.4 General Procedure D: Asymmetric Formal [2+2]-Cycloaddition of 
Arylacetic Acids and N-Sulfonylimines With In Situ Ring Opening 
To a stirred solution of the carboxylic acid (1 equiv.) in dichloromethane (~1 mL/0.2 
mmol) at 0 °C, tosyl chloride (1.5 equiv.) and i-Pr2NEt (1.5 equiv.) were added. The 
solution was stirred at 0 °C for 20 min. The isothiourea catalyst (5 mol%) and the 
imine (1 equiv.) were added followed by i-Pr2NEt (1.5 equiv.) and the solution was 
stirred at room temperature for 5 h. 2.5 M Butyl lithium solution in hexanes (55 
equiv.) was added to methanol (~1 mL/0.2 mmol) at −78°C and this solution was 
added by canula to the reaction mixture. After 1 h, the reaction was quenched using 
water (~1 mL/0.2 mmol), extracted (3 × EtOAc), the combined organic layers were 
dried (MgSO4) and concentrated in vacuo followed by purification by column 
chromatography in the stated conditions to give the β-amino ester product. 
6.2.2.5 General Procedure E: Asymmetric Formal [2+2]-cycloaddition of 
Homoanhydrides and N-sulfonylimines 
To a stirred solution of the imine (1 equiv.) in dichloromethane (~1 mL/0.2 mmol) at 
−78 °C, the isothiourea catalyst (5 mol%) and i-Pr2NEt (1.25 equiv.) were added 
followed by the appropriate anhydride (1.5 equiv.) as a solution in dichloromethane 
(1.2mL/0.3 mmol) dropwise (2.3mL h-1). The solution was then allowed to warm to 
room temperature and stirred for a further 30 min, quenched using 1M HCl (~1 
mL/0.2 mmol), extracted (3 × EtOAc), the combined organic layers were dried 
(MgSO4) and concentrated in vacuo followed by purification by column 
chromatography in the stated conditions to give the β-lactam product. 
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6.2.3 Starting Materials Synthesis 
6.2.3.1 N-sulfonylaldimines 
 
N-sulfonylimines 99, 215 and 249 were all made following literature procedures.4 All 
other sulfonylimines (250-254) were supplied by other members of the group. 
 
N-(4-Bromobenzylidene)-4-methylbenzenesulfonamide 99 
 
 
 
Following General Procedure A, 4-bromobenzaldehyde (9.25 g, 50 mmol) and para-
toluenesulfonamide (8.56 g, 50 mmol) were stirred for 16 h to give the crude product, 
which was recrystallised (THF/hexane) to give the product 99 as a white solid (11.4 g, 
68%) with all data was in accordance with the literature.4 1H NMR (400 MHz, CDCl3) 
δH:  2.49 (3H, s, CH3), 7.34 (2H, d, J 8.2, ArH), 7.68 (2H, d, J 8.1, ArH), 7.76 (2H, d, 
J 8.4, ArH), 7.86 (2H, d, J 8.4, ArH), 8.99 (1H, s, CH).  
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N-Benzylidene-4-methylbenzenesulfonamide 215 
Following General Procedure A, benzaldehyde (5.1 mL, 50 mmol) and para-
toluenesulfonamide (8.56 g, 50 mmol) were stirred for 16 h to give the crude product, 
which was recrystallised (EtOAc/hexane) to give the product 215 as a white solid 
(9.65 g, 74%) with all data was in accordance with the literature.4 1H NMR (400 
MHz, CDCl3) δH: 2.45 (3H, s, CH3), 7.36 (2H, d, J 8.0, ArH), 7.47 (2H, t, J 7.6, ArH), 
7.61 (2H, tt, J 7.4, 2.7, ArH), 7.86-7.97 (4H, m, ArH), 9.02 (1H, s, CH). 
 
N-(4-methoxybenzylidene)-4-methylbenzenesulfonamide 249 
Following General Procedure A, 4-methoxybenzaldehyde (6.1 mL, 50 mmol) and 
para-toluenesulfonamide (8.56 g, 50 mmol) were stirred for 16 h to give the crude 
product, which was recrystallised (THF/hexane) give the product 249 as a white solid 
(11.72 g 81.0%) with all data was in accordance with the literature.4 1H NMR (400 
MHz, CDCl3) δH:  2.42 (3H, s, CH3), 3.84 (3H, s, CH3), 6.95 (2H, d, J 8.6, ArH), 7.30 
(2H, d, J 8.0, ArH), 7.77-7.95 (4H, m, ArH), 8.92 (1H, s, CH).  
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6.2.3.2 Anhydrides 
2-Phenylacetic anhydride 134 
 
Following General Procedure B, phenylacetic acid (0.45 g, 3.33 mmol) and DCC 
(0.35 g, 1.70 mmol) were stirred in toluene (10 mL) to give product 134 as a white 
solid (0.43 g, >99%) with data in accordance to the literature.5 mp 68-70 °C {lit.5 mp 
72-72.5 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.76 (4H, s, 2 CH2), 7.23-7.25 (4H, m, 
ArH), 7.32-7.38 (6H, m, ArH).  
 
2-(4-Methoxyphenyl)acetic anhydride 255  
 
Following General Procedure B, 4-methoxyphenylacetic acid (1.00 g, 6.00 mmol) 
and DCC (0.62 g, 3.00 mmol) were stirred in toluene (25 mL) to give product 255 as 
a white solid (0.94 g, >99%) with data in accordance with the literature.6 mp 46-48 °C 
{Lit.6 60-62 °C}; 1H NMR (300 MHz, CDCl3) δH: 3.66 (4H, s, 2 CH2), 3.80 (6H, s, 2 
CH3), 6.83-6.86 (4H, m, ArH), 7.10-7.13 (4H, m, ArH). 
 
2-(Naphthalen-2-yl)acetic anhydride 223 
 
Following General Procedure B, 2-naphthylacetic acid (1.00 g, 5.40 mmol) and DCC 
(0.56 g, 2.70 mmol) were stirred in toluene (25 mL) to give product 223 as a white 
solid (0.41 g, 43%) with data in accordance with the literature.6 mp 100-104 °C {Lit.6 
104-108 °C}; 1H NMR (300 MHz, CDCl3) δH: 3.88 (4H, s, 2 CH2), 7.27 (2H, d, J 7.4, 
O
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ArH), 7.47-7.51 (4H, m, ArH), 7.63 (2H, s, 2 ArH), 7.70-7.73 (4H, m, ArH), 7.80-
7.83 (2H, m, ArH). 
 
2-(Thiophen-3-yl)acetic anhydride 225 
 
Following General Procedure B, 3-thiopheneacetic acid (0.47 g, 3.33 mmol) and 
DCC (0.35 g, 1.70 mmol) were stirred in toluene (10 mL) to give product 225 as a 
yellow solid (0.44 g, >99%) with data in accordance with the literature.6 mp 36-38 °C 
{Lit.6 40-42 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.79 (4H, s, 2 CH2), 6.99 (2H, dd, J 
5.0, 1.2, ArH), 7.15 (2H, dd, J 2.0, 1.0, ArH), 7.31 (2H, dd, J 5.0, 3.0, ArH). 
 
6.2.4 Optimisation Studies on 100 
 
Isothiourea Catalyst Screen:  
The title compound was prepared according to General Procedure C, from phenyl 
acetic acid (27.2 mg, 0.20 mmol), pivaloyl chloride (37 µL, 0.30 mmol), 2 portions of 
i-Pr2NEt (52 µL, 0.30 mmol) and imine 99 (70.8 mg, 0.20 mmol). All reactions at rt 
for 2 h. 
 
(–)Tetramisole.HCl 22 (9.63 mg, 0.04 mmol, 20 mol%) gave crude 100 (>95:5 dr). 
Chromatographic purification (5:95-90:10 Petrol:EtOAc) gave 100 (>95:5 dr) as a 
white solid (33.6 mg, 37%); 57% ee (ent). 
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(2S,3R)-HBTM-2.1 26 (12.3 mg, 0.04 mmol, 20 mol%) gave crude 100 (>95:5 dr). 
Chromatographic purification (5:95-90:10 Petrol:EtOAc) gave 100 (>95:5 dr) as a 
white solid (80.8 mg, 89%); 57% ee. 
 
(R)-BTM 23 (10.0 mg, 0.04 mmol, 20 mol%) gave crude 100 (>95:5 dr). 
Chromatographic purification (5:95-90:10 Petrol:EtOAc) gave 100 (>95:5 dr) as a 
white solid (80.8 mg, 89%); 57% ee. 
 
Activating Agent Screen: 
The title compound was prepared according to General Procedure C, from phenyl 
acetic acid (27.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of 
i-Pr2NEt (52 µL, 0.30 mmol) and imine 99 (70.8 mg, 0.20 mmol). All reactions at rt  
 
 (2S,3R)-HBTM-2.1 26 (12.3 mg, 0.04 mmol, 20 mol%) for 4.5 h gave crude 100 
(>95:5 dr). Chromatographic purification (5:95-90:10 Petrol:EtOAc) gave 100 (>95:5 
dr) as a white solid (29.1 mg, 32%); 72% ee. 
 
(R)-BTM 23 (10.0 mg, 0.04 mmol, 20 mol%) for 3.5 h gave crude 100 (>95:5 dr). 
Chromatographic purification (5:95-90:10 Petrol:EtOAc) gave 100 (>95:5 dr) as a 
white solid (69.9 mg, 77%); 85% ee. 
 
Solvent and Temperature Screen:  
The title compound was prepared according to General Procedure C, from phenyl 
acetic acid (27.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of 
i-Pr2NEt (52 µL, 0.30 mmol), (R)-BTM 23 (10.0 mg, 0.04 mmol, 20 mol%) and imine 
99 (70.8 mg, 0.20 mmol).  
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Reaction in THF at rt for 2 h gave crude 100 (>95:5 dr). Chromatographic purification 
(5:95-90:10 Petrol:EtOAc) gave 100 (>95:5 dr) as a white solid (51.7 mg, 57%); 59% 
ee. 
 
Reaction in CH2Cl2 at 0 °C for 5 h gave crude 100 (>95:5 dr). Chromatographic 
purification (5:95-90:10 Petrol:EtOAc) gave 100 (>95:5 dr) as a white solid (52.6 mg, 
58%); 93% ee. 
 
Reaction in CH2Cl2 at –10 °C for 18 h gave crude 100 (>95:5 dr). Chromatographic 
purification (5:95-90:10 Petrol:EtOAc) gave 100 (>95:5 dr) as a white solid (15.4 mg, 
17%); 80% ee. 
 
6.2.5 Optimisation Studies on 106 
 
Isothiourea Catalyst Screen:  
The title compound was prepared according to General Procedure D from 
phenylacetic acid (27 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), imine 99 (70.8 mg, 0.20 mmol) and NaN3 
(19.5 mg, 0.30 mmol) and methanol (1 mL). All reactions were carried out for 1 h at 
rt for the cyclisation and 1 h at rt for the ring-opening. 
 
(–)Tetramisole.HCl 22 (9.63 mg, 0.04 mmol, 20 mol%) gave crude 106 (>95:5 dr). 
Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 dr) as a white 
solid (14.5  mg, 16%); 70% ee (ent). 
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(2S,3R)-HBTM-2.1 26 (12.3 mg, 0.04 mmol, 20 mol%) gave crude 106 (>95:5 dr). 
Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 dr) as a white 
solid (21.8 mg, 24%); 83% ee. 
 
(R)-BTM 23 (10.0 mg, 0.04 mmol, 20 mol%) gave crude 106 (>95:5 dr). 
Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 dr) as a white 
solid (27.2 mg, 30%); 74% ee. 
 
Ring Opening Conditions: 
The title compound was prepared according to General Procedure D from 
phenylacetic acid (27 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), (2S,3R)-HBTM-2.1 26 (12.3 mg, 0.04 
mmol, 20 mol%), and imine 99 (70.8 mg, 0.20 mmol). All reactions were carried out 
for 2 h at rt for the cyclisation. 
 
NaN3 (1.3 mg, 0.02 mmol, 10 mol%) and methanol (1 mL) for 4.5 h at rt gave crude 
106 (>95:5 dr). Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 
dr) as a white solid (60.0 mg, 66%); 85% ee. 
 
NaOMe (excess) and methanol (1 mL) for 2 h at rt gave crude 106 (>95:5 dr). 
Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 dr) as a white 
solid (36.4 mg, 40%); 96% ee. 
 
NaOMe (excess) and methanol (1 mL) for 4 h at 0 °C gave crude 106 (>95:5 dr). 
Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 dr) as a white 
solid (48.2 mg, 53%); 96% ee. 
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NaOMe (excess) and methanol (1 mL) for 24 h at –30 °C gave crude 106 (>95:5 dr). 
Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 dr) as a white 
solid (39.1 mg, 43%); 95% ee. 
 
2.5 M Butyl lithium solution in hexanes (0.1 mL, 55 equiv, 11 mmol) and methanol (1 
mL) for 1 h at –78 °C to rt gave crude 106 (>95:5 dr). Chromatographic purification 
(80:20 Petrol:EtOAc) gave 106 (>95:5 dr) as a white solid (56.4 mg, 62%); 93% ee. 
 
Catalyst Loading Screen:  
The title compound was prepared according to General Procedure D from 
phenylacetic acid (27 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 2.5 M Butyl lithium solution in hexanes (0.1 
mL, 55 equiv, 11 mmol) and imine 99 (70.8 mg, 0.20 mmol). All reactions were 
carried out at rt for the cyclisation and –78 °C to rt for the ring-opening. 
 
(2S,3R)-HBTM-2.1 26 (6.17 mg, 0.02 mmol, 10 mol%) for 2 h gave crude 106 (>95:5 
dr). Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 dr) as a 
white solid (48.2 mg, 53%); 95% ee. 
 
(2S,3R)-HBTM-2.1 26 (3.08 mg, 0.01 mmol, 5 mol%) for 2.5 h gave crude 106 
(>95:5 dr). Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 dr) 
as a white solid (45.5 mg, 50%); >99% ee. 
 
(2S,3R)-HBTM-2.1 26 (0.62 mg, 0.002 mmol, 1 mol%) for 2.5 h gave crude 106 
(>95:5 dr). Chromatographic purification (80:20 Petrol:EtOAc) gave 106 (>95:5 dr) 
as a white solid (40.0 mg, 44%); 85% ee. 
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6.2.6 Experimental Procedures 
(3S,4R)-4-(4-Bromophenyl)-3-phenyl-1-tosylazetidin-2-one 100  
 
The title compound was prepared according to General Procedure C, from phenyl 
acetic acid (27.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of 
i-Pr2NEt (52 µL, 0.30 mmol), 23 (10.0 mg, 20 mol%, 0.04 mmol), imine 99 (70.8 mg, 
0.20 mmol) and purified by chromatography (5:95-90:10 Petrol:EtOAc) to afford  100 
as a white solid (52.7 mg, 58%); mp 60-64 ˚C;  −2.3 (c 1.0, CH2Cl2); chiral 
HPLC analysis, Chiralcel OD-H (90:10 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 
rt), tR minor (3R,4S) 19.4 min, tR major (3S,4R) 21.0 min, 88% ee; νmax (KBr) 1797 
(C=O), 1369 (C-N), 1172 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.48 (3H, s, 
SO2ArCH3), 4.22 (1H, d, J 3.4, C(3)H), 4.92 (1H, d, J 3.4, C(4)H), 7.04 (2H, m, 
ArH), 7.18 (2H, m, ArH), 7.32 (5H, m, ArH), 7.47 (2H, m, ArH), 7.75 (2H, m, ArH); 
13C{1H} NMR (125 MHz, CDCl3) δC: 21.8 (SO2ArCCH3), 64.4. (C(3)), 65.1 (C(4)), 
123.4 (CBr), 127.3 (Ph), 127.6 (Ph), 128.1 (Ph), 128.6, 129.3, 130.0, 132.2 (Ph), 
132.5 (Cipso), 135.2 (Cipso), 135.6 (Cipso), 145.6 (CCH3), 165.2 (C(2)); m/z (NSI+) 475 
([M+NH4]+), 100%); HRMS (NSI+) C22H22BrN2O3S+ ([M+NH4]+), requires 473.0528; 
found 473.0539 (−0.2 ppm). 
 
 (3S,4R)-4-(4-Bromophenyl)-3-(p-tolyl)-1-tosylazetidin-2-one 101  
The title compound was prepared according to General Procedure C from p-
tolylacetic acid (30.0 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of iPr2NEt (52 µL, 0.30 mmol), 23 (10 mg, 20 mol%, 0.04 mmol), imine 99 
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(70.8 mg, 0.20 mmol) and purified by chromatography (95:5 Petrol:EtOAc) to afford 
the 101 as a white solid (39.3 mg, 42%); mp 40-44 °C;  −2.5 (c 1.0, CH2Cl2); 
Chiral HPLC analysis, Chiralcel OD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 
211 nm, rt), tR major (3S,4R) 13.6 min, tR minor (3R,4S) 16.1 min, 87% ee; νmax (KBr) 
1795 (C=O), 1368 (C-N), 1158 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.31 (3H, 
s, C(3)ArCH3), 2.47 (3H, s, NSO2ArCH3), 4.17 (1H, d, J 3.4, C(3)H), 4.87 (1H, d, J 
3.4, C(4)H), 6.90 (2H, d, J 8.2, C(3)ArC(2)H), 7.10 (2H, d, J 8.2, C(3)ArC(3)H), 7.15 
(2H, d, J 8.3, SO2ArC(2)H ), 7.31 (2H, d, J 8.6, C(4)ArC(2)H), 7.46 (2H, d, J 8.5, 
C(4)ArC(3)H), 7.73 (2H, d, J 8.3, SO2ArC(2)H);  13C{1H} NMR (125 MHz, CDCl3) 
δC:21.3 (C(3)ArCH3), 21.9 (NSO2ArCH3), 64.3 (C(3)), 65.4 (C(4)), 123.1 
(C(4)ArC(4)), 127.3 (ArC), 127.7 (C(3)ArC(2)), 128.2 (NSO2ArC(2)), 129.6 (Cipso), 
130.0 (ArC), 130.1 (ArC), 132.3 (C(4)ArC(3)), 135.3 (C(3)ArC(1)), 135.7 
(SO2ArC(1)), 138.8 (C(3)ArC(4)), 145.7 (SO2ArC(4)), 165.4 (C(2)); m/z (NSI+) 489 
([M+NH4]+, 100%); HRMS (NSI+) C23H24BrN2O3S+ ([M+NH4]+), requires 487.0682; 
found 487.0686 (−0.7 ppm). 
 
(3S,4R)-4-(4-Bromophenyl)-3-(m-tolyl)-1-tosylazetidin-2-one 102  
 
The title compound was prepared according to General Procedure C from m-
tolylacetic acid (30.0 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of iPr2NEt (52 µL, 0.30 mmol), 23 (10 mg, 20 mol%, 0.04 mmol), imine 99 
(70.8 mg, 0.20 mmol) and purified by chromatography (90:10 Petrol:EtOAc) to afford 
102 as a white solid (50.2 mg, 53%); mp 130-134 ˚C;  −2.6 (c 1.0, CH2Cl2); 
Chiral HPLC analysis, Chiralcel OD-H (80:20 Hexane:IPA, flow rate 0.25 mL min-1, 
211 nm, rt), tR minor (3R,4S) 45.0 min, tR major (3S,4R) 51.5 min, 79% ee; νmax (KBr) 
1806 (C=O), 1370 (C-N), 1172 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.25 (3H, 
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s, NSO2ArCH3), 2.47 (3H, s, C(3)ArCH3) 4.15 (1H, d, J 3.4, C(3)H) 4.87 (1H, d, J 
3.4, C(4)H), 6.72 (1H, s, ArH), 6.80 (1H, d, J 7.7, ArH), 6.71 (1H, d, J 7.7, ArH), 
7.18 (3H, m, ArH), 7.33 (2H, d, J 8.3, ArH), 7.46 (2H, d, J 8.4, ArH), 7.76 (2H, d, J 
8.3, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.4 (NSO2ArCH3), 21.9 
(C(3)ArCH3), 64.8 (C(3)), 65.3 (C(4)), 123.3 (C4)ArC(4)Br), 124.7 (ArC), 127.7 
(ArC), 127.8 (ArC), 128.3, 129.2 (ArC),  129.5 (ArC), 130.2 (Cipso), 132.3 (ArC), 
132.6, 135.4 (Cipso), 135.8 (Cipso), 139.3 (Cipso), 145.7 (NSO2ArC(4)CH3), 165.5 
(C(2)); m/z (NSI+) 489 ([M+NH4]+, 100%); HRMS (NSI+) C23H24BrN2O3S+ 
([M+NH4]+), requires 487.0683; found 487.0686 (–0.5 ppm). 
 
(3S,4R)-4-(4-Bromophenyl)-3-(o-tolyl)-1-tosylazetidin-2-one 103  
 
The title compound was prepared according to General Procedure C from o-
tolylacetic acid (60 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions 
of i-Pr2NEt (52 µL, 0.30 mmol), 23 (10 mg, 20 mol%, 0.04 mmol), imine 99 (70.8 
mg, 0.20 mmol) and purified by chromatography (90:10 Petrol:EtOAc) to afford 103 
as a white solid (53.1 mg, 56 %); mp 32-36 ˚C;   +4.4 (c 0.25, CH2Cl2); 1H NMR 
(400 MHz, CDCl3) δH: 1.97 (3H, s, SO2ArCH3), 2.47 (3H, s, PhCH3), 4.43 (1H, d, J 
3.4, C(3)H), 4.82 (1H, d, J 3.4, C(4)H), 7.03 (1H, m, ArH), 7.18 (5H, m, ArH), 7.31 
(2H, d, J 8.6, ArH), 7.47 (2H, d, 7.47, ArH), 7.71 (2H, d, PhH); 13C{1H} NMR (125 
MHz, CDCl3) δC:  20.3 (SO2PhMe), 22.2 (PhMe), 42.1, 62.7 (C(3)), 63.3 (C(4)), 
123.7, 127.1, 127.2, 128.0, 129.0, 130.0 (Cipso), 130.3 (Ph), 131.3, 132.6 (Ph), 135.8 
(Cipso), 136.6 (Cipso), 145.7 (SO2C5H4CMe), 165.9 (C(2)); m/z (NSI+) 489 ([M+NH4]+, 
100%); HRMS (NSI+) C23H24BrN2O3S+ ([M+NH4]+), requires 487.0681; found 
487.0686 (-0.9 ppm) 
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(3S,4R)-4-(4-Bromophenyl)-3-(4-methoxyphenyl)-1-tosylazetidin-2-one 104  
 
The title compound was prepared according to General Procedure C from p-
methoxyphenylacetic acid (33.0 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 
mmol), 2 portions of i-Pr2NEt (52 µL, 0.30 mmol), 23 (10 mg, 20 mol%, 0.04 mmol), 
imine 99 (70.8 mg, 0.20 mmol) and purified by chromatography (80:20 
Petrol:EtOAc) to afford 104 as a white solid (62.0 mg, 67%); mp 32-36 ˚C;  
−30.0 (c 1.0, CH2Cl2); Chiral HPLC analysis, Chiralcel OD-H (90:10 hexane:IPA, 
flow rate 1.0 mL min-1, 211 nm, rt), tR minor (3R,4S) 33.4 min, tR major (3S,4R) 42.0 
min, 83% ee; 1H NMR (400 MHz, CDCl3) δH: 2.47 (3H, s, NSO2ArCH3), 3.77 (3H, s, 
OCH3), 4.19 (1H, d, J 3.4, C(3)H), 4.85 (1H, d, J 3.4, C(4)H), 6.01 (2H, d J 8.8, 
ArH), 6.93 (2H, d J 8.5, ArH), 7.15 (2H, d, J 8.3, ArH), 7.31 (2H, m, ArH), 7.45 (2H, 
d, J 8.5, ArH), 7.73 (2H, d, J 8.3, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.9 
(NSO2ArCH3), 55.5 (OCH3), 64.1 (C(3)), 65.6 (C(4)), 114.8 (ArC), 123.2, (Cipso), 
124.6 (Cipso), 127.7 (ArC), 128.2 (ArC), 128.6 (ArC), 130.1 (ArC), 132.3 (ArC), 
135.4 (Cipso), 135.7 (Cipso), 145.7 (NSO2ArC(4)CH3), 159.8 (C(3)ArC(4)OCH3), 165.7 
(C(2)); m/z (NSI+) 505 ([M+NH4]+, 100%); HRMS (NSI+) C23H21BrNO4S+ ([M+H]+), 
requires 486.0368; found 486.0369 (−0.2 ppm). 
 
(3S,4S)-4-(4-Bromophenyl)-3-(phenylthio)-1-tosylazetidin-2-one 105 
 
The title compound was prepared according to General Procedure C from 
(phenylthio)acetic acid (33.6 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 23 (10 mg, 20 mol%, 0.04 mmol),  imine 99 
(70.8 mg, 0.20 mmol) and purified by chromatography (90:10 Petrol:EtOAc) to afford 
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105 as a white solid (40.7 mg, 42% as a mixture of anti:syn 85:15). Careful 
purification allowed isolation of an analytical sample for characterisation. 
Data for the anti diastereoisomer: isolated white solid (8.3 mg, 14%); mp 78-84 ˚C; 
 +7.0 (c 0.1, CHCl3); Chiral HPLC analysis, Chiralcel OD-H (90:10 hexane:IPA, 
flow rate 1.0 mL min-1, 211 nm, 30 °C), tR major (3S,4S) 16.1 min, tR minor (3R,4R) 
20.8 min, 61% ee; 1H NMR (400 MHz, CDCl3) δH: 2.46 (3H, s, NSO2ArCH3), 4.11 
(1H, d, J 3.2, C(3)H), 4.70 (1H, d, J 3.2, C(4)H), 7.12-7.24 (2H, m, ArH), 7.21-7.30 
(5H, m, ArH), 7.42-7.47 (4H, m, ArH), 7.57-7.59 (2H, m, ArH); 13C{1H} NMR (125 
MHz, CDCl3) δC:  21.9 (NSO2ArCH3), 61.5 (C(3)), 63.6 (C(4)), 123.5 (CBr), 127.9 
(Ph), 128.1 (Ph), 128.6, 129.3, 129.6, 130.1, 132.3, 134.5, 134.5 (Cipso), 135.3 (Cipso), 
145.6 (CMe), 163.2 (C(2)); m/z (ESI+) 512 ([M+Na]+, 100%); HRMS (NSI+) 
C22H18BrNO3S2+ ([M+Na]+), requires 509.9798; found 509.9804 (−1.1 ppm). 
Selected data for the Syn diastereoisomer: 1H NMR (400 MHz, CDCl3) δH: 2.49 (3H, 
s, NSO2ArCH3), 4.79 (2H, d, J 6.4, CH), 5.35 (2H, d, J 6.1, CH), 6.99-7.02 (2H, m, 
ArH), 7.71-7.76 (2H, m, ArH); Chiral HPLC analysis, Chiralcel OD-H (90:10 
hexane:IPA, flow rate 1.0 mL min-1, 211nm, 24°C), tR major (3R,4S) 25.9 min, tR 
minor (3S,4R) 33.6 min, 62% ee. 
 
(2S,3R)-Methyl-
3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-phenylpropanoate 106 
 
The title compound was prepared according to General Procedure D from 
phenylacetic acid (27 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of iPr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
Butyl lithium solution in hexanes (0.1 mL, 55 equiv, 11 mmol), imine 99 (70.8 mg, 
0.20 mmol) and purified by chromatography (80:20 Petrol:EtOAc) to 106 as a white 
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solid (49.0 mg, 50%); mp 156-159°C;  −24.3 (c 1, CHCl3); chiral HPLC 
analysis, ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 
°C), tR minor (2R,3S) 29.0 min, tR major (2S,3R) 42.7 min, >99% ee; νmax (neat) 3236.6 
(NH), 1739.8 (C=O), 1330.9 (R-SO2N), 1153.4 (R-SO2N); 1H NMR (400 MHz, 
CDCl3) δH: 2.35 (3H, s, ArCH3), 3.61 (3H, s, OCH3), 3.92 (1H, d, J 6.45, C(2)H), 4.80 
(1H, dd, J 8.82, 6.53, C(3)H), 5.98 (1H, d, J 8.64, NH), 6.89-6.91 (2H, m, 
C(3)ArC(2)H), 7.01 (2H, d, J 7.95, C(3)NHSO2ArC(3)H), 7.13-7.16 (2H, m, ArH), 
7.20-7.23 (5H, m, ArH), 7.33 (2H, d, J 8.29, C(3)NHSO2Ar(2)H); 13C{1H} NMR (100 
MHz, CDCl3) δC: 21.6 (ArCH3), 52.6 (OCH3), 57.5 (C(2)), 60.6 (C(3)), 121.7 
(ArCBr), 127.0 (C(3)NHSO2ArC(2)), 128.1 (ArC), 128.6 (ArC), 128.7 (ArC), 128.9 
(C(3)ArC(2)), 129.3 (C(3)NHSO2ArC(3)), 131.5 (ArC), 134.5 (C(2)ArC(1)), 137.5 
(C(3)NHSO2ArC(1)), 137.8 (C(3)ArC(1)), 143.1 (C(3)NHSO2ArC(4)), 172.2 (C(1)); 
m/z (NSI+) 507 ([M+NH4]+, 100%); HRMS (NSI+) C23H23BrNO4S+ ([M+H]+), requires 
488.0523; found 488.0526 (−0.5 ppm). 
 
(2S,3R)-Methyl 3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-(p-
tolyl)propanoate 107 
 
The title compound was prepared according to General Procedure D from p-
tolylacetic acid (30 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions 
of i-Pr2NEt (52 µL, 0.30 mmol), 16 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M butyl lithium 
solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) and purified 
by chromatography (80:20 Petrol:EtOAc ) to give 107 as a white solid (45.8 mg, 
46%); mp 163-168°C;  −26.0 (c 0.25, CHCl3); Chiral HPLC analysis, ChiralPak 
AD-H (80:20 hexane:IPA, flow rate 0.5 mL min-1, 211 nm, 30 °C), tR major (2S,3R) 
33.9 min, tR minor (2R,3S) 38.3 min, 87% ee; νmax (neat) 3252.0 (NH), 1735.9 (C=O), 
1352.1 (R-SO2N), 1159.2 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.28 (3H, s, 
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C(2)ArCH3), 2.35 (3H, s, C(3)NHSO2ArCH3), 3.59 (3H, s, OCH3),  3.89 (1H, d, J 6.5, 
C(2)H), 4.77 (1H, dd, J 8.8, 6.5, C(3)H), 6.03 (1H, d, J 8.8, NH), 6.91 (2H, d, J 8.4, 
C(3)ArC(2)H), 6.99-7.02 (6H, m, ArH), 7.22 (2H, d, J 8.5, C(3)ArC(3)H), 7.33 (2H, 
d, J 8.3, C(3)NHSO2ArC(2)H); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.3 
(C(2)ArCH3), 21.6 (C(3)NHSO2ArCH3), 52.5 (OCH3), 57.1 (C(2)), 60.6 (C(3)), 121.6 
(ArCBr), 127.0 (C(3)NHSO2ArC(2)), 128.8 (C(3)ArC(2)), 128.4 (ArC), 129.3 
(C(3)NHSO2ArC(3)), 129.6 (ArC), 131.4 (C(2)ArC(1)), 131.5 (C(3)ArC(3)), 137.6 
(C(3)NHSO2ArC(1)), 137.9 (C(2)ArC(4)), 138.0 (C(3)ArC(1)), 143.0 
(C(3)NHSO2ArC(4)), 172.4 (C(1)); m/z (NSI+) 519 ([M+NH4]+, 45%), 526 (100%); 
HRMS (NSI+) C24H25BrNO4S+ ([M+H]+), requires 502.0681; found 502.0682 (−0.2 
ppm). 
 
(2S,3R)-Methyl 3-(4-methylphenylsulfonamido)-3-phenyl-2-(m-tolyl)propanoate 108  
 
The title compound was prepared according to General Procedure D from m-
tolylacetic acid (30 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions 
of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M butyl lithium 
solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) and purified 
by chromatography (80:20 Petrol:EtOAc) to give 108 as a white solid (40.7 mg, 
40%); mp 124-130°C;  −25.0 (c 0.1, CHCl3); Chiral HPLC analysis, ChiralPak 
AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR minor (2R,3S) 
39.9 min, tR major (2S,3R) 42.8 min, 74% ee; νmax (neat) 3248.1 (NH), 1735.9 (C=O), 
1159.2 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.23 (3H, s, C(2)ArC(3)CH3), 2.34 
(3H, s, C(3)NHSO2ArCH3), 3.60 (3H, s, OCH3), 3.90 (1H, d, J 6.6, C(2)H), 4.79 (1H, 
dd, J 8.9, 6.7, C(3)H), 6.14 (1H, d, J 8.9, NH), 6.91-6.93 (4H, m, ArH), 7.00 (3H, d, J 
7.9, ArH), 7.07 (1H, t, J 7.9, C(2)ArC(3)H), 7.22 (2H, d, J 8.5, ArH), 7.32 (2H, d, J 
8.3, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.5 (C(2)ArC(3)CH3), 21.6 
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(C(3)NHSO2ArCH3), 52.6 (OCH3), 57.4 (C(2)), 60.6 (C(3)), 121.6 (CBr), 125.6 
(C(3)ArC(2)), 126.9 (ArC), 128.7 (2xArC), 128.8 (ArC), 129.2 (ArC), 129.3 (ArC), 
131.4 (ArC), 134.4 (C(2)ArC(1)), 137.6 (C(3)NHSO2ArC(1)), 138.0 (C(3)ArC(1)), 
138.5 (C(2)ArC(3)), 143.0 (C(3)NHSO2ArC(4)), 172.3 (C(1)); m/z (NSI+) 214(100%), 
519 ([M+NH4]+, 40%); HRMS (NSI+) C24H25BrNO4S+ ([M+H]+), requires 502.0681; 
found 502.0682 (−0.2 ppm). 
 
(2S,3R)-Methyl-3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-
(o-tolyl)propanoate 109 
 
The title compound was prepared according to General Procedure D from o-
tolylacetic acid (150 mg, 1.0 mmol), tosyl chloride (286.5 mg, 1.50 mmol), 2 portions 
of i-Pr2NEt (260 µL, 1.50 mmol), 26 (15.5 mg, 5 mol%, 0.05 mmol), 2.5 M butyl 
lithium solution in hexanes (0.5 mL, 55 mmol), imine 99 (354.0 mg, 1.0 mmol) and 
purified by chromatography (80:20 Petrol:EtOAc) to give 109 as a white solid (304.5 
mg, 61%); mp 124-128°C;  −17.2 (c 0.25, CHCl3); Chiral HPLC analysis, 
ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR minor 
(2R,3S) 16.7 min, tR major (2S,3R) 24.2 min, 76% ee; νmax (neat) 3246.2 (NH), 1745.6 
(C=O),1163.1 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.20 (3H, s, C(2)ArCH3), 
2.34 (3H, s, C(3)NHSO2ArCH3), 3.59 (3H, s, OCH3), 4.20 (1H, d, J 6.8 Hz, C(2)H), 
4.76 (1H, dd, J 8.7, 6.8, C(3)H), 6.30 (1H, d, J 8.8, NH), 6.93-6.96 (2H, m, 
C(3)ArC(2)H), 6.99-7.02 (3H, m, ArH), 7.08 (2H, td, J 1.9, 6.7, C(2)ArC(4)H & 
C(2)ArC(5)H), 7.19-7.21 (2H, m, C(3)ArC(3)H), 7.26-7.28 (1H, m, C(2)ArC(6)H), 
7.33 (2H, d, J 8.3, C(3)NHSO2ArC(2)H); 13C{1H} NMR (125 MHz, CDCl3) δC:  19.7 
(C(2)ArC(2)CH3), 21.6 (C(3)NHSO2ArCH3), 52.5 (CH3O), 52.9 (C(2)), 59.5 (C(3)), 
121.6 (CBr), 126.5 (C(3)NHSO2ArC(2)), 126.9 (C(2)ArC(4)), 127.8 (C(2)ArC(6)), 
128.0 (C(2)ArC(5)), 128.7 (C(3)ArC(2)), 129.3 (ArC), 130.9 (ArC), 132.9 
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(C(3)ArC(3)), 133.0 (C(2)ArC(1)), 135.9 (C(2)ArC(2)), 137.4 (C(3)ArC(1)), 138.0 
(C(3)NHSO2ArC(1)), 143.0 (C(3)NHSO2ArC(4)), 172.6 (C(1)); m/z (NSI+) 521 
([M+NH4]+, 100%); HRMS (NSI+) C24H25BrNO4S+ ([M+H]+), requires 502.0682; 
found 502.0682 (−0.0 ppm). This was recrystallised from CH2Cl2/Petrol to 109 as a 
white solid (209.7 mg, 42%); mp 116-120 ˚C;  −12.0° (c 0.5, CHCl3); Chiral 
HPLC analysis, ChiralPak AD-H (8020 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 
30 °C), tR minor(2R,3S) 16.7 min, tR major (2S,3R) 24.2 min, 96% ee. 
 
(2S,3R)-Methyl 3-(4-bromophenyl)-3-(4-2-(naphthalene-1-yl)propanoate 110 
 
The title compound was prepared according to General Procedure D from 1-
naphthylacetic acid (37.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) 
and purified by chromatography (80:20 hexane:IPA) to give 110 as a white solid 
(49.8 mg, 46%); mp 122-128°C;  −12.2 (c 0.5, CHCl3); Chiral HPLC analysis, 
ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 270 nm, 30 °C), tR major 
(2S,3R) 24.9min, tR minor (2R,3S) 30.6 min, 82% ee; νmax (neat) 3244.3 (NH), 1735.9 
(C=O), 1330.9 (R-SO2N), 1157.3 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.24 
(3H, s, ArCH3), 3.57 (3H, s, OCH3), 4.82 (1H, d, J 4.7, C(2)H), 4.86-4.89 (1H, m, 
C(3)H), 6.47 (1H, d, J 8.7, NH), 6.74 (2H, d, J 8.0, C(3)NHSO2ArC(3)H), 7.07-7.10 
(2H, m, C(3)NHSO2ArC(2)H), 7.21-7.25 (2H, m, C(3)ArC(2)H), 7.27-7.37 (4H, m, 
ArH), 7.46-7.58 (2H, m, ArH), 7.69 (1H, d, J 7.9, ArH), 7.79-7.82 (1H, m, ArH), 7.90 
(1H, d, J 8.4, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC:  21.5 (ArCH3), 52.2 (C(2)), 
52.6 (OCH3),  58.7 (C(3)), 121.8 (CBr), 121.82 (ArC), 125.4 (ArC), 125.9 (ArC), 
126.1 (ArC), 126.4 (C(3)NHSO2ArC(2)), 127.1 (ArC)), 128.5 (C(3)ArC(2)), 128.9 
(ArC), 129.0 (C(3)NHSO2ArC(3)), 129.5 (ArC), 130. 2 (Cipso), 130.7 (Cipso), 131.75 
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(ArC), 134.2 (Cipso), 136.9 (C(3)NHSO2ArC(1)),  139.0 (C(3)ArC(1)), 142.6 
(ArC(4)CH3), 172.8 (C(1)); m/z (NSI+) 555 ([M+NH4]+, 45%), 562 (100%); HRMS 
(NSI+) C27H25BrNO4S+ ([M+H]+), requires 538.0680; found 538.0682 (−0.4 ppm).  
 
(2S,3R)-Methyl 3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-(naphthalen-2-
yl)propanoate  111 
 
The title compound was prepared according to General Procedure D from 2-
naphthylacetic acid (186.0 mg, 1.0 mmol), tosyl chloride (286.5 mg, 1.50 mmol), 2 
portions of i-Pr2NEt (260 µL, 1.50 mmol), 26 (15.5 mg, 5 mol%, 0.05 mmol), 2.5 M 
butyl lithium solution in hexanes (0.5 mL, 55 mmol), imine 99 (354.0 mg, 1.0 mmol) 
and purified by chromatography (80:20 Petrol:EtOAc) to give 111 as a white solid 
(368.5 mg, 68%); mp 164-170°C;  −35.8 (c 0.25, CHCl3); Chiral HPLC analysis, 
ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 220 nm, 30 °C), tR major 
(2S,3R) 24.0 min, tR minor (2R,3S) 27.7 min, 85% ee; νmax (neat) 3209.6 (NH), 1710.9 
(C=O), 1336.7 (R-SO2N), 1163.1 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.17 
(3H, s, ArCH3), 3.61 (3H, s, OCH3), 4.13 (1H, d, J 6.0, C(2)H), 4.87 (1H, dd, J 9.0, 
5.9, C(3)H), 6.23 (1H, d, J 9.0, NH), 6.72 (2H, d, J 7.9, C(3)NHSO2ARC(3)H), 7.04-
7.07 (2H, m, C(3)ArC(2)H), 7.20-7.23 (3H, m, ArH), 7.26-7.29 (2H, m, 
C(3)ArC(3)H), 7.46-7.49 (2H, m, ArH), 7.56 (1H, d, J 1.2, C(2)ArC(3)H), 7.60-7.63 
(1H, m, ArH), 7.67-7.70 (1H, m, ArH), 7.74-7.77 (1H, m, ArH); 13C{1H} NMR (125 
MHz, CDCl3) δC:  21.5 (ArCH3), 52.6 (OCH3), 57.3 (C(2)), 60.6 (C(3)), 121.8 (CBr), 
126.0 (ArC), 126.5 (2xArC), 126.6 (C(3)NHSO2ArC(2)), 127.6 (C(2)ArC(3)), 127.7 
(ArC), 128.1 (ArC), 128.6 (C(3)ArC(2)), 128.7 (C(3)ArC(2)), 129.1 
(C(3)NHSO2ArC(3)), 131.6 (C(3)ArC(3)), 131.9 (C(2)ArC(2)), 132.9 (Cipso), 133.2 
(Cipso), 137.2 (C(3)NHSO2ArC(1)), 138.3 (C(3)ArC(1)), 142.9 (ArC(4)CH3), 172.2 
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(C(1));  m/z HRMS (NSI+) C27H28BrN2O4S+ ([M+NH4]+), requires 555.0945; found 
555.0948 (−0.5 ppm). This was recrystallised from CH2Cl2/Petrol to give 111 as a 
white solid (222.2 mg, 41%); mp 106-112 ˚C;  −39.0° (c 0.5, CHCl3); Chiral 
HPLC analysis, ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 220 nm, 
30 °C), tR major (2S,3R) 24.0 min, tR minor (2R,3S) 27.7 min, 91% ee. 
 
(2S,3R)-methyl 3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-(thiophen-2-
yl)propanoate 112 
 
The title compound was prepared according to General Procedure D from 2- 
thiopheneacetic acid (28.4 mg, 0.2 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) 
and purified by chromatography (80:20 Petrol:EtOAc) to give 112 as a white solid 
(45.0 mg, 46%). mp 154-160°C;  –11.0° (c 0.5, CHCl3); Chiral HPLC analysis, 
ChiralPak AD-H (90:10 Hexane:IPA, flow rate 1.0 mL min-1, 211 nm, rt), tR (2R,3S), 
53.5 min, tR (2S,3R) 109.2 min, 21% ee; νmax (neat) 3244.3 (NH), 1734.0 (C=O), 
1448.5 (thiophene), 1159.2 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.34 (3H, s, 
ArCH3), 3.63 (3H, s, OCH3), 4.04 (1H, d, J 7.0, C(2)H), 4.82 (1H, dd, J 9.1, 7.0, 
C(3)H), 6.19 (1H, d, J 9.1, NH), 6.82-6.85 (2H, m, C(3)ArC(2)H), 6.87 (1H, dd, J 
5.0, 1.3, C(2)ArH), 6.98-7.05 (2H, m, C(3)NHSO2ArC(3)H), 7.07-7.09 (1H, m, 
C(2)ArH), 7.12-7.22 (3H, m, ArH), 7.31-7.42 (2H, m, C(3)NHSO2AR(2)H); 13C{1H} 
NMR (125 MHz, CDCl3) δC: 21.6 (ArCH3), 52.6 (OCH3), 52.9 (C(2)), 60.0 (C(3)), 
121.8 (CBr), 124.0 (C(2)ArC), 126.3 (C(2)ArC), 127.0 (C(3)NHSO2ArC(2)), 127.5 
(C(2)ArC), 128.5 (C(3)ArC(2)), 129.4 (C(3)NHSO2ArC(3)), 131.5 (C(3)ArC(3)), 
134.3 (C(2)ArC(1)), 137.5 (C(3)NHSO2ArC(1), 137.7 (C(3)ArC(1)), 143.3 
(ArC(4)CH3), 172.1 (C(1)); m/z (NSI+) 513 ([M+NH4]+, 100%); HRMS (NSI+) 
C21H21BrNO4S2+ ([M+H]+), requires 494.0091; found 494.0090 (+0.2 ppm 
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(2S,3R)-methyl 3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-2-(thiophen-3-
yl)propanoate 113 
 
The title compound was prepared according to General Procedure D from 3- 
thiopheneacetic acid (28.4 mg, 0.2 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) 
and purified by chromatography (80:20 Petrol:EtOAc) to give 113 as a white solid 
(49.8 mg, 50%); mp 154-160°C;  -11.0 (c 0.5, CHCl3); νmax (neat) 3244.3 (NH), 
1734.0 (C=O), 1448.5 (thiophene), 1159.2 (R-SO2N); 1H NMR (400 MHz, CDCl3) 
δH: 2.35 (3H, s, ArCH3), 3.61 (3H, s, OCH3), 4.03 (1H, d, J 6.1, C(2)H), 4.80 (1H, dd, 
J 8.6, 6.4, C(3)H), 5.97 (1H, d, J 9.1, NH), 6.85-6.87 (2H, m, C(3)ArC(2)H), 6.87-
6.89 (1H, m, C(2)ArC(4)H), 7.02-7.04 (2H, m, C(3)NHSO2ArC(4)H), 7.10-7.11 (1H, 
m, C(2)ArC(2)H), 7.16-7.18 ( 1H, m, C(2)ArC(5)H), 7.21-7.23 (2H, m, 
C(3)ArC(3)H), 7.36-7.38 (2H, m, C(3)NHSO2ArC(2)H); 13C{1H} NMR (125 MHz, 
CDCl3) δC: 21.6 (ArCH3), 52.6 (OCH3), 53.2 (C(2)), 60.1 (C(3)), 121.6 (CBr), 124.0 
(C(2)ArC(2)), 126.2 (C(2)ArC(5)), 127.0 (C(3)NHSO2ArC(2)), 127.5 (C(2)ArC(3)), 
128.6 (C(3)ArC(2)), 129.3 (C(3)NHSO2ArC(3)), 131.4 (C(3)ArC(3)), 134.3 
(C(2)ArC(1)), 137.4 (C(3)ArC(1)), 137.5 (C(3)NHSO2ArC(1)), 143.2 (ArC(4)CH3), 
172.2 (C(1)); m/z (NSI+) 512 ([M+NH4]+, 65%) 517 (100%); HRMS (NSI+) 
C21H21BrNO4S2+ ([M+H]+), requires 494.0087; found 494.0090 (-0.6 ppm). 
 
(2S,3R)-methyl 3-(4-bromophenyl)-2-(1-methyl-1H-indol-3-yl)-3-(4-
methylphenylsulfonamido)propanoate 114 
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The title compound was prepared according to General Procedure D from 2- 
thiopheneacetic acid (28.4 mg, 0.2 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) 
and purified by chromatography (80:20 Petrol:EtOAc) to give 114 as a brown solid 
(59.6 mg, 55%); mp 58-64°C;  –13.0 (c 0.5, CHCl3); Chiral HPLC analysis, 
ChiralPak AD-H (80:20 hexane:IPA, flow rate 1 mL min-1, 211 nm) tR (2R,3S) 40.6 
min, tR (2S,3R) 44.5 min, 23%; νmax (neat) 3365.8 (NH), 3273.2 (NH), 1558.5 (indole), 
1506.4 (indole), 1338.6 (R-SO2N), 1157.3 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 
2.32 (3H, s, ArCH3), 3.59 (3H, s, OCH3), 3.70 (3H, s, NCH3), 4.30 (1H, d, J 4.89 (1H, 
dd, J 8.3, 4.8, C(2)H), 6.43 (1H, d J 8.3, NH), 6.81-6.91 (3H, m, NHSO2ArC(3)H), 
7.02 (1H, s, C(2)ArC(2)H), 7.09-7.19 (3H, m, ArH), 7.20 -7.32 (4H, m, ArH), 7.32-
7.42 (2H, m, C(3)NHSO2ArC(2)H), 7.46-7.49 (1H, m, ArH); 13C{1H} NMR (125 
MHz, CDCl3) δC: 21.6 (ArCH3), 32.9 (NCH3), 48.5 (OCH3), 52.4 (C(2)), 59.1 (C(3)), 
107.5 (Cipso), 109.6 (ArC), 118.2 (ArC), 119.7 (ArC), 121.6 (CBr), 122.1 (ArC), 126.5 
(Cipso), 126.6(ArC), 128.0 (C(2)ArC(2)), 128.4 (ArC), 128.9 (C(2)NHSO2ArC(3)), 
131.6 (C(2)NHSO2ArC(2)), 136.8 (C(2)ArC(1)), 137.2 (C(3)NHSO2ArC(1)), 138.9 
C(3)ArC(1)), 142.7 (C(3)NHSO2ArC(4)), 173.0 (C(1)); m/z (NSI+) 559 ([M+NH4]+, 
100%); HRMS (NSI+) C26H26BrN2O4S+ ([M+H]+), requires 541.0788; found 541.0791 
(-0.6 ppm). 
 
(2S,3R)-Methyl 2,3-bis(4-bromophenyl)-3-(4-methylphenylsulfonamido)propanoate 
115  
 
The title compound was prepared according to General Procedure D from 4-
bromophenylacetic acid (43.0 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 
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2 portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) 
and purified by chromatography (80:20 Petrol:EtOAc) to give 115 as a white solid 
(49.6 mg, 43%); mp 168-172°C;  −28.0 (c 1.0, CHCl3); Chiral HPLC analysis, 
ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 220 nm, 30 °C), tR major 
(2S,3R) 15.7 min, tR minor (2R,3S) 18.5 min, 98% ee; νmax (neat) 3367.7 (NH), 3298.3 
(NH), 1718.6 (C=O), 1708.9 (C=O), 1338.6 (R-SO2N), 1155.4 (R-SO2N); 1H NMR 
(400 MHz, CDCl3) δH: 2.38 (3H, s, ArCH3), 3.59 (3H, s, OCH3), 3.90 (1H, d, J 6.3, 
C(2)H), 4.73 (1H, dd, J 9.1, 6.3, C(3)H), 6.09 (1H, d, J 9.1, NH), 6.94-6.96 (2H, m, 
C(3)ArC(2)H), 6.99-7.01 (2H, m, C(2)ArC(2)H), 7.02-7.05 (2H, m, ArH), 7.24-7.26 
(1H, m, ArH), 7.27-7.29 (3H, m, ArH), 7.31-7.33 (2H, m, C(3)NHSO2ArC(2)H); 
13C{1H} NMR (125 MHz, CDCl3) δC: 21.7 (ArCH3), 52.7 (OCH3), 56.7 (C(2)), 60.5 
(C(3)), 121.9 (C(3)ArC(4)Br), 122.4 (C(2)ArC(4)Br), 126.8 (C(3)NHSO2ArC(2)), 
128.6 (C(3)ArC(2)), 129.4 (C(2)ArC(2)), 130.1 (C(3)NHSO2ArC(3)), 131.7 
(C(3)ArC(3)), 131.9 (C(2)ArC(3)), 133.6 (C(2)ArC(1)), 137.4 (C(3)NHSO2ArC(1)), 
137.7 (C(3)ArC(1)), 143.4 (ArC(4)CH3), 171.9 (C(1)); m/z (NSI+) 582 ([M+NH4]+, 
35%), 589 (100%); HRMS (NSI+) C23H22Br2NO4S+ ([M+H]+), requires 565.9630; 
found 565.931 (−0.1 ppm). 
 
(2S,3R)-Methyl 3-(4-bromophenyl)-2-(4-methoxyphenyl)-3-(4-
methylphenylsulfonamido)propanoate 116 
 
The title compound was prepared according to General Procedure D from p-
methoxyphenylacetic acid (33.0 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 
mmol), 2 portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 
2.5 M butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 
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mmol) and purified by chromatography (80:20 Petrol:EtOAc) to give 116 as a white 
solid (43.2 mg, 42%); mp 168-172°C;  −27.6 (c 0.5, CHCl3); Chiral HPLC 
analysis, ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 220 nm, 30 
°C), tR major (2S,3R) 24.1 min, tR minor (2R,3S) 27.1 min, 76% ee; νmax (neat) 3253.9 
(NH), 1734.0 (C=O), 1157.3 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.35 (3H, s, 
ArCH3),  3.60 (3H, s, C(1)(O)OCH3), 3.76 (3H, s, ArOCH3), 3.86 (1H, d, J 6.66, 
C(2)H), 4.73-4.77 (1H, dd, J 8.79, 6.49, C(3)H), 5.97-5.99 (1H, d, J 8.89, NH), 6.69 
(2H, d, J 8.79, C(2)ArC(2)H), 6.89 (2H, d, J 8.62, C(3)ArC(2)H), 6.99-7.01 (2H, m, 
C(3)NHSO2ArC(3)H), 7.04 (2H, d, J 8.81, C(2)ArC(3)H), 7.21 (2H, d, J 8.52, 
C(3)ArC(3)H), 7.32-7.34 (2H, m, C(3)NHSO2ArC(2)H); 13C{1H} NMR (125 MHz, 
CDCl3) δC: 21.6 (ArCH3), 52.5 (C(1)(O)OCH3), 55.3 (ArOCH3), 56.6 (C(2)), 60.7 
(C(3)), 114.2 (C(2)ArC(2)), 121.6 (CBr), 126.5 (C(2)ArC(1)), 127.0 
(C(3)NHSO2ArC(2)), 128.7 (C(3)ArC(2)), 129.3 (ArC), 129.6 (ArC), 131.5 
(C(3)ArC(3)), 137.6 (C(3)NHSO2ArC(1)), 137.9 (C(3)ArC(1)), 143.0 (ArC(4)CH3), 
159.4 (ArC(4)OCH3), 172.5 (C(1)); m/z (NSI+) 535 ([M+NH4]+, 90%), 542 (100%); 
HRMS (NSI+) C24H25BrNO5S+ ([M+H]+), requires 518.0630; found 518.0631 (−0.3 
ppm). 
 
(2S,3R)-Methyl 
3-(4-bromophenyl)-2-(4-chlorophenyl)-3-(4-methylphenylsulfonamido)propanoate 
117 
 
The title compound was prepared according to General Procedure D from 4-
chlorophenylacetic acid (34.1mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) 
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and purified by chromatography (80:20 Petrol:EtOAc) to give 117 as a white solid 
(71.3 mg, 68%); mp 120-124°C;  −27.2 (c 0.5, CHCl3); Chiral HPLC analysis, 
ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR major 
(2S,3R) 15.6 min, tR minor (2R,3S) 17.7 min, 78% ee; νmax (neat) 3304.1 (NH), 3257.8 
(NH), 1735.9 (C=O), 1718.6 (C=O), 1153.4 (R-SO2N), 1089.8 (C-Cl); 1H NMR (400 
MHz, CDCl3) δH: 2.37 (3H, s,  CH3), 3.60 (3H, s, CH3OC(1)), 3.91 (1H, d, J 6.4, 
C(2)H), 4.74 (1H, dd, J 9.2, 6.4, C(3)H), 6.13 (1H, d, J 9.1, NH), 6.90-6.96 (2H, m, 
C(3)CCH), 6.99-7.08 (4H, m, ArH), 7.09-7.15 (2H, m, C(2)CCH), 7.23-7.29 (2H, m, 
CHCBr), 7.30-7.36 (2H, m, SO2CCH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.3 
(CH3), 52.4 (CH3C(1)), 56.3 (C(2)), 60.2 (C(3)), 121.5 (CBr), 126.7 (SO2CArC), 
128.4 (C(3)CArCH), 128.8 (ArC), 129.2 (C(2)CCH), 129.6 (ArC), 131.5 (ArCCBr), 
132.7 (C(2)ArC), 133.9 (ArCCl), 137.1 (SO2C), 137.4 (C(3)ArC), 143.0 (ArCCH3), 
171.6 (C(1)(O)); m/z (NSI+) 522 ([M+NH4]+, 50%), 546 (100%); HRMS (NSI+) 
C23H22BrClNO4S+ ([M+H]+), requires 522.0134; found 522.0136 (−0.4 ppm). 
 
(2S,3R)-Methyl 3-(4-bromophenyl)-2-(4-fluorophenyl)-3-(4-
methylphenylsulfonamido)propanoate 118  
 
The title compound was prepared according to General Procedure D from 4-
fluorophenylacetic acid (30.8 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) 
and purified by chromatography (80:20 Petrol:EtOAc) to give 118 as a white solid 
(56.5 mg, 56%); mp 138-144°C;  −22.2 (c 0.5, CHCl3); Chiral HPLC analysis, 
Chiralcel OD-H (80:20 hexane:IPA, flow rate 0.5 mL min-1, 211 nm, 30 °C), tR minor 
(2R,3S) 17.8 min, tR major (2S,3R) 22.4 min, 76% ee; νmax (neat) 3273.2 (NH), 1718.6 
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(C=O), 1153.4 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.35 (3H, s, ArCH3), 3.61 
(3H, s, OCH3), 3.91 (1H, d, J 6.6, C(2)H), 4.75 (1H, dd, J 8.8, 6.8, C(3)H), 6.05 (1H, 
d, J 9.0, NH), 6.85 (2H, t, J 8.6, C(2)ArC(3)H), 6.90 (2H, d, J 8.4, C(3)ArC(2)H), 
7.02 (2H, d, J 8.0, C(3)NHSO2ArC(3)H), 7.10 (2H, dd, J 8.6, 5.3, C(2)ARC(2)H), 
7.23 (2H, d, J 8.4, C(3)ArC(3)H), 7.34 (2H, d, J 8.2, NHSO2ARC(2)H); 13C{1H} 
NMR (125 MHz, CDCl3) δC: 21.5 (ArCH3), 52.7 (OCH3), 56.6 (C(2)), 60.7 (C(3)),  
115.8 (d, J 21.3, C(2)ArC(3)), 121.8 (CBr), 126.9 (C(3)NHSO2ArC(2)), 128.6 
(C(3)ArC(2)), 129.4 (C(3)NHSO2ArC(3)), 130.2 (d, J 7.5, C(2)ArC(2)), 130.3 (d, J 
3.8, C(2)ArC(1)), 131.6 (C(3)ArC(3)), 137.5 (C(3)ArC1)), 137.7 (C(3)NHSO2C(1)), 
143.3 (ArC(4)CH3), 162.5 (d, J 246.3, ArCF), 172.1 (C(1)); 19F{1H} NMR (470 MHz, 
CDCl3) δF: −114.3 (ArF); m/z (NSI+) 524 ([M+NH4]+, 100%); HRMS (NSI+) 
C23H22BrFNO4S+ ([M+H]+), requires 506.0430; found 506.0431 (−0.3 ppm). 
 
(2S,3R)-Methyl 
2-([1,1'-biphenyl]-4-yl)-3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)propanoat
e 120 
 
The title compound was prepared according to General Procedure D from 
biphenylacetic acid (42.4 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) 
and purified by chromatography (80:20 Petrol:EtOAc) to give 120 as a white solid 
(49.7 mg, 44%); mp 148-154°C;  −45.5 (c 0.5, CHCl3); Chiral HPLC analysis, 
ChiralPak AD-H (90:10 hexane:IPA, flow rate 1.0 mL min-1, 220 nm, 30 °C), tR major 
(2S,3R) 39.4 min, tR minor (2R,3S) 50.3 min, 73% ee; νmax (neat) 3306.0 (NH), 1718.6 
(C=O), 1153.4 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.20 (3H, s, ArCH3), 3.63 
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(3H, s, OCH3), 4.00 (1H, d, J 6.5, C(2)H), 4.84 (1H, dd, J 9.1, 6.5, C(3)H), 6.23 (1H, 
d, J 9.1, NH), 6.93-7.01 (4H, m, ArH), 7.16-7.22 (2H, m, C(3)NHSO2ArC(3)H), 7.22-
7.26 (2H, m, C(3)ArC(3)H), 7.31-7.36 (3H, m, ArH), 7.36-7.48 (4H, m, ArH), 7.50-
7.57 (2H, m, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.4 (ArCH3), 52.6 (OCH3), 
57.1 (C(2)), 60.7 (C(3)), 121.2 (CBr), 127.0 (NHSO2ArC(2)), 127.2 (ArC), 127.4 
(ArC), 127.7 (ArC), 128.7 (ArC), 128.9 (ArC), 129.0 (ArC), 129.2 (NHSO2ArC(3)), 
131.5 (C(3)ArC(3)), 133.5 (Cipso), 137.6 (C(3)NHSO2ArC(1)), 138.0 (C(3)ArC(1)), 
140.2 (C(2)ArC(1)), 140.8 (Cipso), 143.1 (ArC(4)CH3), 172.3 (C(1)) ; m/z (NSI+) 581 
([M+NH4]+, 70%), 588 (100%); HRMS (NSI+) C29H27BrNO4S+ ([M+H]+), requires 
564.0838; found 564.0839 (−0.1 ppm). 
 
(2S,3S)-Methyl 3-(4-bromophenyl)-3-(4-methylphenylsulfonamido)-
2-(phenylthio)propanoate 121 
 
The title compound was prepared according to General Procedure D from 
(phenylthio)acetic acid (33.6 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 99 (70.8 mg, 0.20 mmol) 
and purified by chromatography (80:20 Petrol:EtOAc) to give 121 as a white solid 
and a mixture of diastereoisomers (73.8 mg, 71%). Careful purification allowed an 
analytical sample of each diastereoisomer to be obtained for characterisation 
Data for the anti diastereoisomer: isolated white solid (8.3 mg, 14%); mp 120-124°C; 
 +6.0° (c 0.2, CHCl3); Chiral HPLC analysis, ChiralPak AD-H (80:20 
hexane:IPA, flow rate 1.0 mL min-1, 220 nm, 30 °C), tR major (2S,3S) 20.4 min, tR 
minor (2R,3R) 24.7 min, 61% ee; νmax (neat) 3288.6 (NH), 1710.9 (C=O), 1338.6 (R-
SO2N), 1159.2 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.37 (3H, s, ArCH3), 3.52 
(3H, s, OCH3), 3.85 (1H, d, J 5.3, C(2)H), 4.82 (1H, dd, J 8.8, 5.3, C(3)H), 6.18 ( 1H, 
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d, J 8.8, NH), 6.90 (2H, d, J 8.4, C(3)ArC(2)H), 7.10-7.15 (2H, m, 
C(3)NHSO2ArC(3)H), 7.25-7.31 (7H, m, ArH), 7.53-7.55 (2H, m, 
C(3)NHSO2ArC(2)H); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.6 (ArCH3), 52.7 
(OCH3), 56.8 (C(2)), 58.7 (C(3)), 122.2 (CBr), 127.3 (C(3)NHSO2ArC(3)), 128.6 
(C(3)ArC(2)), 128.8 (ArC), 129.4 (C(3)NHSO2ArC(2)), 129.5 (ArC), 131.7 
(C(3)ArC(3)), 132.8, SArC(1)), 133.3 (ArC), 136.8 (C(3)ArC(1), 137.6 (SO2ArC(1)), 
143.5 (ArC(4)CH3), 170.9 (C(1)); m/z (NSI+) 537 ([M+NH4]+, 75%), 544 (100%); 
HRMS (NSI+) C23H22BrNO4S2Na+ ([M+Na]+), requires 542.0060; found 542.0066 
(−1.1 ppm).  
Selected data for the syn diastereoisomer: isolated as a colourless oil (6.2mg, 8%), 1H 
NMR (400 MHz, CDCl3) δH: 2.41 (3H, s, ArCH3), 3.50 (3H, s, OCH3), 3.80 (1H, d, J 
9.1, C(2)H), 4.55-4.58 (1H, m, C(3)H), 5.70-5.75 (1H, m, NH), 6.97-7.00 (2H, m, 
C(3)ArC(2)H), 7.13-7.16 (2H, m, C(3)NHSO2ArC(3)H), 7.22-7.24 (2H, m, 
C(3)ArC(3)H), 7.32-7.43 (5H, m, ArH), 7.43-7.46 (2H, m, 
C(3)NHSO2ArC(2)H13C{1H} NMR (125 MHz, CDCl3) δC: 21.7 (ArCH3), 52.6 
(OCH3), 56.9 (C(2)), 57.3 (C(3)), 122.5 (CBr), 127.4 (C(3)NHSO2ARC(2)), 129.2 
(ArC), 129.5 (C(3)NHSO2ArC(3)), 129.5 (ArC), 129.9 (C(3)ArC(2)), 130.8 
(SArC(1)), 131.4 (C(3)ArC(3)), 134.0 (ArC), 135.7 (C(3)ArC(1)), 136.9 
(SO2ArC(1)), 143.7 (ArC(4)CH3),169.1 (C(1)); Chiral HPLC analysis, ChiralPak AD-
H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 220 nm, 30°C), tR major: 30.6 min, tR 
minor: 38.4 min, 57% ee. 
 
(2R,3S)-Methyl 3-(4-methylphenylsulfonamido)-2,3-diphenylpropanoate 122 
 
The title compound was prepared according to General Procedure D from 
phenylacetic acid (136.0 mg, 1.0 mmol), tosyl chloride (286.5 mg, 1.50 mmol), 2 
portions of i-Pr2NEt (260 µL, 1.50 mmol), 26 (15.5 mg, 5 mol%, 0.05 mmol), 2.5 M 
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butyl lithium solution in hexanes (0.5 mL, 55 mmol), imine 215 (51.9 mg, 0.2 mmol) 
and purified by chromatography (80:20 Petrol:EtOAc) to give 122 as a white solid 
(219.3 mg, 54%); mp 162-165°C;  −25.6° (c 0.5, CHCl3); Chiral HPLC analysis, 
ChiralPak AD-H (90:10 hexane:IPA, flow rate 0.5 mL min-1, 211 nm, 30 °C), tR minor 
(2S,3R) 61.7min, tR major (2R,3S) 82.0 min, 80% ee; νmax (neat) 3282.8 (NH), 1714.7 
(C=O), 1159.2 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.30 (3H, s, ArCH3), 3.59 
(3H, s, OCH3), 3.97 (1H, d, J 6.5, C(2)H), 4.85 (1H, dd, J 9.1, 6.5, C(3)H), 6.01 (1H, 
d, J 9.1, NH), 6.98 (2H, d, J 8.0, C(3)NHSO2ArC(3)H), 7.00-7.03 (2H, m, ArH), 7.10 
(3H, m, ArH), 7.16-7.20 (5H, m, ArH), 7.34-7.36 (2H, m, C(3)NHSO2ArC(2)H); 
13C{1H} NMR (125 MHz, CDCl3) δC: 21.5 (ArCH3), 52.5 (OCH3), 57.8 (C(2)), 61.2 
(C(3)), 126.8 (ArC), 127.0 (C(3)NHSO2ArC(2)), 127.6 (ArC), 127.9 (ArC), 128.4 
(ArC), 128.6 (ArC), 128.8 (ArC), 129.2 (C(3)NHSO2ArC(3)), 134.9 (C(2)ArC(1)), 
138.8 (C(3)NHSO2C(1)), 142.8 (ArC(4)CH3), 151.1 (C(3)ArC(1)), 172.4 (C(1)); m/z 
(NSI+) 427 ([M+NH4]+, 100%); HRMS (NSI+) C23H24NO4S+ ([M+H]+), requires 
410.1422; found 410.1421 (+0.4 ppm). This was recrystallised from CH2Cl2/Petrol to 
give 122 as a white solid (105.6 mg, 26%); mp 168-172 ˚C;  −30.8° (c 0.5 in 
CHCl3); Chiral HPLC analysis, ChiralPak AD-H (90:10 hexane:IPA, flow rate 0.5 mL 
min-1, 211 nm, 30 °C), tR minor (2S,3R) 61.7min, tR major (2R,3S) 82.0 min, 93% ee. 
 
(2S,3R)-Methyl 3-(furan-2-yl)-3-(4-methylphenylsulfonamido)-2-phenylpropanoate 
124 
 
The title compound was prepared according to General Procedure D from 
phenylacetic acid (27.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 252 (53.6 mg, 0.20 
mmol) and purified by chromatography (80:20 Petrol:EtOAc) to give 124 as a white 
22
D][!
22
D][!
MeO
O NHTs
O
124
Chapter 6: Experimental 
 
152 
solid (43.7 mg, 55%); mp 154-160°C;  −4.6 (c 0.5, CHCl3); Chiral HPLC 
analysis, Chiralcel OJ-H (90:10 hexane:IPA, flow rate 0.5 mL min-1, 211 nm, 30 °C), 
tR major (2S,3R) 45.3 min, tR minor (2R,3S) 53.9 min, 69% ee; νmax (neat) 3263.6 
(NH), 1726.3 (C=O), 1163.1 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.43 (3H, s, 
ArCH3), 3.65 (3H, s, OCH3), 4.12 (1H, d, J 7.1, C(2)H), 4.97 (1H, dd, J 9.7, 7.1, 
C(3)H), 5.66 (1H, d, J 9.8, NH), 5.84 (1H, d, J 3.3, C(3)ArC(3)H), 6.04 (1H, dd, J 
3.2, 1.8, C(3)ArC(4)H), 7.09 (2H, d, J 8.0, NHSO2ArC(3)H), 7.13 (3H, dd, J 9.3, 1.2, 
ArH), 7.20 (3H dd, J 4.8,2.4, ArH), 7.46 (2H, d, J 8.2, SO2ArC(2)H); 13C{1H} NMR 
(125 MHz, CDCl3) δC: 21.6 (ArCH3), 52.5 (OCH3), 55.0 (C(2)), 55.4 (C(3)), 108.4 
(ArC), 110.4 (ArC), 127.0 (ArC), 128.0 (ArC), 128.6 (C(3)NHSO2ArC(3)), 128.7 
(C(2)ArC(1)), 129.4 (C(3)NHSO2ArC(1)), 134.4 (ArC), 137.7 (C(3)NHSO2ArC(1)), 
142.0 (C(3)NHSO2ArC(4)), 143.0 (ArC(4)CH3), 151.1 (C(3)ArC(1)), 172.0 (C(1)); 
m/z (NSI+) 229 (100%), 417 ([M+NH4]+, 55%); HRMS (NSI+) C21H22NO5S+ 
([M+H]+), requires 400.1209; found 400.1213 (−1.0 ppm). 
 
(2S,3R)-Methyl 3-(4-methylphenylsulfonamido)-2-phenyl-3-(4-
(trifluoromethyl)phenyl)propanoate 125 
 
The title compound was prepared according to General Procedure D from 
phenylacetic acid (27.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 251 (65.5 mg, 0.20 
mmol) and purified by chromatography (80:20 Petrol:EtOAc) to give 125 as a white 
solid (46.4 mg, 49%); mp 118-124°C;  −17.6 (c 0.5, CHCl3); Chiral HPLC 
analysis, ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 
°C), tR minor (2R,3S) 15.9 min, tR major (2S,3R) 20.9 min, 47% ee; νmax (neat) 3236.6 
(NH), 1741.7 (C=O), 1323.2 (R-SO2N), 1161.2 (R-SO2N), 1116.8 (CF3); 1H NMR 
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(400 MHz, CDCl3) δH: 2.28 (3H, s, ArCH3), 3.64 (3H,s, OCH3), 3.96 (1H, d, J 7.3, 
C(2)H), 4.94 (1H, dd, J 9.1, 7.3, (C(3)H), 6.34 (1H, d, J 9.1, NH), 6.95 (2H, d J 8.3, 
C(3)NHSO2ArC(3)H), 7.07-7.10 (2H, m, ArH), 7.16-7.19 (5H, m, ArH), 7.29-7.34 
(4H, m, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.4 (ArCH3), 52.7 (OCH3), 57.6 
(C(2)), 60.8 (C(3)), 124.0 (q, J 271.3, CF3), 125.2 (q, J 5, C(3)ArC(3)), 126.9 (ArC), 
127.6 (ArC), 128.2 (ArC), 128.6 (ArC), 128.9 (ArC), 129.3 (ArC), 129.7 (q, J 36.6, 
C(3)ArC(4)CF3), 134.3 (C(2)ArC(1)), 137.4 (C(3)NHSO2ArC(1)), 142.4 
(C(3)ArC(1)), 143.2 (C(3)NHSO2ArC(4)CH3), 172.2 (C(1)); 19F{1H} NMR (470 
MHz, CDCl3) δF: −63.2 (CF3); m/z (NSI+) 495 ([M+NH4]+, 100%); HRMS (NSI+) 
C24H23F3NO4S+ ([M+H]+), requires 478.1289; found 478.1294 (−1.1 ppm). 
 
(2S,3R)-Methyl 3-(4-methylphenylsulfonamido)-3-(naphthalen-1-yl)-2-
phenylpropanoate 126  
 
The title compound was prepared according to General Procedure D from 
phenylacetic acid (27.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 253 (61.9 mg, 0.20 
mmol) and purified by chromatography (80:20 Petrol:EtOAc) to give 126 as a white 
solid (57.6 mg, 63%); mp 122-128°C;  −30.4° (c 0.5, CHCl3); Chiral HPLC 
analysis, Chiralcel OD-H (95:5 hexane:IPA, flow rate 0.4 mL min-1, 211 nm, 30 °C), 
tR minor (2R,3S) 80.1 min, tR major (2S,3R) 101.2 min, 56% ee; νmax (neat) 3286.6 
(NH), 1720.5 (C=O), 1161.2 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.21 (3H, s, 
ArCH3), 3.53 (3H, s, OCH3), 4.23 (1H, d, J 5.0, C(2)H), 5.62 (1H, dd, J 9.2, 5.0, 
C(3)H), 6.63 (1H, d, J 9.0, NH), 6.72-6.86 (2H, m, ArH), 7.15-7.25 (6H, m, ArH), 
7.30-7.38 (3H, m, ArH), 7.48 (1H, ddd, J 8.0, 6.8, 1.2, ArH), 7.56 (1H, ddd, J 8.5, 
6.8, 1.5, ArH), 7.64 (1H, d, J 8.1, ArH), 7.75-7.83 (1H, m, ArH), 8.00 (1H, d, J 8.5, 
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ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.3 (ArCH3), 52.5 (OCH3), 57.6 (C(2)), 
61.3 (C(3)), 124.3 (ArC), 126.2 (ArC), 126.3 (ArC), 126.6 (ArC), 126.9 (ArC), 127.6 
(ArC), 127.9 (ArC), 128.0 (ArC), 128.3 (ArC), 128.7 (ArC), 128.8 (ArC), 129.1 
(ArC), 132.7 (Cipso), 133.0 (Cipso), 134.8 (Cipso), 135.7 (Cipso), 137.6 (Cipso), 142.8 
(ArC(4)CH3), 172.5 (C(1)); m/z (NSI+) 477 ([M+NH4]+, 80%), 482 (100%); HRMS 
(NSI+) C27H25NO4SNa+ ([M+Na]+), requires 482.1387; found 482.1397 (−2.0 ppm). 
 
(2S,3R)-Methyl 3-(4-methylphenylsulfonamido)-3-(naphthalen-2-yl)-2-
phenylpropanoate 127 
 
The title compound was prepared according to General Procedure D from 
phenylacetic acid (27.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 253 (61.9 mg, 0.20 
mmol) and purified by chromatography (80:20 Petrol:EtOAc) to give 127 as a white 
solid (50.3 mg, 55%) as a white solid; mp 164-170°C;  −24.4° (c 0.5, CHCl3); 
Chiral HPLC analysis, ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 
211 nm, 30 °C), tR minor (2R,3S) 18.5 min, tR major (2S,3R) 21.2 min, 95% ee; νmax 
(neat) 3257.8 (NH), 1722.4 (C=O), 1165.0 (R-SO2N); 1H NMR (400 MHz, CDCl3) 
δH: 2.08 (3H, s, ArCH3), 3.61 (3H, s, OCH3), 4.09 (1H, d, J 6.7, C(2)H), 5.03 (1H, dd, 
J 9.2, 6.7, C(3)H), 6.18 (1H, d, J 9.2, NH), 6.77-6.80 (2H, m, ArH), 7.04-7.26 (5H, m, 
ArH), 7.27-7.37 (4H, m, ArH), 7.39-7.43 (2H, m, ArH), 7.52-7.64 (2H, m, ArH), 
7.69-7.72 (1H, m, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.3 (ArCH3), 52.5 
(OCH3), 57.7 (C(2)), 61.3 (C(3)), 124.3 (ArC), 126.1 (ArC), 126.2 (ArC), 126.6 
(ArC), 126.9 (ArC), 127.5 (ArC), 127.9 (ArC), 128.0 (ArC), 128.3 (ArC), 128.7 
(ArC), 128.8 (ArC), 129.1 (ArC), 132.7 (Cipso), 132.9 (Cipso), 134.8 (Cipso), 135.6 
(Cipso), 137.6 (Cipso), 142.8 (ArC(4)CH3), 172.5 (C(1)); m/z (NSI+) 477 ([M+NH4]+, 
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80%), 482 (100%); HRMS (NSI+) C27H25NO4SNa+ ([M+Na]+), requires 482.1387; 
found 482.1397 (−2.0 ppm). 
 
(2S,3R)-Methyl 3-(4-nitrophenylsulfonamido)-2,3-diphenylpropanoate 128 
 
The title compound was prepared according to General Procedure D from 
phenylacetic acid (27.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 
portions of i-Pr2NEt (52 µL, 0.30 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), 2.5 M 
butyl lithium solution in hexanes (0.1 mL, 11 mmol), imine 254 (58.1 mg, 0.20 
mmol) and purified by chromatography (80:20 Petrol:EtOAc) to give 128 as a white 
solid (47.4 mg, 54%); mp 158-162°C;  −20.8° (c 0.5, CHCl3); Chiral HPLC 
analysis, Chiralcel OD-H (90:10 hexane:IPA, flow rate 0.5 mL min-1, 211 nm, 30 °C), 
tR minor (2R,3S) 63.7 min, tR major (2S,3R) 106.7 min, 75% ee; νmax (neat) 3240.4 
(NH), 1739.8 (C=O), 1390.0 (NO2), 1323.2 (RSO2N), 1161.2 (RSO2N); 1H NMR (400 
MHz, CDCl3) δH: 3.60 (s, 3H, OCH3), 4.02 (1H, d, J 5.4, C(2)H), 4.86 (1H, dd, J 9.2, 
5.4, C(3)H), 6.59 (1H, d, J 9.2, NH), 7.09-7.12 (3H, m, ArH), 7.14-7.23 (7H, m, 
ArH), 7.58 (2H, d, J 8.8, NHSO2ArC(2)H), 7.98 (2H, d, J 8.8, NHSO2ArC(3)H); 
13C{1H} NMR (125 MHz, CDCl3) δC: 52.6 (OCH3), 57.1 (C(2)), 61.7 (C(3)), 123.8 
(NHSO2ArC(3)), 126.7 (ArC), 128.0 (ArC), 128.1 (ArC), 128.2 (ArC), 128.3 (ArC), 
128.7 (ArC), 129.0 (NHSOArC(2)), 134.8 (NHSO2ArC(1)), 138.5 (Cipso), 146.5 
(Cipso), 149.4 (CNO2), 172.6 (C(1)); m/z (NSI+) 458 ([M+NH4]+, 100%); HRMS (NSI+) 
C22H24N3O6S+ ([M+NH4]+), requires 458.1382; found 458.1380 (+0.4 ppm). 
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(3S,4R)-4,3-Diphenyl-1-tosylazetidin-2-one 135  
The title compound was prepared according to General Procedure E from imine 215 
(338.0 mg, 1.0 mmol), 26 (15.5 mg, 5 mol%, 0.05 mmol), i-Pr2NEt (215 µL, 1.25 
mmol), benzoic anhydride 134 (381.0 mg, 1.5 mmol) and purified by chromatography 
(90:10 Petrol:EtOAc) to give 135 as a white solid (228.7 mg, 60%); Chiral HPLC 
analysis, Chiralcel OD-H (90:10 hexane:IPA, flow rate 1.0 mL min-1, 254 nm, 30 °C), 
tR major (3S,4R) 14.8 min, tR minor (3R,4S) 19.6 min, 89% ee; 1H NMR (400 MHz, 
CDCl3) δH: 2.45 (3H, s, CH3), 4.27 (1H, d, J 3.4, C(3)H), 4.98 (1H, d, J 3.4, C(4)H), 
7.06 (2H, m, Ph), 7.26-7.34 (10H, m, Ph), 7.71 (2H, m, Ph). All NMR data was in 
accordance to the literature.7 This was recrystallised from CH2Cl2/Petrol to give the 
135 as a white solid (129.5 mg, 34%); mp 91-98 ˚C {lit. mp 123-124 ˚C};  
+35.6° (c 0.5, CHCl3); Chiral HPLC analysis, Chiralcel OD-H (90:10 hexane:IPA, 
flow rate 1.0 mL min-1, 254 nm, 30 °C), tR major (3S,4R) 14.8 min, tR minor (3R,4S) 
19.6 min, >99% ee. 
 
(3S,4R)-3-Phenyl-1-tosyl-4-(4-(trifluoromethyl)phenyl)azetidin-2-one 136 
The title compound was prepared according to General Procedure E from imine 251  
(65.5 mg, 0.20 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), i-Pr2Net (43.0 µL, 0.25 
mmol), benzoic anhydride 134 (76.2 mg, 0.30 mmol) and purified by chromatography 
(80:20 Petrol:EtOAc) to give 136 as a white gum (41.9 mg, 47%);  +17.2° (c 
0.5, CHCl3); Chiral HPLC analysis, Chiralcel OD-H (95:5 hexane:IPA, flow rate 0.25 
mL min-1, 211 nm, 30 °C), tR minor (3R,4S) 82.7 min, tR major (3S,4R) 90.2 min, 68% 
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ee; νmax (neat) 1796 (C=O), 1323 (R-SO2N), 1167 (R-SO2N); 1H NMR (400 MHz, 
CDCl3) δH: 2.47 (3H, s, NSO2ArCH3), 4.25 (1H, d, J 3.4, C(3)H), 5.00 (1H, d, J 3.4, 
C(4)H), 6.98-7.08 (2H, m, ArH),  7.29-7.37 (5H, m, ArH), 7.40-7.43 (2H, m, ArH), 
7.55-7.63 (2H, m, ArH), 7.73-7.76 (2H, m, ArH); 13C{1H} NMR (125 MHz, CDCl3) 
δC: 21.9 (NSO2ArCH3), 64.6 (C(3)), 65.0 (C(4)), 123.9 (q, J 217, CF3), 126.2 (q, J 3, 
C(4)ArC(3)), 126.9 (ArC), 127.4 (ArC), 127.7 (ArC), 128.8 (ArC), 129.5 (ArC), 
130.2 (ArC), 131.5 (q, J 26, C(4)ArC(4)CF3), 132.5 (Cipso), 135.5 (Cipso), 140.3 
(C(4)ArC(1)), 145.9 (NSO2ArC(4)CH3), 165.1 (C(1)); 19F{1H} (282 MHz, CDCl3) δF: 
62.7 (CF3); m/z (NSI+) 463 ([M+NH4]+, 100%); HRMS (NSI+) C23H19BF3NO3S1+ 
([M+H]+), requires 446.1031; found 446.1032 (−0.3 ppm). 
 
(3S,4R)-4-(Naphthalene-2-yl)-3-phenyl-1-tosylazetidin-2-one 138 
 
The title compound was prepared according to General Procedure E from imine 250 
(61.9 mg, 0.20 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), i-Pr2NEt (43.0 µL, 0.25 
mmol), benzoic anhydride 134 (76.2 mg, 0.30 mmol) and purified by chromatography 
(80:20 Petrol:EtOAc) to give 138 as a white solid (47.8 mg, 56%); mp 38-44 °C; 
−8.8° (c 0.25, CHCl3); Chiral HPLC analysis, ChiralPak AD-H (80:20 
hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR major (3S,4R) 19.3 min, tR 
minor (3R,4S) 41.5 min, 92% ee; νmax (neat) 2920, 1792 (C=O), 1456 (C-N), 1364 (R-
SO2N), 1166 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.41 (3H, s, NSO2ArCH3), 
4.36 (1H, d, J 3.0, C(3)H), 5.16 (1H, d, J 3.0,  C(4)H), 7.11-7.14 (2H, m, ArH), 7.16-
7.24 (2H, m, ArH), 7.31-7.35 (3H, m, ArH), 7.48-7.57 (2H, m, ArH), 7.69- 7.72 (3H, 
m, ArH), 7.72-7.76 (2H, m, ArH), 7.80 (1H, d, J 8.5, ArH), 7.82-7.89 (1H, m, ArH); 
13C{1H} NMR (125 MHz, CDCl3) δC: 21.8 (NSO2ArCH3), 64.5 (C(3)), 66.2 (C(4)), 
123.3 (ArC), 126.7 (ArC), 126.9 (ArC), 127.0 (ArC), 127.4 (ArC), 127.8 (ArC), 127.9 
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(ArC), 128.2 (ArC), 128.6 (ArC), 129.2 (ArC), 129.4 (ArC), 130.0 (ArC), 133.0 
(Cipso), 133.1 (Cipso), 133.3 (Cipso), 133.6 (Cipso), 135.8 (C(3)ArC(1)), 145.5 
(NSO2ArC(4)CH3), 165.5 (C(2)); m/z (NSI+) 445 ([M+NH4]+, 100%); HRMS (NSI+) 
C26H25N2O3S+ ([M+NH4]+), requires 445.1578; found 445.1580 (-0.5 ppm).  
Selected data for the syn diastereoisomer: 1H NMR (400 MHz, CDCl3) δH: 2.43 (3H, 
s, NSO2ArCH3), 5.04 (1H, J 6.8, CH), 5.65 (1H, J 6.9, CH); Chiral HPLC analysis, 
ChiralPak AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR 
major: 18.1 min, tR minor: 25.6 min, 54% ee. 
 
 (3S,4R)-1-((4-Nitrophenyl)sulfonyl)-3,4-diphenylazetidin-2-one 140 
The title compound was prepared according to General Procedure E from imine 251 
(58.1 mg, 0.20 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), i-Pr2NEt (43.0 µL, 0.25 
mmol), benzoic anhydride 134 (72.6 mg, 0.30 mmol) and purified by chromatography 
(90:10 Petrol:EtOAc) to give 140 as a white solid (41.6 mg, 51%). mp 108-114 ˚C; 
 −2.1° (c 0.9, CHCl3); Chiral HPLC analysis, ChiralPak AD-H (80:20 
hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR minor (3R,4S) 28.3 min, tR 
major (3S,4R) 32.6 min, 85% ee;  νmax (KBr) 1797 (C=O), 1529 (NO2), 1379 (C-N), 
1176 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 4.42 (1H, d, J 3.45, C(3)H), 5.12 
(1H, d, J 3.43, C(4)H), 7.17-7.20 (2H, m, ArH), 7.24-7.25 (1H, m, ArH), 7.32-7.40 
(7H, m, ArH), 7.92-7.97 (2H, m, NSO2ArC(2)H), 8.27-8.29 (2H, m, NSO2ArC(3)H); 
13C{1H} NMR (100 MHz, CDCl3) δC: 64.2 (C(3)), 66.3 (C(4)), 124.3 (NSO2ArC(3)), 
126.8 (ArC), 127.0 (ArC), 128.6 (ArC), 128.8 (NSO2ArC(2)), 129.1 (ArC), 129.3 
(ArC), 129.6 (ArC), 132.2 (C(4)ArC(1)), 135.0 (C(3)ArC(1)), 144.1 (NSO2ArC(1)), 
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150.7 (NSO2ArC(4)), 164.8 (C(2)); m/z (APCI+) 409 ([M+H]+,100%); HRMS 
(APCI+) C21H17N2O5S+ ([M+H]+), requires 409.0851; found 409.0853(−0.4 ppm). 
 
 (3S,4R)-4-(4-bromophenyl)-3-(thiophen-3-yl)-1-tosylazetidin-2-one 142 
 
The title compound was prepared according to General Procedure E from imine 99 
(70.8 mg, 0.2 mmol), 26 (3.1 mg, 5 mol%, 0.01 mmol), i-Pr2NEt (43.0 µL, 0.25 
mmol), anhydride 134 (79.9 mg, 0.3 mmol) and purified by chromatography (80:20 
Petrol:EtOAc) to give 142 as a white solid (43.5 mg, 47%); mp 104-106 ˚C; 
+20.0° (c 0.5, CHCl3); Chiral HPLC analysis, Chiralcel OD-H (90:10 hexane:IPA, 
flow rate 1.0 mL min-1, 220nM, 30°C), tR minor (3R,4S) 26.6 min, tR major (3S,4R) 
34.1 min, 82% ee; νmax (neat) 3109 (thiophene CH), 1792 (C=O), 1487 (C-N), 1373 
(R-SO2N), 1173 (R-SO2N); 1H NMR (400 MHz, CDCl3) δH: 2.47 (3H, s, 
NSO2ArCH3), 4.29 (1H, d, J 3.3, C(3)H), 4.87 (1H, d, J 3.3, C(4)H), 6.76 (1H, dd, J 
1.3, 5.0, C(3)ArH), 7.08 (1H, dt, J 0.9, 1.8, C(3)ArH), 7.16-7.18 (2H, m, ArH), 7.31-
7.34 (3H, m, ArH), 7.46-7.48 (2H, m, ArH), 7.72-7.74 (2H, m, ArH); 13C{1H} NMR 
(125 MHz, CDCl3) δC: 21.9 (NSO2ArCH3), 60.1 (C(3)), 64.9 (C(4)), 123.4 (C(3)ArC), 
125.8 (C(3)ArC), 127.6 (ArC), 127.7 (ArC), 128.2 (ArC), 130.1 (ArC), 132.1 (Cipso), 
135.2 (Cipso), 135.5 (Cipso), 145.8 (NSO2ArC(4)CH3), 164.9 (C(2)), 185.4 (Cipso); m/z 
(NSI+) 579 ([M+NH4]+, 85%), 481 ([M+NH4]+, 100%); HRMS (NSI+) 
C20H17BrNO3S2+ ([M+NH4]+), requires 461.9830; found 461.9828 (+0.5 ppm). 
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6.2.7 Detosylation reaction 
(3S,4R)-4-(4-Bromophenyl)-3-phenylazetidin-2-one 144 
Using a modified version of the procedure by Lectka et al.8 N-tosylazetidinone 100 
(54.1 mg, 0.12 mmol, 1 equiv.) was stirred in THF (1mL) at room temperature and 
SmI2 (7.80 mL, 0.72 mmol, 6 equiv.) was added dropwise until the colour remained 
consistent. The reaction mixture was stirred for 5 min, quenched with NaHCO3 (5 
mL), extracted (3 × EtOAc), dried (MgSO4) and concentrated in vacuo to give the 
crude product as a yellow oil. Following purification by column chromatography 
(60:40 Petrol:EtOAc) 144 was isolated as a colourless oil (14.6 mg, 48%).  
−55.6° (c 0.5, CHCl3); Chiral HPLC analysis, Chiralcel OD-H (80:20 hexane:IPA, 
flow rate 1.0 mL min-1, 211nm, 25°C), tR major (3S,4R) 29.2 min, tR minor (3R,4S) 
38.9 min, 90% ee; νmax (neat) 3263 (NH), 1751 (C=O); 1H NMR (400 MHz, CDCl3) 
δH: 4.17 (1H, d, J 2.40, C(3)H), 4.65 (1H, d, J 2.40, C(4)H), 6.34 (1H, br s, NH), 
7.28-7.32 (4H, m, ArH), 7.34-7.39 (2H, m, ArH), 7.53-7.55 (2H, m, ArH); 13C{1H} 
NMR (125 MHz, CDCl3) δC: 59.8 (C(3)), 66.4 (C(4)), 122.5 (CBr), 127.4 (ArC), 
127.5 (ArC), 128.1 (ArC), 129.2 (ArC), 132.3 (ArC), 134.5 (Cipso), 138.7 (Cipso), 
168.8 (C(2)); m/z (NSI+) 324 (100%), 319 ([M+NH4]+, 85%); HRMS (NSI+) 
C15H13BrNO+ ([M+H]+), requires 302.0178; found 302.0175 (+1.0 ppm). 
 
6.2.8 Control Experiments 
6.2.8.1 Control Experiment (a) 
β-lactam 139 was prepared according to General Procedure C from phenyl acetic 
acid (27.2 mg, 0.20 mmol), tosyl chloride (57.3 mg, 0.30 mmol), 2 portions of i-
Pr2NEt (52 µL, 0.30 mmol), 26 (10 mg, 20 mol%, 0.04 mmol) and imine 250 (70.8 
mg, 0.20 mmol). The reaction was monitored over time using 1H NMR for changes in 
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the diastereomeric ratio. The results are shown in table S1 and from this it was 
concluded that syn product is initially formed in a small quantity however under the 
reaction conditions it is epimerised to the anti product to give the observed ratio of 
products. 
 
Table S1 
6.2.8.2 Control Experiment (b) 
A sample of β-lactam 139 (3.3 mg, 0.007 mmol) with of a known dr (anti:syn 21:79) 
and ees  (anti 90%, syn 52%) was dissolved in dichloromethane (1 mL) and treated 
with i-Pr2Net (100 µL, 0.6 mmol) and 26 (3.1 mg, 0.01 mmol). The reaction was 
stirred at room temperature for 3 h, quenched with 1 M HCl, extracted (3 × CH2Cl2), 
dried (MgSO4) and concentrated in vacuo to give the crude product (dr >95:5) with 
identical spectroscopic data as previously reported; Chiral HPLC analysis, ChiralPak 
AD-H (80:20 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR minor (3S,4R)  
19.3 min, tR major (3R,4S) 41.5 min, 32% ee. 
Obtaining (ent)-anti-139 (>95:5 dr, 32% ee) is consistent with the minor syn-
diastereoisomer having preferentially the (3S,4S)-configuration and in situ 
epimerization generating ent-139 preferentially. 
  
dr (anti:syn)
86:14
86:14
86:14
>95:5
time / mins
15
60
120
300
conversion
18
60
72
80
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6.3 Experimental for Chapter 3 
6.3.1 General Experimental Procedures 
6.3.1.1 General Procedure F: Potassium Fluoride Mediated 
Hydrophosphonation of Cinnamaldehydes 
Using a modified version of the procedure described by Texier-Boullet and Foucaud9 
the requisite aldehyde (1.0 equiv.) and desired phosphite (2.0 equiv.) were added to 
solid potassium fluoride (5.0 equiv.) and stirred vigorously at rt for 16 h before 
diluting with CH2Cl2 and stirring vigorously at rt for a further 2 h. The suspension was 
filtered and the filtrate concentrated in vacuo to give the crude product. 
6.3.1.2 General Procedure G: Parikh–Doering Oxidation 
Following the procedure described by Evans et al.,10 to a solution of the requisite 
allylic alcohol (1.0 equiv.) in CH2Cl2 at −10 °C was added a saturated solution of 
SO3.pyridine (3.0 equiv.) in DMSO and i-Pr2NEt (3.0 equiv.) and the reaction stirred 
at −10 °C until complete by tlc (warming to rt if necessary). Upon completion the 
reaction was diluted with Et2O and washed consecutively with H2O, saturated aqueous 
NaHCO3, saturated aqueous CuSO4 and brine. The ethereal solution was dried over 
MgSO4 and concentrated in vacuo to give the crude product. 
6.3.1.3 General Procedure H: Asymmetric Intermolecular Michael Addition-
Lactonisation Followed by In Situ Methanolysis 
To a solution of acetic acid (1.0 equiv.) in CH2Cl2 (0.1M) was added i-Pr2NEt (1.5 
equiv.) and pivaloyl chloride (1.5 equiv.) at 0 °C. The reaction mixture was stirred at 
0 °C for 20 min. after which the ice bath was replaced with a dry ice/acetone bath and 
the reaction cooled to −78 °C and (2S,3R)-HBTM-2.1 (1 mol%), the desired 
phosphonate acceptor (1.5 equiv.) as a solution in CH2Cl2 (0.1M) and i-Pr2NEt (2.5 
equiv.) were added and the reaction stirred at −78 °C for 24 h. MeOH (0.2M) was 
added and the reaction stirred at −78 °C warming to room temperature for a further 24 
h. 1M HCl was added to quench the reaction. The organic phase was separated and the 
aqueous phase extracted with CH2Cl2 (2 ×). The combined organics were dried 
(MgSO4) and concentrated in vacuo to give the crude reaction mixture which was 
purified by column chromatography. 
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6.3.1.4 General Procedure I: Selective Reduction Followed By Lactonisation 
To a solution of the requisite diester (1.0 equiv.) in THF (3 mL) at 0 °C was added 
DIBAL-H (2.2 equiv.) and the reaction stirred for 90 min. 1 M HCl (5 mL) was added 
and the biphasic mixture stirred vigorously for 5 min. The organic phase was removed 
and the aqueous phase was extracted with CH2Cl2 (5 × 15 mL). The combine organic 
layers were dried (MgSO4), filtered and concentrated in vacuo to give the 
intermediate alcohol which was redissolved in CH2Cl2 and treated with TFA (2 drops). 
The solution stirred at rt for 1 h before concentration in vacuo. The resultant solid was 
re-dissolved in CH2Cl2 and washed with sat. aqueous NaHCO3 (2 × 2 mL). The 
organic phase was dried (MgSO4) and concentrated in vacuo to give the crude 
product, which was purified by column chromatography under the described 
conditions. 
6.3.2 Starting Material Synthesis 
6.3.2.1 ?-Ketophosphonates 
(E)-Dimethyl (1-hydroxy-3-phenylallyl)phosphonate 160 
 
Following General Procedure F, to a solution of cinnamaldehyde 158 (21.0 mL, 167 
mmol) and dimethyl phosphite 159 (15.3 mL, 167 mmol) in CH2Cl2 (220 mL) was 
added triethylamine (23.3 mL, 167 mmol) and the reaction mixture stirred at rt for 72 
h before concentration in vacuo gave the crude product. Trituration with Et2O gave 
160 as a colourless solid (23.8 g, 58% yield) with spectroscopic data in accordance 
with the literature10 and which was used in the next step without further purification; 
mp 97-99 °C; {lit.10 101-102 °C; 1H (300 MHz, CDCl3) δH: 3.84 (6H, d, J 10.4, 
OCH3), 4.07 (1H, br s, OH), 4.73 (1H, ddd, J 12.9, 6.3, 1.5, C(OH)H), 6.34 (1H, ddd, 
J 15.9, 6.3, 5.4, C(2)H), 6.81 (1H, ddd, J 15.9, 4.8, 1.5, C(3)H), 7.24-7.36 (3H, m, 
ArH(3,4)), 7.39-7.45 (2H, m, ArH(2)); 31P{1H} (121 MHz, CDCl3) δP: 28.8. 
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(E)-Dimethyl cinnamoylphosphonate 161 
 
Following General Procedure G, (E)-dimethyl (1-hydroxy-3-phenylallyl)phosphonate 
160 (12.0 g, 49.5 mmol), SO3.pyridine (23.6 g, 149 mmol), i-Pr2NEt (25.9 mL, 149 
mmol) and DMSO (100 mL) were stirred in CH2Cl2 (400 mL) at –10 ºC for 4 h to 
give 161 as a yellow oil (8.10 g, 68%) with spectroscopic data in accordance to the 
literature,10 which was used without further purification; 1H (300 MHz, CDCl3) δH: 
3.90 (6H, d, J 10.8, OCH3), 7.08 (1H, dd, J 16.3, 12.9, C(2)H), 7.40-7.47 (3H, m, 
ArC(3,4)H), 7.61-7.67 (2H, m, ArC(2)H), 8.12 (1H, d, J 16.3, C(3)H); 31P{1H} (121 
MHz, CDCl3) δP: 0.5. 
 
 (E)-Diisopropyl (1-hydroxy-3-phenylallyl)phosphonate 256 
 
Following General Procedure F, cinnamaldehyde (2.52 mL, 20 mmol), diisopropyl 
phosphite (3.34 mL, 17.0 mmol) and potassium fluoride (5.80 g, 50.0 mmol) were 
stirred at rt for 48 h to gve the crude product 256 as a yellow oil, which was used in 
the next step without further purification; 1H (300 MHz, CDCl3) δH: 0.89-1.05 (12H, 
m, 4 i-PrCH3), 4.26-4.50 (3H, m, 2 i-PrCH and C(1)H), 5.77 (1H, br s, OH), 6.07 (1H, 
dt, J 15.9, 5.4, C(2)H), 6.48 (1H, dd, J 15.9, 4.7, C(3)H), 6.98-7.06 (5H, m, ArH); 
31P{1H} (121 MHz, CDCl3) δP: 20.2. 
 
(E)-Diisopropyl cinnamoylphosphonate 163 
  
Following General Procedure G, allylic alcohol 256 (5.96 g, 20.0 mmol), 
SO3.pyridine (4.69 g, 30.0 mmol), i-Pr2NEt (5.23 mL, 30.0 mmol) and DMSO (20 
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mL) were stirred in CH2Cl2 (100 mL) at –10 ºC for 1 h to give the crude product. 
Purification via column chromatography on silica gel (Petrol:EtOAc 60:40) gave 163 
as a yellow oil (2.41 g, 41% over two steps) with spectroscopic data in accordance 
with the literature;11 1H (300 MHz, CDCl3) δH: 1.34-1.43 (12H, m, 4 i-PrCH3), 4.67-
4.87 (2H, m, 2 i-PrCH), 7.11 (1H, dd, J 16.3, 10.8, C(2)H), 7.39-7.46 (3H, m, 
ArH(3,4)), 7.59-7.66 (2H, m, ArH(2)), 8.09 (1H, d. J 16.3, C(3)H); 31P{1H} (121 
MHz, CDCl3) δP:  3.1. 
 
6.3.3 Optimisation Studies on 162 
 
 
Solvent Screen: 
 
To a solution of phenylacetic acid (54.4 mg, 0.40 mmol, 1 equiv.), was added i-
Pr2NEt (104.6 μL, 0.60 mmol, 1.5 equiv.) and pivaloyl chloride (74.0 μL, 0.60 mmol, 
1.5 equiv.) at 0 °C. The desired phosphonate acceptor 161 (144.1 mg, 0.60 mmol, 1.5 
equiv.) as a solution, (2S,3R)-HBTM-2.1 26 (1.2 mg, 0.004 mmol, 1 mol%), and i-
Pr2NEt (174.3 μL, 1 mmol, 2.5 equiv.)  were added. All reactions were carried out for 
18h at rt.  
 
In CH2Cl2 (2+2 mL) gave crude 162 (88:12 dr). Chromatographic purification (40:60 
Petrol:EtOAc) gave 162 (>95:5 dr) as a yellow oil (73.4 mg, 51%); 86% ee. 
 
In THF (2+2 mL) gave crude 162 (50% conversion, 88:12 dr). Chromatographic 
purification (40:60 Petrol:EtOAc) gave 162 (>95:5 dr) as a yellow oil (59.0 mg, 
41%%); 97% ee. 
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Asymmetric Catalyst Screen: 
 
To a solution of phenylacetic acid (54.4 mg, 0.40 mmol, 1 equiv.) in CH2Cl2 (2 mL), 
was added i-Pr2NEt (104.6 μL, 0.60 mmol, 1.5 equiv.) and pivaloyl chloride (74.0 μL, 
0.60 mmol, 1.5 equiv.) at 0 °C. The desired phosphonate acceptor 161 (144.1 mg, 
0.60 mmol, 1.5 equiv.) as a solution in CH2Cl2 (2 mL) and i-Pr2NEt (174.3 μL, 1 
mmol, 2.5 equiv.)  were added. All reactions were carried out for 2h at rt.  
 
With (2S,3R)-HBTM-2.1 26 (12 mg, 0.04 mmol, 10 mol%) gave crude 162 (88:12 
dr). Chromatographic purification (40:60 Petrol:EtOAc) gave 162 (>95:5 dr) as a 
yellow oil (73.4 mg, 51%); 86% ee. 
 
With (R)-BTM 23 (10 mg, 0.04 mmol, 10 mol%) gave crude 162 (74:26 dr). 
Chromatographic purification (40:60 Petrol:EtOAc) gave 162 (>95:5 dr) as a yellow 
oil (60.4 mg, 42%); 56% ee. 
 
6.3.4 Experimental Procedures 
(3R,4S)-Dimethyl (2-oxo-3,4-diphenyl-3,4-dihydro-2H-pyran-6-yl)phosphonate 162 
 
To a solution of phenylacetic acid 98 (54.4 mg, 0.40 mmol, 1 equiv.), in CH2Cl2 (2 
mL, 0.1M) was added i-Pr2NEt (104.6 μL, 0.60 mmol, 1.5 equiv.) and pivaloyl 
chloride (74.0 μL, 0.60 mmol, 1.5 equiv.) at 0 °C. The reaction mixture was stirred at 
0 °C for 20 min after which the ice bath was replaced with a dry ice/acetone bath and 
the reaction cooled to −78 °C and (2S,3R)-HBTM-2.1 26 (1.2 mg, 0.004 mmol, 1 
mol%), the desired phosphonate acceptor 161 (144.1 mg, 0.60 mmol, 1.5 equiv.) as a 
solution in CH2Cl2 (2 mL, 0.1M) and i-Pr2NEt (174.3 μL, 1 mmol, 2.5 equiv.) were 
added and the reaction stirred at −78 °C for 24 h. 1M HCl was added to quench the 
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reaction. The organic phase was separated and the aqueous phase extracted CH2Cl2 (2 
× 5 mL). The combined organics were dried (MgSO4) and concentrated in vacuo to 
give the crude reaction mixture. Purification via column chromatography on silica gel 
(Petrol:EtOAc 40:60) gave 162 (119.4 mg, 83%) as a yellow oil.  −45.0 (c 1.0, 
CHCl3); Chiral HPLC analysis, Chiralpak AD-H (90:10 hexane:IPA, flow rate 1.0 
mLmin-1, 220 nm, 24 °C) tR (3R,4S) major 30.4 min, tR (3S,4R) minor 33.6 min, 98% 
ee; νmax (film) 3029.0 (C-H), 2958.0, 1776.0 (C=O), 1452.0, 1260.0 (P=O), 1050.0 (P-
O); 1H NMR (400 MHz, CDCl3) δH: 3.81 (3H, d, J 11.2, OCH3), 3.89 (3H, d, J 11.2, 
OCH3), 3.96 (1H, d, J 8.5, C(3)H), 4.07 (1H, m, C(4)H), 6.53 (1H, dd, J 10.2, 3.8, 
C(5)H), 7.04 (2H, m, ArH), 7.11 (2H, m, ArH), 7.22-7.29 (6H, m, ArH); 13C{1H} 
NMR (100 MHz, CDCl3) δC: 45.7 (d, J 12.6, C(4)), 52.7 (C(3)), 53.8 (app. t, J 6.0, 2 
OCH3), 123.2 (d, J 19.3, C(5)), 127.5 (2 ArC), 128.0 (C(4)ArC(4)), 128.1 (ArC), 
128.3 (2 ArC), 128.9 (2 ArC), 129.1 (2 ArC), 135.4 (Cipso), 138.9 (C(4)ArC(1)), 143.4 
(d, J 232.0, C(6)), 167.0 (d, J 8.5, C(2)); 31P{1H} NMR  (121 MHz, CDCl3) δP: + 
7.12; HRMS (ASAP) C19H20O5P [M+H]+, found 359.1043, requires 359.1042 (−0.2 
ppm).  
 
 (2R,3R)-Dimethyl 2,3-diphenylpentanedioate 164 
 
Following General Procedure H, phenylacetic acid 98 (476 mg, 3.50 mmol), i-Pr2NEt 
(0.87 mL, 5.00 mmol) and pivaloyl chloride (0.62 mL, 5.00 mmol) in CH2Cl2 (4.50 
mL) with isothiourea 26 (10.9 mg, 0.05 mmol), (E)-diisopropyl 
cinnamoylphosphonate 163 (1.50 g, 5.00 mmol) in CH2Cl2 (4.50 mL) and i-Pr2NEt 
(1.45 mL, 8.50 mmol) for 24 h at −78 °C followed by addition of MeOH (9 mL) and a 
further 24 h at −78 °C gave the crude product (>95:5 dr anti:syn). Purification via 
column chromatography on silica gel (Petrol:EtOAc 90:10) gave diester 164 (0.95 g, 
87%, >95:5 dr) as a colourless solid. mp 62-63 °C;  –125.7 (c 0.3, CHCl3); 
Chiral HPLC analysis, Chiralpak AD-H (95:5 hexane:IPA, flowrate 1 mLmin-1, 220 
nm, 30 °C) tR(2S,3S) minor 10.6 min, tR(2R,3R) major 12.5 min, 98% ee; νmax (film) 
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2957 (C–H), 1777 (C=O), 1603, 1508, 1456, 1263, 1225 (C–O), 1113 (C–O), 1016; 
1H NMR (400 MHz, CDCl3) δH: 2.76-2.86 (2H, m, CH2), 3.51 (3H, s, C(5)O2CH3), 
3.69 (3H, s, C(1)O2CH3), 3.83-3.93 (2H, m, C(2)H and C(3)H), 6.98-7.14 (10H, m, 
ArH); 13C{1H} NMR (100 MHz, CDCl3) δC: 39.3 (C(4)), 45.6 (C(3)), 51.7 
(C(5)O2CH3), 52.3 (C(1)O2CH3), 57.3 (C(2)), 126.8 (ArC(4)), 127.4 (ArC(4)), 128.2 
(4 ArC), 128.4 (2 ArC), 128.7 (2 ArC), 136.7 (C(2)ArC(1)), 140.3 (C(3)ArC(1)), 
172.0 (C(5)), 173.5 (C(1)); HRMS (NSI+) C19H21O4 [M+H]+ found 313.1439, requires 
313.1434; (+1.5 ppm).  
 
(2R,3R)-Dimethyl 2-(4-methoxyphenyl)-3-phenylpentanedioate 166 
 
Following General Procedure H, 2-(4-methoxyphenyl)acetic acid (32.0 mg, 0.20 
mmol), i-Pr2NEt (52.3 μL, 0.30 mmol) and pivaloyl chloride (37.0 μL, 0.30 mmol) in 
CH2Cl2 (2 mL) with isothiourea 26 (6.2 mg, 0.02 mmol), (E)-dimethyl 
cinnamoylphosphonate 163 (72.1 mg, 0.30 mmol) in CH2Cl2 (2 mL) and i-Pr2NEt 
(87.1 μL, 0.50 mmol) for 24 h at −78 °C followed by addition of MeOH (2 mL) and a 
further 24 h at −78 °C gave the crude product (93:7 dr anti:syn). Purification via 
column chromatography on silica gel (Petrol:EtOAc 90:10) gave diester 166 (36.1 
mg, 56%, 94:6 dr) as a colourless solid; mp 99-101 °C;  –135.1 (c 0.2, CHCl3); 
Chiral HPLC analysis, Chiralpak AD-H (95:5 hexane:IPA, flowrate 1 mL min-1, 254 
nm, RT) tR(2S,3S) minor 14.8 min, tR(2R,3R) major 22.3 min, 98% ee; νmax (film) 
2953 (C–H), 1734 (C=O), 1728 (C=O), 1510, 1437, 1246 (C–O), 1178 (C–O); 1H 
NMR (300 MHz, CDCl3) δH: 2.72-2.84 (2H, m, CH2), 3.51 (3H, s, C(5)O2CH3), 3.67 
(3H, s, OCH3), 3.70 (3H, s, OCH3), 3.75-3.85 (2H, m, C(2)H and C(3)H), 6.62-6.70 
(2H, m, C(2)ArC(3)H), 6.96-7.16 (7H, m, C(2)ArC(2)H and C(3)ArCH); 13C{1H} 
NMR (75 MHz, CDCl3) δC: 39.4 (C(4)), 45.6 (C(3)), 51.7 (C(5)O2CH3), 52.2 (OCH3), 
55.2 (OCH3), 56.4 (C(2)), 113.8 (2 C(2)ArC(3)), 126.8 (C(3)ArC(4)), 128.3 (4 
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C(3)ArC(2,3)), 128.8 (C(2)ArC(1)), 129.7 (2 C(2)ArC(2)), 140.4 (C(3)ArC(1)), 158.8 
(C(2)ArC(4)), 172.0 (C(5)), 173.8 (C(1)); HRMS (NSI)+ C20H23O5+ [M+H]+, found 
343.1545, requires 343.1540 (+1.5 ppm). 
 
(2R,3R)-Dimethyl 2-(4-fluorophenyl)-3-phenylpentanedioate 167 
 
Following General Procedure H, 2-(4-fluorophenyl)acetic acid (30.8 mg, 0.20 
mmol), i-Pr2NEt (52.3 μL, 0.30 mmol) and pivaloyl chloride (37.0 μL, 0.30 mmol) in 
CH2Cl2 (2 mL) with isothiourea 26 (0.6 mg, 0.002 mmol), (E)-dimethyl 
cinnamoylphosphonate 163 (72.1 mg, 0.30 mmol) in CH2Cl2 (2 mL) and i-Pr2NEt 
(87.1 μL, 0.50 mmol) for 24 h at −78 °C followed by addition of MeOH (2 mL) and a 
further 24 h at −78 °C gave the crude product (91:9 dr anti:syn). Purification via 
column chromatography on silica gel (Petrol:EtOAc 90:10) gave diester 167 (46.2 
mg, 70%, >98:2 dr) as a colourless solid. mp 86-88 °C;  –119.5 (c 0.2, CHCl3); 
Chiral HPLC analysis, Chiralpak AD-H (95:5 hexane:IPA, flowrate 1 mL min-1, 220 
nm, RT) tR(2S,3S) minor 11.5 min, tR(2R,3R) major 13.9 min, 98% ee; νmax (film) 
2841 (C–H), 1745 (C=O), 1730 (C=O), 1508, 1435, 1229 (C–O), 1206 (C–O), 1080, 
1018; 1H NMR (300 MHz, CDCl3) δH: 2.76-2.81 (2H, m, CH2), 3.51 (3H, s, 
C(5)O2CH3), 3.70 (3H, s, C(1)O2CH3), 3.80-3.83 (2H, m, C(2)H and C(3)H), 6.77-
6.85 (2H, m, C(2)ArC(3)H, 6.95-6.99 (2H, m, ArH), 7.05-7.12 (5H, m, ArH); 
13C{1H} NMR (75 MHz, CDCl3) δC: 39.4 (C(4)), 45.7 (C(3)), 51.7 (C(5)O2CH3), 52.4 
(C(1)O2CH3), 56.5 (C(2)), 115.3 (d, J 21.4, 2 C(2)ArC(3)), 126.9 (C(3)ArC(4)), 128.2 
(2 ArC), 128.3 (2 ArC), 130.3 (d, J 8.1, 2 C(2)ArC(2)), 132.5 (d, J 3.3, C(2)ArC(1)), 
140.1 (C(3)ArC(1)), 162.1 (d, J 246.0, (C(2)ArC(4)), 171.9 (C(5)), 173.4 (C(1)); 
19F{1H} NMR (282 MHz, CDCl3) δF:–115.6; HRMS (NSI)+ C19H20FO4+ [M+H]+, 
found 331.1345, requires 331.1340 (+1.5 ppm). 
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(2R,3R)-Dimethyl 2-(1-methyl-1H-indol-3-yl)-3-phenylpentanedioate 168 
 
Following General Procedure H, 1-methyl-3-indoleacetic acid (37.8 mg, 0.20 mmol), 
i-Pr2NEt (52.3 μL, 0.30 mmol) and pivaloyl chloride (37.0 μL, 0.30 mmol) in CH2Cl2 
(2 mL) with isothiourea 26 (0.6 mg, 0.002 mmol), (E)-diisopropyl 
cinnamoylphosphonate 163 (72.1 mg, 0.30 mmol) in CH2Cl2 (2 mL) and i-Pr2NEt 
(87.1 μL, 0.50 mmol) for 24 h at −78 °C followed by addition of MeOH (2 mL) and a 
further 24 h at −78 °C gave the crude product (86:14 dr anti:syn). Purification via 
column chromatography on silica gel (Petrol:EtOAc 90:10) gave diester 168 (73.1 
mg, 62%, 86:14 dr) as a brown oil.  –39.8 (c 1.0, CHCl3); Chiral HPLC analysis, 
Chiralpak AD-H (95:5 hexane:IPA, flowrate 1 mLmin-1, 220 nm) tR(2S,3S) minor 
23.3 min, tR(2R,3R) major 49.6 min, 88% ee; νmax (film) 2951 (C–H), 1732 (C=O), 
1717 (C=O), 1612, 1472, 1200 (C–O), 1085, 1013; 1H NMR (300 MHz, CDCl3) δH: 
2.87 (2H, d, J 7.4, CH2), 3.49 (3H, s, C(5)O2CH3), 3.65 (3H, s, CH3), 3.65 (3H, s, 
CH3), 3.94-4.03 (1H, m, C(3)H), 4.26 (1H, d, J 9.1, C(2)H), 6.85 (1H, s, 
indoleC(2)H), 7.04-7.25 (8H, m, ArH), 7.60 (1H, dt, J 7.9, 1.0, ArH); 13C{1H} NMR 
(100 MHz, CDCl3) δC: 32.9 (NCH3), 38.5 (C(4)), 44.7 (C(3)), 48.6 (C(2)), 51.6 
(C(5)O2CH3), 52.1 (C(1)O2CH3), 109.3 (indoleC(7)), 109.6 (indoleC(3)), 119.3 (ArC), 
119.3 (ArC), 121.7 (ArC), 126.8 (ArC(4)), 128.0 (2 ArC), 128.2 (2 ArC), 128.3 
(indoleC(2)), 128.6 (indoleC(3a)), 136.8 (indoleC(7a)), 141.2 (ArC(1)), 172.4 (C(5)), 
173.9 (C(1)); HRMS (NSI)+ C22H24NO4+ [M+H]+, found 366.1703, requires 366.1700 
(+0.9 ppm). 
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(2S,3R)-Dimethyl 3-phenyl-2-(thiophen-3-yl)pentanedioate 170  
 
Following General Procedure H, 3-thiopheneacetic acid (56.9 mg, 0.40 mmol), i-
Pr2NEt (104.6 μL, 0.45 mmol) and pivaloyl chloride (74.0 μL, 0.45 mmol) in CH2Cl2 
(2 mL) with 26 (1.24 mg, 0.004 mmol), (E)-diisopropyl cinnamoylphosphonate 163 
(177.8 mg, 0.60 mmol) in CH2Cl2 (2 mL) and i-Pr2NEt (174.3 μL, 1.00 mmol) for 24 
h at −78 °C followed by addition of MeOH (2 mL) and a further 24 h at −78 °C 
warming to room temperature gave the crude product (>95:5 dr anti:syn). Purification 
via column chromatography on silica gel (Petrol:EtOAc 90:10) gave diester 170 
(109.6 mg, 86%, >95:5 dr) as a white solid. mp 60-64 °C;  −69.0° (c 0.5, 
CHCl3); Chiral HPLC analysis, Chiralcel AD-H (90:10 hexane:IPA, flow rate 0.5 
mLmin-1, 211 nm, 30 ˚C), tR(2R,3S) minor 15.4 min, tR(2S,3R) major 17.7 min, >99% 
ee; νmax (film) 2958 (C-H), 2359, 1732 (C=O), 1072; 1H NMR (300 MHz, CDCl3) δH: 
2.77-2.80 (2H, m, CH2), 3.52 (3H, s, C(5)O2Me), 3.71 (3H, s, C(1)O2Me), 3.75-3.83 
(1H, m, C(3)H), 4.00 (1H, d, J 10.2, C(2)H), 6.85 (1H, dd, J 5.0, 1.3, C(2)ArH), 6.91 
(1H, dd, J 3.0, 1.3, C(2)ArH), 6.99-7.03 (2H, m), 7.08-7.20 (4H, m); 13C{1H} NMR 
(75 MHz, CDCl3) δC: 38.8 (C(4)), 45.8 (C(3)), 51.7 (C(5)O2CH3), 52.3 (C(1)O2CH3), 
52.8 (C(2)), 123.2 (C(2)ArC(3)), 125.3 (C(2)ArC), 127.0 (C(3)ArC(4)), 127.6 
(C(2)ArC), 128.1 (2 C(3)ArC(2)), 128.3 (2 C(3)ArC(3)), 136.7 (C(2)ArC), 140.4 
(C(3)ArC(1)), 172.0 (C(5)), 173.2 (C(1)); HRMS (NSI)+ C15H15O2S+ [M+H]+, found 
259.0787, requires 259.0790 (+1.1 ppm). 
 
(2S,3R)-Dimethyl 3-phenyl-2-((E)-prop-1-en-1-yl)pentanedioate 171 
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Following General Procedure H, 3-pentanoic acid (40.6 μL, 0.40 mmol), i-Pr2NEt 
(104.6 μL, 0.45 mmol) and pivaloyl chloride (74.0 μL, 0.45 mmol) in CH2Cl2 (2 mL) 
with 26 (1.24 mg, 0.004 mmol), (E)-diisopropyl cinnamoylphosphonate 163 (177.8 
mg, 0.60 mmol) in CH2Cl2 (2 mL) and i-Pr2NEt (174.3 μL, 1.00 mmol) for 24 h at 
−78 °C followed by addition of MeOH (2 mL) and a further 24 h at −78 °C warming 
to room temperature gave the crude product (>95:5 dr anti:syn). Purification via 
column chromatography on silica gel (Petrol:EtOAc 95:5-80:20) gave diester 171 
(81.3 mg, 74%, >95:5 dr) as a colourless oil.  −27.8° (c 0.5, CHCl3); Chiral 
HPLC analysis, Chiralcel OD-H (97:3 hexane:IPA, flow rate 0.5 mLmin-1, 211 nm, 
RT), tR(2R,3S) minor 19.5 min, tR(2S,3R) major 39.8 min, >99% ee; νmax (film) 3030 
(=CH stretch), 1732 (C=O), 963 (C=C); 1H NMR (300 MHz, CDCl3) δH: 1.55 (3H, 
dd, J 6.1, 1.3, C(2)C(3’)H3), 2.70 (2H, d, J 7.5, C(4)H2), 3.28 (1H, t, J 8.6, C(2)H), 
3.53 (3H, s, C(5)O2CH3), 3.57 (2H, q, J 7.7, C(3)H), 3.66 (3H, s, C(1)O2CH3), 5.23-
5.32 (1H, ddq, J 15.2, 8.8, 1.3, C(2)C(1’)H)), 5.33-5.44 (1H, dq, J 15.2, 6.3, 
C(2)C(2’)H)), 7.09-7.14 (2H, m, C(3)ArC(2)H), 7.16-7.22 (1H, m, C(3)ArC(4)H), 
7.23-7.29 (2H, m, C(3)ArC(3)H); 13C{1H} NMR (100 MHz, CDCl3) δC: 17.9 
(C(2)C(3’)H3), 38.4 (C(4)), 44.1 (C(3)), 51.6 (C(5)O2CH3), 51.8 (C(1)O2CH3), 54.4 
(C(2)), 126.1 (C(1’)), 127.0 (C(3)ArC(4)), 128.2 (2 C(3)ArC(2)), 128.3 (2 
C(3)ArC(3)), 130.0 (C(2’)), 140.3 (C(3)ArC(1)), 172.1 (C(5)), 173.6 (C(1)); HRMS 
(NSI)+ C16H24O4N+ [M+NH4]+, found 294.1700, requires 294.1703 (+1.1 ppm). 
 
(2S,3R)-Dimethyl 3-pheyl-2-((E)-styryl)pentanedioate 172 
 
Following General Procedure H, trans-styrylacetic acid (64.9 mg, 0.40 mmol), i-
Pr2NEt (104.6 μL, 0.45 mmol) and pivaloyl chloride (74.0 μL, 0.45 mmol) in CH2Cl2 
(2 mL) with 26 (1.24 mg, 0.004 mmol), (E)-diisopropyl cinnamoylphosphonate 163 
(177.8 mg, 0.60 mmol) in CH2Cl2 (2 mL) and i-Pr2NEt (174.3 μL, 1.00 mmol) for 24 
h at −78 °C followed by addition of MeOH (2 mL) and a further 24 h at −78 °C 
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warming to room temperature gave the crude product (>95:5 dr anti:syn). Purification 
via column chromatography on silica gel (Petrol:EtOAc 95:5-80:20) gave diester 172 
(102.4 mg, 77%, 90:10 dr) as a white solid; mp 62-54 °C;  −23.0° (c 1.0, 
CHCl3); Chiral HPLC analysis, Chiralcel AD-H (80:20 hexane:IPA, flow rate 1.0 
mLmin-1, 211 nm, RT), tR(2S,3R) major 28.4 min, tR(2R,3S) minor 36.4 min, 27% ee; 
νmax (neat) 3028 (=CH stretch), 1732 (C=O), 966 (C=C); 1H NMR (300 MHz, CDCl3) 
δH: 2.73-2.82 (2H, m, C(4)H2), 3.49 (1H, ddd, J 9.3,8.0, 0.8, C(2)H), 3.56 (3H, s, 
C(5)O2CH3), 3.69 (3H, s, C(1)O2CH3), 3.74 (1H, m, C(3)H), 6.00 (1H, dd, J 15.9, 9.4, 
C(1’)H), 6.29 (1H, d, J 15.9, C(2’)H), 7.09-7.33 (10H, m, ArH); 13C{1H} NMR (100 
MHz, CDCl3) δC: 38.4 (C(4)), 44.5 (C(3)), 51.8 (C(5)O2CH3), 52.2 (C(1)O2CH3), 54.7 
(C(2)), 125.0 (C(1’)), 126.5 (2 ArC), 127.3 (ArC), 127.8 (ArC), 128.3 (2 ArC), 128.6 
(4 ArC), 133.9 (C(2’)), 136.7 (C(2’)ArC(1)), 140.1 (C(3)ArC(1)), 172.1 (C(5)), 173.2 
(C(1)); HRMS (NSI)+ C21H23O4 [M], found 339.1592, requires 339.1591 (+0.3 ppm). 
 
(2S,3R)-Dimethyl3-phenyl-2-((E)-3-phenylprop-1-en-1-yl) pentanedioate 173 
 
Following General Procedure H, (E)-5-phenylpent-3-enoic acid (70.5 mg, 0.40 
mmol), i-Pr2NEt (104.6 μL, 0.45 mmol) and pivaloyl chloride (74.0 μL, 0.45 mmol) 
in CH2Cl2 (2 mL) with 26 (1.24 mg, 0.004 mmol), (E)-diisopropyl 
cinnamoylphosphonate 163 (177.8 mg, 0.60 mmol) in CH2Cl2 (2 mL) and i-Pr2NEt 
(174.3 μL, 1.00 mmol) for 24 h at −78 °C followed by addition of MeOH (2 mL) and 
a further 24 h at −78 °C warming to room temperature gave the crude product (>95:5 
dr anti:syn). Purification via column chromatography on silica gel (Petrol:EtOAc 
95:5-85:15) gave diester 173 (107.7 mg, 76%, >95:5 dr) as a colourless oil.  
−6.9° (c 1.0 in CHCl3); Chiral HPLC analysis, Chiralcel OJ-H (99.5:0.5 hexane:IPA, 
flow rate 1.5 mLmin-1, 211 nm, 40 ˚C), tR(2S,3R) major 34.8 min, tR(2R,3S) minor 
40.5 min, >99% ee; νmax (neat) 3028 (=CH stretch), 1736 (C=O), 974 (C=C);  1H 
NMR (400 MHz, CDCl3) δH: 2.69 (2H, d, J 7.5, C(4)H2), 3.21 (2H, d, J 6.5, C(3’)H2), 
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3.33 (1H, t, J 9.2, C(2)H), 3.53 (3H, s, C(5)O2CH3), 3.53-3.65 (1H, m, C(3)H), 3.71 
(3H, s, C(1)O2CH3), 5.33 (1H, ddt, J 15.3, 9.2, 1.1, C(2)C(1’)H), 5.47 (1H, dt, J 15.4, 
6.6, C(2)C(2’)H), 6.73-6.81 (2H, m, ArH), 7.07-7.22 (5H, m, ArH), 7.22-7.34 (3H, m, 
ArH); 13C{1H} NMR (100 MHz, CDCl3) δC: 38.7 (CH2), 38.9 (CH2), 44.4 (C(3)), 51.7 
(C(5)O2CH3), 52.1 (C(1)O2CH3), 54.8 (C(2)), 126.1 (C(1’)), 127.1 (ArC), 127.3 
(ArC), 128.3 (2 ArC), 128.4 (2 ArC), 128.5 (2 ArC), 128.6 (2 ArC), 133.7 (C(2’)), 
139.8 (C(3’)ArC(1)), 140.5 (C(3)ArC(1)), 172.0 (C(5)), 173.6 (C(1)); HRMS (NSI)+ 
C22H25O4 [M], found 353.1747, requires 353.1747 (−0.1 ppm). 
 
 (3R,4R)-3-(4-Methoxyphenyl)-4-phenyltetrahydro-2H-pyran-2-one 177 
 
Following General Procedure I, 166 (99.9 mg, 0.3 mmol) and DIBAL-H (660 μL, 
0.66 mmol) in THF (2 mL) was stirred at 0 °C for 90 min to give the crude 
intermediate. This was dissolved in CH2Cl2 (2 mL), treated with TFA (2 drops) and 
stirred at room temperature for 1 h. The crude product (>95:5 dr anti:syn) was 
purified via column chromatography on silica gel (Petrol:EtOAc 80:20-60:40) gave 
the product 177 (41.9mg, 49%) as a white solid. mp 76-80 °C;  −191.2° (c 0.5, 
CHCl3); Chiral HPLC analysis, Chiralcel AD-H (90:10 hexane:IPA, flow rate 1 mL 
min-1, 211 nm, 30 ˚C), tR(3R,4R) major 27.9 min, tR(3S,4S) minor 35.2 min, >99% ee; 
νmax (film) 1728 (C=O), 1514, 1175 (C-O); 1H NMR (400 MHz, CDCl3) δH:  2.17-2.39 
(2H, m, C(5)H2), 3.24-3.37 (1H, m, C(4)H), 3.74 (3H, s, OCH3), 3.81 (1H, d, J 10.8, 
C(3)H)), 4.46-4.70 (2H, m, C(6)H2), 6.74 (2H, d, J 8.7, C(3)ArC(3)H), 6.86-6.95 (2H, 
m, C(3)ArC(2)H), 6.97-7.07 (2H, m, ArH), 7.13-7.24 (3H, m, ArH); 13C{1H} NMR 
(75 MHz, CDCl3) δC: 30.9 (C(5)), 46.7 (CH3), 54.6 (CH), 55.3 (CH), 68.7 (C(6)), 
114.1 (2 C(3)ArC(3)), 127.2 (2 C(3)ArC(2), C(4)ArC(4)), 128.8 (2 C(4)ArC), 129.9 
(2 C(4)ArC), 130.0 (C(3)ArC(1)), 142.2 (C(4)ArC(1)), 158.7 (C(3)ArC(1)), 172.5 
(C(2)); HRMS (NSI)+ C18H19O3+ [M+H]+, found 283.1330, requires 283.1329 (+0.5 
ppm). 
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(3R,4R)-3-(4-Fluorophenyl)-4-phenyltetrahydro-2H-pyran-2-one 178 
 
Following General Procedure I, 167 (87.4 mg, 0.26 mmol) and DIBAL-H (570 μL, 
0.57 mmol) in THF (2 mL) was stirred at 0 °C for 90 min to give the crude 
intermediate. This was dissolved in CH2Cl2 (2 mL), treated with TFA (2 drops) and 
stirred at room temperature for 1 h. The crude product (>95:5 dr anti:syn) was 
purified via column chromatography on silica gel (Petrol:EtOAc 70:30) gave 178 
(44.6 mg, 63%) as a white solid; mp 120-124 °C;  −22.8° (c 0.5, CHCl3); Chiral 
HPLC analysis, Chiralcel AD-H (95:5 hexane:IPA, flow rate 1 mL min-1, 211 nm, 30 
˚C), tR(3R,4R) major 28.2 min, tR(3S,4S) minor 37.3 min, >99% ee; νmax (film) 1717 
(C=O), 1508, 1209 (C-F), 1186 (C-O); 1H NMR (400 MHz, CDCl3) δH: 2.26-2.34 
(2H, m, C(5)H2), 3.22-3.34 (1H, m, C(4)H), 3.86 (1H, d, J 11.2, C(3)H)), 4.60 (1H, 
ddd, J 11.4, 9.6, 4.0, C(6)HAHB) 4.67 (1H, dt, J 11.4, 4.6, C(6)HAHB), 6.90-6.94 (2H, 
m, ArH), 6.94-7.00 (2H, m, ArH), 7.01-7.05 (2H, m, ArH), 7.19-7.30 (3H, m, ArH); 
13C{1H} NMR (100 MHz, CDCl3) δC: 30.9 (C(5)), 46.8 (CH), 54.7 (CH), 68.8 (C(6)), 
115.5 (d, J 21.7, 2 C(3)ArC(3)), 127.2 (2 C(4)ArC), 127.4 (C(4)ArC), 128.9 (2 
C(4)ArC), 130.5 (d, J 8.1, 2 C(3)ArC(2), 133.6 (d, J 2.8, C(3)ArC(1)), 141.8 
(C(4)ArC), 162.0 (d, J 246.0, C(3)ArC(4)), 172.0 (C(2)); 19F{1H}  NMR (376 MHz, 
CDCl3) δF: –115.2; HRMS (NSI)+ C17H16O2F+ [M+H]+, found 271.1130, requires 
271.1129 (+0.4 ppm). 
 
(3R,4R)-3-(Thiophen-2-yl)-4-phenyltetrahydro-2H-pyran-2-one 179 
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Following General Procedure I, 169 (57.3 mg, 0.18 mmol) and DIBAL-H (400 µL, 
0.40 mmol) in THF (2 mL) was stirred at 0 °C for 90 min to give the crude 
intermediate. This was dissolved in CH2Cl2 (2 mL), treated with TFA (2 drops) and 
stirred at room temperature for 1 h. The crude product (>95:5 dr anti:syn) was 
purified via column chromatography on silica gel (Petrol:EtOAc 70:30) gave the 
product as a white solid (13.8 mg, 30%). mp 90-96 °C;  −82.5° (c 0.2, CHCl3); 
Chiral HPLC analysis, Chiralcel AD-H (95:5 hexane:IPA, flow rate 1 mL min-1, 211 
nm, 30 ˚C), tR (2R,3R) major: 32.1 min, tR (2S,3S) minor: 47.4 min, 70% ee; (400 
MHz, CDCl3) 2.24-2.32 (2H, m, C(5)H2), 3.36-3.44 (1H, m, C(4)H), 4.22 (1H, d, J 
12, C(3)H)), 4.55-4.59 (2H, m, C(6)H2), 6.72-6.74 (1H, m, ArH), 6.82-6.84 (1H, m, 
ArH), 7.11-7.29 (6H, ArH); HRMS (NSI)+ C15H15O2S+ [M+H]+, found 259.0796, 
requires 259.0787 (+1.1 ppm). 
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6.4 Experimental for Chapter 4 
6.4.1 General Experimental Procedures 
6.4.1.1 General Procedure J: Synthesis of N-Sulfonyl Oxaziridine Starting 
Materials 
To a solution of saturated aqueous sodium bicarbonate (1 M), 
benzyltrimethylammonium chloride (0.11 equiv.) and the appropriate N-sulfonyl 
imine (1 equiv.) as a solution in chloroform (1 M) was added. The mixture was cooled 
to 0 °C and a solution of m-CPBA (1.1 equiv.) in chloroform (0.5 M) was added 
dropwise at 0 °C and stirred for 1 h. The organic layer was separated, washed with 
water, 10% sodium sulphite solution, water and brine before drying (MgSO4) and 
concentrating in vacuo, keeping the bath temperature below 40 °C. The crude product 
was recrystallised from ethyl acetate/petrol without heating. 
6.4.1.2 General Procedure K: Asymmetric Organocatalytic Formation of 
Oxazolidin-4-ones 
To a solution of the appropriate anhydride (1.5 equiv.) and cesium chloride (2 equiv.) 
in CH2Cl2 (0.2 M) at −78 °C, the appropriate oxaziridine (1 equiv.) and (2S,3R)-
HBTM-2.1 (10 mol%) were added. The reaction mixture was stirred at −78 °C 
allowing to warm to room temperature over 16 h before being quenched with 1 M 
HCl, extracted with CH2Cl2 (2×), dried (MgSO4) and concentrated in vacuo. The 
crude product was purified via column chromatography on silica gel (eluent 
petrol:Et2O 80:20 unless otherwise stated).   
6.4.2 Starting Materials 
6.4.2.1 Oxaziridines 
3-Phenyl-2-tosyl-1,2-oxaziridine 211  
 
Following General Procedure J, benzyltrimethyammonium chloride (0.28 g, 1.49 
mmol), (E)-N-(benzylidene)-4-methylbenzenesulfonamide 215 (3.5 g, 13.5 mmol) 
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and m-CPBA (3.34 g, 14.9 mmol, <77%) were stirred at 0 °C for 1 h. The resulting 
yellow solid was recrystallised to give 211 as a white solid (3.82 g, >99%) with data 
in accordance with the literature. 12 mp 92-94 °C {Lit.12 85-85 °C}; 1H NMR (400 
MHz, CDCl3) δH: 2.49 (3H, s, CH3), 5.45 (1H, s, CH), 7.31-7.55 (7H, m, ArH), 7.87-
7.97 (2H, m, ArH). 
 
3-(2-Chlorophenyl)-2-tosyl-1,2-oxaziridine 219  
 
Following General Procedure J, benzyltrimethyammonium chloride (0.23 g, 1.25 
mmol), (E)-N-(2-chlorobenzylidene)-4-methylbenzenesulfonamide 257 (3.34 g, 11.4 
mmol) and m-CPBA (2.81 g, 12.5 mmol, <77%) were stirred at 0 °C for 1 h. The 
resulting yellow solid was recrystallised to give 219 as a white solid (2.97 g, 84%) 
with data in accordance with the literature.13 mp 92-94 °C {Lit. 105-107 °C13}; 1H 
NMR (400 MHz, CDCl3) δH: 2.50 (3H, s, CH3), 5.86 (1H, s, CH), 7.26-7.29 (2H, m, 
ArH), 7.37-7.45 (4H, m, ArH), 7.94 (2H, d, J 8.4, ArH). 
 
3-Nitro-4-(3-phenyl-1,2-oxaziridin-2-yl)benzenesulfonic acid 258 
 
Following General Procedure J, benzyltrimethyammonium chloride (0.08 g, 0.41 
mmol), (E)-4-(benzylideneamino)-3-nitrobenzenesulfonic acid 254(1.08 g, 3.72 
mmol) and m-CPBA (0.92 g, 4.09 mmol, <77%) were stirred at 0 °C for 1 h. The 
resulting yellow solid was recrystallised to give 258 as a pale yellow solid (0.66 g, 
58%) with data in accordance with the literature.12 mp 84-86 °C {Lit.12 94-95 °C}; 1H 
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NMR (400 MHz, CDCl3) δH: 5.60 (1H, s, CH), 7.39-7.48 (4H, m, ArH), 7.47-7.54 
(1H, m, ArH), 8.27 (2H, d, J 8.8, SO2ArH), 8.48 (2H, d, J 8.8, SO2ArH). 
 
3-(4-Bromophenyl)-2-tosyl-1,2-oxaziridine 220 
 
Following General Procedure J, benzyltrimethyammonium chloride (0.22 g, 1.18 
mmol), (E)-N-(4-bromobenzylidene)-4-methylbenzenesulfonamide 99 (3.63 g, 10.7 
mmol) and m-CPBA (2.64 g, 11.8 mmol, <77%) were stirred at 0 °C for 1 h. The 
resulting white solid was recrystallised to give 220 as a white solid (2.03 g, 54%) with 
data in accordance with the literature.14 mp 98-100 °C {Lit.14 92-93 °C}; 1H NMR 
(400 MHz, CDCl3) δH: 2.50 (3H, s, CH3), 5.42 (1H, s, CH), 7.28-7.34 (2H, m, ArH), 
7.43 (2H, d, J 8.1, ArH), 7.54 (2H, d, J 8.5, ArH), 7.92 (2H, d, J 8.3, ArH). 
 
6.4.2.2 Homoanhydrides 
2-(4-Fluorophenyl)acetic anhydride 259 
 
Following General Procedure B, 4-fluorophenylacetic acid (1.00 g, 6.49 mmol) and 
DCC (0.74 g, 3.57 mmol) were stirred in toluene (20 mL) to give product 259 as a 
white solid (0.94 g, >99%) with data in accordance with the literature. mp 46-48 °C 
{Lit.6 36-38 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.70 (4H, s, 2 CH2), 6.94-7.08 (4H, 
m, ArH), 7.11-7.22 (4H, m, ArH); 19F NMR (376 MHz, CDCl3) δF: −115.1 (ArF). 
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2-(o-Tolyl)acetic anhydride 224 
 
Following General Procedure B, o-tolylacetic acid (0.50g, 3.33 mmol) and DCC 
(0.35 g, 1.70 mmol) were stirred in toluene (10 mL) to give product 224 as a sticky oil 
(0.47 g, >99%) with data in accordance with the literature.15 1H NMR (500 MHz, 
CDCl3) δH: 2.24 (6H, s, 2 CH3), 3.72 (4H, s, 2 × CH2), 7.07-7.11 (2H, m, ArH), 7.11-
7.25 (6H, m, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 19.6 (CH3), 40.2 (CH2), 
126.4 (ArC), 128.1 (ArC), 130.5 (ArC), 130.7 (ArC), 130.9 (ArC(1)), 137.1 
ArC(2)CH3), 167.0 (C=O). 
  
2-(m-Tolyl)acetic anhydride 260 
 
Following General Procedure B, m-tolylacetic acid (0.50 g, 3.33 mmol) and DCC 
(0.35 g, 1.70 mmol) were stirred in toluene (10 mL) to give product 260 as a yellow 
oil (0.47 g, >99%) with data in accordance with the literature.15 1H NMR (400 MHz, 
CDCl3) δH: 2.27 (6H, s, 2 × CH3), 3.54 (4H, s, 2 × CH2), 6.99-7.02 (3H, m, ArH), 
7.12-7.18 (5H, m, ArH). 
 
2-(p-Tolyl)acetic anhydride 261  
 
Following General Procedure B, p-tolylacetic acid (0.50 g, 3.33 mmol) and DCC 
(0.35 g, 1.70 mmol) were stirred in toluene (10 mL) to give product 261 as a white 
solid (0.47 g, >99%) with data in accordance with the literature. 15 mp 46-48 °C {Lit.15  
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56-57 °C}; 1H NMR (400 MHz, CDCl3) δH: 2.39 (6H, s, 2 × CH3), 3.72 (4H, s, 2 × 
CH2), 7.12-7.19 (8H, m, ArH).  
 
 (E)-Pent-3-enoic anhydride 236 
 
Following General Procedure B, 3-pentenoic acid (1.36 mL, 13.3 mmol) and DCC 
(1.40 g, 6.80 mmol) were stirred in toluene (40 mL) to give product 236 as a pale 
yellow oil (1.20 g, >99%). νmax (neat) 3000 (=CH), 2920 (C-H), 1819 (C=O), 1749 
(C=O), 1699 (C=C), 1031 (C-O); 1H NMR (400 MHz, CDCl3) δH: 1.69-1.73 (6H, m, 
2 × CH3), 3.11-3.20 (4H, m, 2 × CH2), 5.42-5.57 (2H, m, 2 × CH), 5.57-5.70 (2H, m, 
2 CH); 13C{1H} NMR (100 MHz, CDCl3) δC: 18.1 (CH3), 39.0 (CH2), 120.9 (CH), 
131.2 (CH), 167.9 (C=O); m/z (ASAP+) 200 ([M+NH4]+, 75%); HRMS (ASAP+) 
C10H18O3N+ ([M+NH4]+), requires 200.1281; found 200.1277 (–2.1 ppm). 
 
2-(4-(Trifluoromethyl)phenyl)acetic anhydride 226 
 
Following General Procedure B, p-trifluoromethylphenyl acid (0.68g, 3.33 mmol) 
and DCC (0.35 g, 1.70 mmol) were stirred in toluene (10 mL) to give product 226 as 
an off white solid (0.65 g, >99%). mp 58-60 °C; νmax (neat) 2933 (C-H), 1813 (C=O), 
1749 (C=O), 1062 (C-O), 766 (CF3); 1H NMR (500 MHz, CDCl3) δH: 3.80 (4H, s, 2 
CH2), 7.33 (4H, d, J 8.1, ArH), 7.59 (4H, d, J 8.1, ArH); 13C{1H} NMR (125 MHz, 
CDCl3) δC: 41.8 (CH2), 124.1 (q, 1JCF 272.1, CF3), 125.9 (q, 3JCF 4.1, ArC(3)), 129.9 
(ArC(2)), 130.3 (q, 2JCF 32.8, ArC(4)), 135.8 (ArC(1)), 166.0 (C=O); 19F NMR (376 
MHz, CDCl3) δF: −115.1 (ArF); m/z HRMS C18H13F6O3+ ([M+H]+), requires 
391.0763; found 391.0759 (–1.1 ppm) 
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6.4.3 Optimisation Studies on 216 
 
Catalyst Loading Screen: 
 
To a solution of phenylacetic acid (27.2 mg, 0.20 mmol, 1 equiv.), was added i-
Pr2NEt (52.0 μL, 0.30 mmol, 1.5 equiv.) and pivaloyl chloride (37.0 μL, 0.30 mmol, 
1.5 equiv.) at 0 °C and stirred for 20 min. Oxaziridine 219 (62.0 mg, 0.2 mmol), i-
Pr2NEt (87.2 μL, 0.50 mmol, 2.5 equiv.) stirred at –78 °C to room temperature for 1 h  
 
(2S,3R)-HBTM-2.1 26 (6.17 mg, 0.02 mmol, 10 mol%) gave crude 216 (69:31 dr). 
Chromatographic purification (80:20 Petrol:Et2O) gave 216 as a white solid and 
mixture of diastereoisomers (51.2 mg, 60%); >99%/>99% ee. By 1H NMR, 13% 
imine was observed. 
 
(2S,3R)-HBTM-2.1 26 (3.08 mg, 0.01 mmol, 5 mol%) gave crude 216 (73:27 dr). 
Chromatographic purification (80:20 Petrol:Et2O) gave 216 as a white solid and 
mixture of diastereoisomers (53.0 mg, 62%); 44%/>ND ee. By 1H NMR, 16% imine 
was observed. 
 
6.4.4 Experimental Procedures 
(2R,5R)-2,5-Diphenyl-3-tosyloxazolidin-4-one (anti-214) and (2S,5R)-2,5-diphenyl-
3-tosyloxazolidin-4-one (syn-214)  
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Following General Procedure K, homoanhydride 134 (76.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (55.1 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred in dichloromethane (1 mL) at –78 °C 
to room temperature for 16 h to give the crude product (57:43 anti:syn). Purification 
yielded the product as a mixture of diastereoisomers (54:46 anti:syn) as a white solid 
(65.2 mg, 83%). mp 154-157 ˚C;  +11.8 (c 0.5, CHCl3); νmax (neat) 1751 (C=O), 
1373 (C-N), 1175 (R-SO2N), 1088 (C-O); m/z (NSI+) 395 ([M+H]+, 100%); HMRS 
(NSI+) C22H20NSO4+ ([M+H]+) requires 394.1108; found 394.1108 (0 ppm). 
Data for the anti diastereoisomer 214: Chiral HPLC analysis, Chiralcel AD-H (95:5 
hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 40 ˚C) tR major (2R,5R): 27.1 min, tR 
minor (2S,5S): 53.9 min, 97% ee;  1H NMR (500 MHz, CDCl3) δH: 2.41 (3H, s, CH3), 
5.44 (1H, d, J 1.2, C(5)H), 6.71 (1H, d, J 1.3, C(2)H), 7.17-7.19 (2H, m, 
SO2ArC(3)H), 7.37-7.40 (10H, m, ArCH), 7.50-7.55 (2H, m, SO2ArC(2)H); 13C{1H} 
NMR (125 MHz, CDCl3) δC: 21.8 (CH3), 77.4 (C(5)), 91.3 (C(2)), 126.5 
(C(5)ArC(2)), 127.5 (C(2)ArC(2)), 128.4 (SO2ArC(2)), 128.8 (ArC), 129.0 (ArC), 
129.2 (ArC), 129.6 (SO2ArC(3)), 130.3 (ArC), 134.4 (C(5)ArC(1)), 134.8 
(C(2)ArC(1)), 136.6 (SO2ArC(1)), 145.8 (SO2ArC(4)), 168.8 (C(4)). 
Selected data for the syn diastereoisomer 214: Chiral HPLC analysis, Chiralcel AD-H 
(95:5 hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 40 ˚C) tR major (2S,5R): 25.1 min, 
tR minor (2R,5S): 30.4 min, 94% ee; 1H NMR (500 MHz, CDCl3) δH: 2.39 (3H, s, 
CH3), 5.41 (1H, d, J 1.3, C(5)H), 6.59 (1H, d, J 1.4, C(2)H); 13C{1H} NMR (125 
MHz, CDCl3) δC: 21.8 (CH3), 78.7 (C(5)), 90.9 (C(2)), 126.4 (C(5)ArC(2)), 128.3 
(C(2)ArC(2)), 128.4 (SO2ArC(2)), 128.6 (ArC), 128.7 (ArC), 129.6 (SO2ArC(3)), 
130.5 (ArC), 134.0 (C(5)ArC(1)), 135.1 (C(2)ArC(1)), 136.4 (SO2ArC(1)), 145.7 
(SO2ArC(4)), 168.6 (C(4)). 
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(2R,5R)-2-(2-Chlorophenyl)-5-phenyl-3-tosyloxazolidin-4-one (anti-216) and 
(2S,5R)-2-(2-chlorophenyl)-5-phenyl-3-tosyloxazolidin-4-one (syn-216)  
 
Following General Procedure K, homoanhydride 134 (76.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 219 (62.0 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (55:45 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (56:44 anti:syn) as a white solid (66.6 mg, 78%). Careful 
purification allowed isolation of an analytical sample of each diastereoisomer for full 
characterisation. 
Data for the anti diastereoisomer XX: white solid, mp 150-152 ˚C; −16.6 (c 0.5, 
CHCl3); Chiral HPLC analysis, Chiralcel AD-H (95:5 hexane:IPA, flow rate 1.5 mL 
min-1, 211 nm, 30 °C) tR major (2R,5R): 23.0 min, tR minor (2S,5S): 53.2 min, 78% ee; 
1H NMR (500 MHz, CDCl3) δH: 2.43 (3H, s, CH3), 5.38 (1H, d, J 1.3, C(5)H), 7.02 
(1H, d, J 1.4, C(2)H), 7.14-7.25 (2H, m, SO2ArC(3)H), 7.28-7.47 (9H, m, ArCH), 
7.56-7.69 (2H, m, SO2ArC(2)H). 
Data for the syn diastereoisomer XX: white solid with data in accordance with the 
literature.16 156-158 ˚C {Lit.16 182-184 ˚C};  +40.2 (CHCl3, c 0.5); Chiral HPLC 
analysis, Chiralcel AD-H (95:5 hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 30 °C), 
tR major (2S,5R): 40.4 min, tR minor (2R,5S): 46.0 min, 78% ee; 1H NMR (500 MHz, 
CDCl3) δH: 2.43 (3H, s, CH3), 5.35 (1H, d, J 1.3, C(5)H), 7.06 (1H, s, C(2)H), 7.23-
7.31 (2H, m, SO2ArC(3)H), 7.28-7.50 (9H, m), 7.75-7.64 (2H, m, SO2ArC(3)H). 
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(2R,5R)-2-(4-Bromophenyl)-5-phenyl-3-tosyloxazolidin-4-one (anti-217) and 
(2S,5R)-2-(4-Bromophenyl)-5-phenyl-3-tosyloxazolidin-4-one (syn-217)  
 
Following General Procedure K, homoanhydride 134 (76.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 220 (70.8 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (55:45 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (47:53 anti:syn) as a white solid (77.5mg, 82%). Careful 
purification allowed isolation of an analytical sample of each diastereoisomer for full 
characterisation. 
Data for the anti diastereoisomer 217: white solid, mp 96-100 ˚C; +8.0 (c 0.5, 
CHCl3); νmax (neat) 1751 (C=O), 1373 (C-N), 1172 (R-SO2N), 1068 (C-O); Chiral 
HPLC analysis, Chiralcel OD-H (90:10 hexane;IPA, flow rate 1.0 mL min-1, 211 nm, 
30 °C) tR major (2R,5R): 17.2 min, tR minor (2S,5S): 20.5 min, 99% ee; 1H NMR (500 
MHz, CDCl3) δH: 2.41 (3H, s, CH3), 5.39 (1H, d, J 1.4, C(5)H), 6.54 (1H, d, J 1.4, 
C(2)H), 7.16-7.24 (2H, m, SO2ArC(3)H), 7.23-7.30 (3H, m, ArH), 7.30-7.41 (4H, m, 
ArH), 7.46-7.56 (4H, m, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.9 (CH3), 79.0 
(C(5)), 90.2 (C(2)), 124.8 (C(2)ArC(4)), 126.3 (C(5)ArC(2)), 128.3 (C(2)ArC(2)), 
128.8 (SO2ArC(2)), 129.1 (ArC), 129.7 (C(2)ArC(1)), 130.0 (SO2ArC(3)), 131.9 
(ArC), 133.8 (C(5)ArC(1)), 134.9 (ArC), 135.6 (SO2ArC(1)), 146.0 (SO2ArC(4)), 
168.5 (C(4)); m/z (NSI+) 472 ([M+NH4]+, 60%); HMRS (NSI+) C22H19BrNSO4+ 
([M+NH4]+) requires 472.0213; found 472.0203 (–2.1 ppm). 
Data for the syn diastereoisomer 217: white solid, mp 162-168 ˚C;  −14.0 (c 0.5, 
CHCl3); νmax (neat) 1751 (C=O), 1375 (C-N), 1170 (R-SO2N), 1090 (C-O); Chiral 
HPLC analysis, Chiralcel OD-H (90:10 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 
30 °C) tR major (2R,5S): 15.5 min, tR minor (2S,5R): 24.6 min, 89% ee; 1H NMR (500 
MHz, CDCl3) δH: 2.43 (3H, s, CH3), 5.40 (1H, d, J 1.2, C(5)H), 6.64 (1H, d, J 1.2, 
C(2)H), 7.19-7.25 (2H, m, ArH), 7.24-7.31 (4H, m, ArH), 7.31-7.40 (5H, m, ArH), 
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7.49-7.55 (2H, m, SO2ArC(2)H); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.9 (CH3), 
78.8 (C(5)), 90.6 (C(2)), 124.6 (C(2)ArC(4)), 126.5 (C(5)ArC(2)), 128.3 
(C(2)ArC(2)), 129.0 (SO2ArC(2)), 129.2 (ArC), 129.4 (ArC), 129.7 (ArC), 132.0 
(SO2ArC(3)), 134.2 (ArC), 134.8 (C(5)ArC(1)), 135.7 (SO2ArC(1)), 146.0 (SO2-
ArC(4)), 168.7 (C(4)).  
 
3-Nitro-4-((2R,5R)-4-oxo-2,5-diphenyloxazolidin-3-yl)benzenesulfonic (anti-222) 
acid and 3-nitro-4-((2S,5R)-4-oxo-2,5-diphenyloxazolidin-3-yl)benzenesulfonic acid 
(syn-222)  
 
Following General Procedure K, homoanhydride 134 (76.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (64.5 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26(6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (59:41 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (52:48 anti:syn) as a white solid (62.0 mg, 73%).  
Data for the anti diastereoisomer 222: white solid, mp 146-150 ˚C; +68.2 (c 0.5, 
CHCl3); νmax (neat) 1751 (C=O), 1531 (NO2), 1384 (C-N), 1180 (R-SO2N), 1086 (C-
O); Chiral HPLC analysis, Chiralcel AD-H (80:20 hexane:IPA, flow rate 1.25 mL 
min-1, 211 nm, 40 ˚C) tR major (2R,5R): 27.3 min, tR minor (2S,5S): 29.9 min, 85% ee; 
1H NMR (500 MHz, CDCl3) δH: 5.51 (1H, d, J 1.2, C(5)H), 6.72 (1H, d, J 1.2, 
C(2)H), 7.29-7.45 (9H, m, ArH), 7.45-7.57 (1H, m, ArH) 7.68-7.83 (2H, m, SO-
2ArC(3)H), 8.12-8.26 (2H, m, SO2ArC(2)H); 13C{1H} NMR (125 MHz, CDCl3) δC: 
78.9 (C(5)), 91.5 (C(2)), 124.1 (ArC), 126.3 (C(5)ArC(2)), 127.7 (C(2)ArC(2)), 129.0 
(SO2ArC(2)), 129.2 (2 ArC), 129.6 (ArC), 129.6 (SO2ArC(3)), 130.8 (ArC), 133.9 
(Cipso), 136.1 (C(5)ArC(1)), 143.1 (SO2ArC(1)), 151.0 (SO2ArC(4)), 168.7 (C(4)); m/z 
(NSI+) 425 ([M+H]+, 100%); HMRS C21H17N2O6S+ ([M+H]+) requires 425.0802; 
found 425.0801 (–0.2 ppm). 
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Selected data for the syn diastereoisomer 222: white solid, mp 90-94 ˚C;  −48.0 
(c 0.1, CHCl3); νmax (neat) 1749 (C=O), 1533 (NO2), 1386 (C-N), 1182 (R-SO2N), 
1087 (C-O); Chiral HPLC analysis, Chiralcel AD-H (80:20 hexane:IPA, flow rate 1.5 
mL min-1, 211 nm, 30 °C) tR major (2S,5R): 18.3 min, tR minor (2R,5S): 20.7 min, 80% 
ee; 1H NMR (500 MHz, CDCl3) δH: 5.49 (1H, d, J 1.3, C(5)H), 6.62 (1H, d, J 1.4, 
C(2)H), 7.30-7.45 (9H, m, ArH), 7.66 (2H, d, J 8.9, SO2ArC(3)H), 8.16 (2H, d, J 8.9 
SO2ArC(2)H); 13C{1H} NMR (125 MHz, CDCl3) δC: 79.0 (C(5)), 90.9 (C(2)), 124.1 
(C(5)ArC(2)), 126.4 (C(2)ArC(2)), 128.7 (SO2ArC(2)), 128.8 (ArC), 128.9 (ArC), 
129.3 (ArC), 129.5 (SO2ArC(3)), 131.0 (ArC), 133.4 (C(5)ArC(1)), 135.6 
(C(2)ArC(1)), 143.5 (SO2ArC(4)), 168.5 (C(4)). 
 
(2R,5R)-5-(4-Fluorophenyl)-2-phenyl-3-tosyloxazolidin-4-one (anti-227) and 
(2S,5R)-5-(4-fluorophenyl)-2-phenyl-3-tosyloxazolidin-4-one (syn-227)  
 
Following General Procedure K, homoanhydride 259 (87.1 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (55.1 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26(6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (54:46 anti:syn). Purification yielded the the product as a 
mixture of diastereoisomers (55:45 anti:syn) as a white solid (60.4 mg, 73%). mp 84-
90 ˚C;  +5.6 (c 0.5, CHCl3); νmax (neat) 1749 (C=O), 1508, 1373 (C-N), 1174 (R-
SO2N), 1068 (C-O); m/z (NSI+) 412 ([M+H]+, 100%); HMRS (NSI+) C22H19FNSO4+ 
([M+H]+) requires 412.1013; found 412.1007 (–1.5 ppm). 
Data for the anti diastereoisomer 227: Chiral HPLC analysis, Chiralcel OD-H (90:10 
hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C), tR minor (2S,5S): 17.0 min, tR 
major (2R,5R): 18.9 min, 99% ee; 1H NMR (500 MHz, CDCl3) δH: 2.41 (3H, s, CH3), 
5.40 (1H, s, C(5)H), 6.70 (1H, d, J 1.3, C(2)H), 6.97-7.14 (2H, m, ArH), 7.13-7.23 
(2H, m, ArH), 7.30-7.44 (5H, m, ArH), 7.40-7.52 (2H, m, ArH), 7.49-7.60 (2H, m, 
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ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.9 (CH3), 78.1 (C(5)), 91.3 (C(2)), 
116.0 (d, 2JCF 21.8, C(5)ArC(3)), 127.5 (C(2)ArC(4)), 128.3 (C(2)ArC(2)), 128.4 
(ArC), 128.6 (SO2ArC(2)), 129.9 (SO2ArC(3)), 130.3 (d, 4JCF 3.2, C(5)ArC(1)), 130.4 
(ArC), 135.0 (SO2ArC(1)), 136.0 (ArC), 145.9 (SO2ArC(4)), 163.3 (d, 1JCF 246, 
C(5)ArC(4)), 168.6 (C(4)). 19F{1H} NMR (282 MHz, CDCl3) δF: –112.3. 
Selected data for the syn diastereoisomer 227: Chiral HPLC analysis, Chiralcel OD-H 
(90:10 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C) tR major (2S,5R): 16.0 
min, tR minor (2R,5S): 27.6 min, 99% ee; 1H NMR (500 MHz, CDCl3) δH: 2.39 (3H, s, 
CH3), 5.38 (1H, s, C(5)H), 6.57 (1H, d, J 1.4, C(2)H); 13C{1H} NMR (125 MHz, 
CDCl3) δC: 21.9 (CH3), 78.5 (C(5)), 91.0 (C(2)), 116.0 (d, 2JCF 21.9, C(5)ArC(3)), 
128.2 (C(2)ArC(2)), 128.5 (SO2ArC(2)), 129.9 (d, 4JCF 3.4, C(5)ArC(1)), 130.6 
(SO2ArC(3)), 134.9 (ArC), 136.3 (SO2ArC(1)), 145.8 (SO2ArC(4)), 163.2 (d, 1JCF 246, 
C(5)ArC(4)), 168.4 (C(4)); 19F{1H} NMR (282 MHz, CDCl3 δF: –112.8. 
 
(2R,5R)-5-(4-Methoxyphenyl)-2-phenyl-3-tosyloxazolidin-4-one and  (anti-228) 
(2S,5R)-5-(4-methoxyphenyl)-2-phenyl-3-tosyloxazolidin-4-one (syn-228)  
 
Following General Procedure K, homoanhydride 255 (94.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (55.1 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (55:45 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (55:45 anti:syn) as a colourless oil (75.4 mg, 89%).  
+7.8 (c 0.5, CHCl3); νmax (neat) 1749 (C=O), 1373 (C-N), 1175 (R-SO2N), 1088 (C-
O); m/z (NSI) 424 ([M+H]+, 100%); HMRS (NSI) C23H22NSO5+ ([M+H]+) requires 
424.1213; found 424.1214 (0.2 ppm). 
Data for the anti diastereoisomer 228: Chiral HPLC analysis, Chiralcel OD-H (90:10 
hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C) tR minor (2S,5S): 30.3 min, tR 
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major (2R,5R): 33.4 min, 97% ee;  1H NMR (500 MHz, CDCl3) δH: 2.41 (3H, s, 
SO2ArCH3), 3.80 (3H, s, OCH3), 5.37 (1H, s, C(5)H), 6.68 (1H, d, J 1.2, C(2)H), 
6.87-6.92 (2H, m, C(5)ArC(3)H), 7.16-7.23 (2H, m, SO2ArC(2)H), 7.22-7.29 (2H, m, 
ArH), 7.36-7.40 (3H, m, ArH), 7.46-7.48 (2H, m, ArH), 7.51-7.58 (2H, m, ArH); 
13C{1H} NMR (125 MHz, CDCl3) δC: 21.9 (ArCH3), 55.5 (OCH3), 78.6 (C(5)), 91.1 
(C(2)), 114.4 (C(5)ArC(3)), 126.5 (C(5)ArC(1)), 127.5 (C(2)ArC(2)), 128.3 
(C(5)ArC(2)), 128.4 (SO2ArC(2)), 128.6 (ArC), 128.8 (ArC), 129.6 (SO2ArC(3)), 
130.0 (ArC), 134.9 (SO2ArC(1)), 136.7 (C(2)ArC(1)), 145.7 (SO2ArC(4)), 160.4 
(C(5)ArC(4)), 169.1 (C(4)). 
Selected data for the syn diastereoisomer 228: Chiral HPLC analysis, Chiralcel OD-H 
(90:10 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C) tR major (2S,5R): 25.2 
min, tR minor (2R,5S): 27.6 min, 94% ee;  1H NMR (500 MHz, CDCl3) δH: 2.39 (3H, s, 
SO2ArCH3), 3.78 (3H, s, OCH3), 5.35 (1H, s, C(5)H), 6.55 (1H, d, J 1.4, C(2)H), 
6.86-6.89 (2H, m, C(5)ArC(3)H), 7.15-7.18 (2H, m, SO2ArC(2)H); 13C{1H} NMR 
(125 MHz, CDCl3) δC: 21.8 (ArCH3), 55.5 (OCH3), 79.0 (C(5)), 90.8 (C(2)), 114.2 
(C(5)ArC(3)), 126.1 (C(5)ArC(1)), 127.5 (C(2)ArC(2)), 128.3 (C(5)ArC(2)), 128.4 
(SO2ArC(2)), 128.6 (ArC), 128.8 (ArC), 129.6 (SO2ArC(3)), 130.0 (ArC), 135.2 
(SO2ArC(1)), 136.4 (C(2)ArC(1)), 145.6 (SO2ArC(4)), 160.4 (C(5)ArC(4)), 169.0 
(C(4)). 
 
(2R,5R)-5-(Naphthalen-2-yl)-2-phenyl-3-tosyloxazolidin-4-one (anti-229) and 
(2S,5R)-5-(naphthalen-2-yl)-2-phenyl-3-tosyloxazolidin-4-one (syn-229)  
 
Following General Procedure K, homoanhydride 223 (106.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (55.1 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (53:47 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (58:42 anti:syn) as a white solid (47.0 mg, 48%). mp 
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136-140 ˚C;  +31.8 (c 0.5, CHCl3); νmax (neat) 1749 (C=O), 1373 (C-N), 1175 
(R-SO2N), 1088 (C-O); m/z (NSI+) 461 ([M+NH4]+, 60%); HMRS (NSI+) 
C26H22NSO4+ ([M+NH4]+) requires 444.1264; found 444.1254 (–2.3 ppm). 
Data for the anti diastereoisomer 229: Chiral HPLC analysis, Chiralcel AD-H (90:10 
hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 40 °C) tR major (2R,5R): 24.3 min, tR 
minor (2S,5S): 57.9 min, 94% ee; 1H NMR (500 MHz, CDCl3) δH: 2.39 (3H, s, 
ArCH3), 5.60 (1H, s, C(5)H), 6.77 (1H, d, J 1.2, C(2)H), 7.16-7.20 (2H, m, SO-
2ArC(2)H), 7.35-7.60 (9H, m, ArH), 7.79-7.89 (4H, m, ArH); 13C{1H} NMR (125 
MHz, CDCl3) δC: 21.8 (ArCH3), 78.9 (C(5)), 91.4 (C(2)), 123.7 (ArC), 126.1 (ArC), 
126.7 (ArC), 126.8 (ArC), 127.5 (C(2)ArC(2)), 127.9 (ArC), 128.3 (ArC), 128.4 
(SO2ArC(2)), 128.7 (ArC), 128.9 (ArC), 129.6 (SO2ArC(3)), 130.3 (ArC), 131.7 
(C(5)ArC(1)), 133.1 (Cipso), 133.6 (Cipso), 134.8 (SO2ArC(1)), 136.7 (C(2)ArC(1)), 
145.8 (SO2ArC(4)), 168.8 (C(4)). 
Selected data for the syn diastereoisomer 229: Chiral HPLC analysis, Chiralcel AD-H 
(90:10 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 40 °C) tR major (2S,5R): 20.9 
min, tR minor (2R,5S): 32.0 min, 90% ee;  1H NMR (500 MHz, CDCl3) δH: 2.37 (3H, s, 
ArCH3), 5.59 (1H, s, C(5)H), 6.65 (1H, d, J 1.2, C(2)H), 7.11-7.16 (2H, m, SO-
2ArC(2)H); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.8 (ArCH3), 79.2 (C(5)), 91.1 
(C(2)), 123.6 (ArC), 125.8 (ArC), 126.5 (ArC), 126.7 (ArC), 127.5 (C(2)ArC(2)), 
127.8 (ArC), 128.3 (C(5)ArC(2)), 128.5 (SO2ArC(2)), 128.6 (ArC), 129.0 (ArC), 
129.6 (SO2ArC(3)), 130.5 (ArC), 131.5 (C(5)ArC(1)), 133.0 (Cipso), 133.5 (Cipso), 
135.2 (SO2ArC(1)), 136.5 (C(2)ArC(1)), 145.7 (SO2ArC(4)), 168.6 (C(4)). 
 
(2R,5R)-2-Phenyl-5-(o-tolyl)-3-tosyloxazolidin-4-one (anti-230) and (2S,5R)-2-
phenyl-5-(o-tolyl)-3-tosyloxazolidin-4-one (syn-230) 
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Following General Procedure K, homoanhydride 224 (84.7 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (55.1 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (53:47 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (58:42 anti:syn) as a white solid (78.5 mg, 96%). Careful 
purification allowed isolation of an analytical sample of each diastereoisomer for full 
characterisation. 
Data for the anti diastereoisomer 230: white solid, mp 90-96 ˚C;  +42.8 (c 0.5, 
CHCl3); νmax (neat) 1749 (C=O), 1373 (C-N), 1175 (R-SO2N), 1088 (C-O); Chiral 
HPLC analysis, Chiralpak AD-H (90:10 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 
40 °C) tR minor (2S,5S): 22.9 min, tR major (2R,5R): 26.5 min, >99% ee; m/z (NSI+) 
408 ([M+H]+, 100%); HMRS (NSI+) C23H22NSO4+ ([M+H]+, 100%) requires 
408.1264; found 408.1258 (–1.5 ppm); 1H NMR (500 MHz, CDCl3) δH: 2.30 (3H, s, 
C(5)ArCH3), 2.43 (3H, s, SO2ArCH3), 5.60 (1H, d, J 1.2, C(5)H), 6.70 (1H, d, J 1.2, 
C(2)H), 7.14-7.20 (3H, m, ArH), 7.20-7.25 (2H, m, ArH), 7.37-7.47 (5H, m, ArH), 
7.58-7.64 (2H, m, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 19.3 (C(5)ArCH3), 
21.9 (SO2ArCH3), 77.4 (C(5)), 91.0 (C(2)), 126.4 (ArC), 127.4 (C(2)ArC(2)), 127.6 
(ArC), 128.5 (SO2ArC(2)), 128.9 (2 ArC), 129.5 (ArC), 129.7 (SO2ArC(3)), 130.2 
(ArC), 131.3 (ArC), 132.8 (C(5)ArC(1)), 134.8 (SO2ArC(1)), 136.9 (C(2)ArC(1)), 
137.3 (C(5)ArC(2)CH3), 145.8 (SO2ArC(4)), 169.1 (C(4)); m/z (NSI+) 408 ([M+H]+, 
99%) HMRS (NSI+) C23H22NSO4+ ([M+H]+) requires 408.1264; found 408.1258 (–1.5 
ppm). 
Data for the syn diastereoisomer 230: white solid, mp 126-132 ˚C;  −56.2 (c 0.5, 
CHCl3); νmax (neat) 1749 (C=O), 1373 (C-N), 1172 (R-SO2N), 1088 (C-O); Chiral 
HPLC analysis, Chiralpak AD-H (90:10 hexane: IPA, flow rate 1.0 mL min-1, 211 
nm, 40 °C) tR minor (2R,5S): 16.8 min, tR major (2S,5R): 18.8 min, >99% ee; 1H NMR 
(500 MHz, CDCl3) δH: 2.40 (3H, s, C(5)ArCH3), 2.45 (3H, s, SO2ArCH3), 5.66 (1H, d, 
J 1.6, C(5)H), 6.57 (1H, d, J 1.6, C(2)H), 7.12-7.19 (3H, m, ArH), 7.19-7.25 (2H, m, 
ArH), 7.29-7.34 (1H, m, ArH), 7.35-7.52 (7H, m, ArH); 13C{1H} NMR (125 MHz, 
CDCl3) δC: 19.7 (C(5)ArCH3), 21.8 (SO2ArCH3), 77.4 (C(5)), 90.8 (C(2)), 126.3 
(ArC), 126.6 (ArC), 128.2 (C(2)ArC(2)), 128.6 (SO2ArC(2)), 128.6 (2 ArC), 129.2 
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(ArC), 129.6 (SO2ArC(3)), 130.5 (ArC), 131.0 (ArC), 132.2 (C(5)ArC(1)), 135.3 
(SO2ArC(1)), 136.1 (C(2)ArC(1)), 137.1 (C(5)ArC(2)CH3), 145.6 (SO2ArC(4)), 168.8 
(C(4)). 
 
(2R,5R)-2-Phenyl-5-(m-tolyl)-3-tosyloxazolidin-4-one (anti-231) and (2S,5R)-2-
phenyl-5-(m-tolyl)-3-tosyloxazolidin-4-one (syn-231)  
 
Following General Procedure K, homoanhydride 260 (84.7 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (55.1 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (51:49 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (54.46 anti:syn) as a colourless oil (64.4 mg, 79%).   
+11.6( c 0.5, CHCl3); νmax (neat) 1751 (C=O), 1373 (C-N), 1175 (R-SO2N), 1088 (C-
O); m/z 408 (NSI+) ([M+H]+, 100%); HMRS (NSI+) C23H22NSO4+ ([M+H]+) requires 
408.1264; found 408.1257 (–1.7 ppm). 
Data for the anti diastereoisomer 231: Chiralpak AD-H (90:10 hexane:IPA, flow rate 
1.0 mL min-1, 211 nm, 40 °C) tR major (2R,5R): 20.9 min, tR minor (2S,5S): 42.0 min, 
92% ee;  1H NMR (500 MHz, CDCl3) δH: 2.20 (3H, s, C(5)ArCH3), 2.27 (3H, s, 
SO2ArCH3), 5.25 (1H, s, C(5)H), 6.57 (1H, d, J 1.3, C(2)H), 6.96-7.08 (4H, m, ArH), 
7.08-7.15 (2H, m, ArH), 7.21-7.29 (3H, m, ArH), 7.29-7.38 (2H, m, ArH), 7.37-7.27 
(2H, m, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.5 (C(5)ArCH3), 21.8 
(SO2ArCH3), 78.8 (C(5)), 91.3 (C(2)), 123.8 (ArC), 127.2 (ArC), 127.5 (ArC), 128.4 
(C(2)ArC(2)), 128.6 (SO2ArC(2)), 128.8 (2 x ArC), 129.6 (SO2ArC(3)), 130.1 (ArC), 
130.3 (ArC), 134.4 (C(5)ArC(1)), 134.9 (SO2ArC(1)), 136.7 (C(2)ArC(1)), 138.8 
(C(5)ArC(2)CH3), 145.7 (SO2ArC(4)), 169.0 (C(4)). 
Selected data for the syn diastereoisomer 231: Chiralpak AD-H (90:10 hexane:IPA, 
flow rate 1.0 mL min-1, 211 nm, 40 °C) tR major (2S,5R): 19.1 min, tR minor (2R,5S): 
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26.3 min, 94% ee; 1H NMR (500 MHz, CDCl3) δH: 2.18 (3H, s, C(5)ArCH3), 2.25 
(3H, s, SO2ArCH3), 5.23 (1H, d, J 1.2, C(5)H), 6.44 (1H, d, J 1.4, C(2)H); 13C{1H} 
NMR (125 MHz, CDCl3) δC: 21.6 (C(5)ArCH3), 21.8 (SO2ArCH3), 79.1 (C(5)), 90.9 
(C(2)), 123.4 (ArC), 127.1 (ArC), 127.5 (2 ArC), 128.3 (C(2)ArC(2)), 128.4 
(SO2ArC(2)), 128.9 (ArC), 129.6 (SO2ArC(3)), 129.8 (ArC), 130.5 (ArC), 133.9 
(C(5)ArC(1)), 135.1 (SO2ArC(1)), 136.5 (C(2)ArC(1)), 138.4 (C(5)ArC(2)CH3), 
145.6 (SO2ArC(4)), 168.7 (C(4)). 
 
(2R,5R)-2-Phenyl-5-(p-tolyl)-3-tosyloxazolidin-4-one (anti-232) and (2S,5R)-2-
phenyl-5-(p-tolyl)-3-tosyloxazolidin-4-one (syn-232) 
 
Following General Procedure K, homoanhydride 261 (84.7 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (55.1 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (53:47 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (54.46 anti:syn) as a white solid (71.6 mg, 88%). mp 
138-142 ˚C;  −3.0 (c 0.5, CHCl3); νmax (neat) 1749 (C=O), 1373 (C-N), 1175 (R-
SO2N); m/z (NSI+) 408 ([M+H]+, 85%); HMRS (NSI+) C23H22NSO4+ ([M+H]+) 
requires 408.1264; found 408.1259 (–1.2 ppm). 
Data for the anti diastereoisomer 232: Chiral HPLC analysis, Chiralcel OD-H (90:10 
hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C) tR major (2R,5R): 17.2 min, tR 
minor (2S,5S): 22.5 min, 97% ee;  1H NMR (500 MHz, CDCl3) δH: 2.35 (3H, s, 
C(5)ArCH3), 2.41 (3H, s, SO2ArCH3), 5.39 (1H, s, C(5)H), 6.69 (1H, d, J 1.2, C(2)H), 
7.16-7.21 (4H, m, ArH), 7.24 (2H, d, J 8.1, ArH), 7.34-7.43 (3H, m, ArH), 7.40-7.50 
(2H, m, ArH), 7.50-7.58 (2H, m, ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.3 
(C(5)ArCH3), 21.7 (SO2ArCH3), 78.7 (C(5)), 91.1 (C(2)), 126.5 (C(5)ArC(2)), 127.4 
(2 ArC), 128.2 (C(2)ArC(2)), 128.7 (SO2ArC(2)), 129.5 (SO2ArC(3)), 129.6 (2 ArC), 
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130.1 (ArC), 131.4 (C(5)ArC(1)), 134.8 (SO2ArC(1)), 136.6 (C(2)ArC(1)), 139.2 
(C(5)ArC(4)), 145.6 (SO2ArC(4)), 168.9 (C(4)). 
Selected data for the syn diastereoisomer 232: Chiral HPLC analysis, Chiralcel OD-H 
(90:10 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C) tR major (2S,5R): 15.3 
min, tR minor (2R,5S): 26.7 min, 97% ee; 1H NMR (500 MHz, CDCl3) δH: 2.33 (3H, s, 
C(5)ArCH3), 2.39 (3H, s, SO2ArCH3), 5.38 (1H, s, C(5)H); 13C{1H} NMR (125 MHz, 
CDCl3) δC: 21.2 (C(5)ArCH3), 21.7 (SO2ArCH3), 79.0 (C(5)), 90.7 (C(2)), 126.3 
(C(5)ArC(2)), 128.1 (C(2)ArC(2)), 128.3 (2 ArC), 128.5 (SO2ArC(2)), 129.3 
(SO2ArC(3)), 130.3 (ArC), 131.0 (C(5)ArC(1)), 134.8 (SO2ArC(1)), 136.3 
(C(2)ArC(1)), 138.8 (C(5)ArC(4)), 145.4 (SO2ArC(4)), 168.7 (C(4)). 
 
(2R,5R)-2-Phenyl-5-(thiophen-3-yl)-3-tosyloxazolidin-4-one (anti-233) and (2S,5R)-
2-phenyl-5-(thiophen-3-yl)-3-tosyloxazolidin-4-one (syn-233) 
 
Following General Procedure K, homoanhydride 225 (79.9 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (55.1 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (59:41 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (59:41 anti:syn) as a waxy white solid (62.8 mg, 79%). 
mp 90-96 ˚C;  +32.8 (c 0.5, CHCl3); νmax (neat) 1751 (C=O), 1373 (C-N), 1175 
(R-SO2N), 1088 (C-O); m/z (NSI+) 400 ([M+NH4]+, 75%); HMRS (NSI+) 
C20H18NS2O4+ ([M+NH4]+) requires 400.0672; found 400.0667 (–1.2 ppm). 
Data for the anti diastereoisomer 233: Chiral HPLC analysis, Chiralpak IA (80:20 
hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 30 °C) tR major (2R,5R): 8.7 min, tR 
minor (2S,5S): 13.2 min, 87% ee;  1H NMR (500 MHz, CDCl3) δH: 2.35 (3H, s, 
SO2ArCH3), 5.44 (1H, s, C(5)H), 6.55 (1H, d, J 1.2, C(2)H), 6.98-7.02 (1H, m, ArH), 
7.11-7.15 (2H, m, SO2ArH), 7.19 (1H, s, C(5)ArC(2)H), 7.28 (2H, dd, J 1.8, 1.0, 
ArH) 7.32 (2H, app. s, ArH), 7.33-7.41 (2H, m, ArH), 7.46 (2H, d, J 8.4, SO2ArH); 
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13C{1H} NMR (125 MHz, CDCl3) δC: 21.7 (SO2ArCH3), 75.5 (C(5)), 91.1 (C(2)), 
123.7 (C(5)ArC(2)), 125.5 (ArC), 127.1 (ArC), 127.5 (ArC), 128.2 (C(2)ArC(2)), 
128.7 (SO2ArC(2)), 129.5 (SO2ArC(3)), 130.9 (C(5)ArC(1)), 134.7 (SO2ArC(1)), 
135.0 (C(2)ArC(1)), 136.3 (C(5)ArC(4)), 145.7 (SO2ArC(4)), 168.3 (C(4)). 
Data for the syn diastereoisomer 233: Chiral HPLC analysis, Chiralpak IA (80:20 
hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 30 °C) tR major (2S,5R): 9.4 min, tR 
minor (2R,5S): 9.8 min, 81% ee;  1H NMR (500 MHz, CDCl3) δH: 2.32 (3H, s, 
SO2ArCH3), 5.43 (1H, d, J 1.2 C(5)H), 6.49 (1H, d, J 1.3, C(2)H), 7.04-7.07 (1H, m, 
ArH), 7.01-7.10 (2H, m, SO2ArH), 7.24 (1H, s, C(5)ArC(2)H), 7.33-7.41 (2H, m, 
SO2ArH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.7 (SO2ArCH3), 76.2 (C(5)), 91.0 
(C(2)), 123.2 (C(5)ArC(2)), 126.6 (ArC), 128.1 (2 ArC), 128.2 (C(2)ArC(2)), 128.5 
(SO2ArC(2)), 130.3 (2 ArC), 134.6 (SO2ArC(1)), 134.9 (C(2)ArC(1)), 136.3 
(C(5)ArC(4)), 145.6 (SO2ArC(4)), 168.0 (C(4)). 
 
(2R,5R)-2-Phenyl-5-((E)-prop-1-en-1-yl)-3-tosyloxazolidin-4-one (anti-234) and 
(2S,5R)-2-phenyl-5-((E)-prop-1-en-1-yl)-3-tosyloxazolidin-4-one (syn-234) 
 
Following General Procedure K, homoanhydride 136 (1.20g mg, 6.5 mmol), cesium 
carbonate (2.8 g, 8.6 mmol), oxaziridine 211 (1.20 g, 4.3 mmol) and (2S,3R)-HBTM-
2.1 26 (0.13 g, 0.43 mmol) were stirred at –78 °C for 24 h to give the crude product 
(49:51 anti:syn). Purification yielded the product as a mixture of diastereoisomers 
(54:46 anti:syn) as a colourless oil (1.41 g, 61%).  
Data for the anti diastereoisomer 234: colourless oil,  +10.0 (c 0.2, CHCl3); νmax 
(neat) 1749 (C=O), 1373 (C-N), 1175 (R-SO2N), 1090 (C-O); Chiral HPLC analysis, 
Chiralcel OD-H (95:5 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C) tR minor 
(2S,5S): 19.0 min, tR major (2R,5R): 22.3 min, >99% ee; 1H NMR (500 MHz, CDCl3) 
δH: 1.66-1.71 (3H, m, CHCH3), 2.34 (3H, s, ArCH3), 4.76 (1H, dq, J 6.7, 1.1, C(5)H), 
5.44 (1H, td, J 6.8, 1.7, CH), 5.83-5.91 (1H, m, CH), 6.47 (1H, d, J 1.2, C(2)H), 7.05-
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7.15 (2H, m, SO2ArC(3)H), 7.20-7.31 (3H, m, ArCH), 7.31-7.40 (2H, m, ArCH), 
7.42-7.54 (2H, m, SO2ArC(2)H); 13C{1H} NMR (125 MHz, CDCl3) δC: 17.9 (CHCH3), 
21.7 (ArCH3), 78.0 (C(5)), 90.8 (C(2)), 123.3 (CHCHCH3), 127.3 (C(5)ArC(2)), 
128.0 (ArC), 128.2 (ArC), 128.3 (SO2ArC(2)), 128.4 (ArC), 128.6 (ArC), 129.4 
(SO2ArC(3)), 130.0 (ArC), 133.5 (CHCH3), 134.8 (C(2)ArC(1)), 136.6 (SO2ArC(1)), 
145.6 (SO2ArC(4)), 169.0 (C(4)); m/z (NSI+) 358 ([M+H]+, 100%) HMRS (NSI+) 
C19H20NSO4+ ([M+H]+) requires 358.1108; found 358.1105 (–0.7 ppm). 
Selected data for the syn diastereoisomer 234: colourless oil, +2.6 (c 0.1, 
CHCl3); Chiral HPLC analysis, Chiralcel OD-H (95:5 hexane:IPA, flow rate 1.0 mL 
min-1, 211 nm, 30 °C), tR major (2S,5R): 21.0 min, tR minor (2R,5S): 29.9 min, >99% 
ee; 1H NMR (500 MHz, CDCl3) δH: 2.42 (3H, s, CH3), 4.80-4.87 (1H, m, C(5)H), 
5.47-5.57 (1H, m, CH), 5.87-5.99 (1H, m, CH), 6.45 (1H, d, J 1.2, C(2)H); 13C{1H} 
NMR (125 MHz, CDCl3) δC: 78.8 (C(5)), 90.7 (C(2)), 123.7 (CHCHCH3), 
(SO2ArC(3)), 130.2 (ArC), 134.0 (CHCH3), 135.1 (C(2)ArC(1)), 136.5 (SO2ArC(1)), 
145.4 (SO2ArC(4)), 168.9 (C(4)). 
 
(2R,5R)-2-Phenyl-3-tosyl-5-(4-(trifluoromethyl)phenyl)oxazolidin-4-one (anti-235) 
and (2S,5R)-2-phenyl-3-tosyl-5-(4-(trifluoromethyl)phenyl)oxazolidin-4-one (syn-
235)  
 
Following General Procedure K, homoanhydride 226 (117.1 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), oxaziridine 211 (55.1 mg, 0.2 mmol) and (2S,3R)-
HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 °C to room temperature for 16 
h to give the crude product (49:51 anti:syn). Purification yielded the product as a 
mixture of diastereoisomers (48:52 anti:syn) as a white solid (62.9 mg, 68%).   
Data for the anti diastereoisomer 235: colourless oil, +69.0 (c 0.1, CHCl3); νmax 
(neat) 1749 (C=O), 1489 (C-F); Chiral HPLC analysis, Chiralcel OD-H (90:10 
22
D][!
O
N
O Ts
Ph O
N
O Ts
Ph
235
F3C F3C
22
D][!
Chapter 6: Experimental 
 
197 
hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C) tR minor (2S,5S): 19.8 min, tR 
major (2R,5R): 22.6 min, 43% ee; 1H NMR (500 MHz, CDCl3) δH: 2.41 (3H, s, CH3), 
5.48 (1H, s, C(5)H), 6.72 (1H, d, J 1.3, C(2)H), 7.12-7.23 (2H, m, SO2ArC(3)H), 
7.32-7.45 (4H, m, ArCH), 7.49-7.53 (2H, m, SO2ArC(2)H), 7.53-7.57 (3H, m, ArCH), 
7.64-7.66 (2H, m, ArCH); 13C{1H} NMR (125 MHz, CDCl3) δC: 21.9 (CH3), 77.9 
(C(5)), 91.5 (C(2)), 125.9 (q, 3JCF 4.0, C(5)ArC(3)), 126.6 (C(2)ArC(2)), 126.9 (q, 1JCF 
272.4, CF3), 127.5, 128.4 (C(5)ArC(2)), 129.0 (SO2ArC(2)), 129.6 (ArC), 130.5 
(ArC), 131.4 (q, 2JCF 32.5, C(5)ArC(4)), 134.6 (C(2)ArC(1)), 136.3 (SO2ArC(1)),  
138.2 (Cipso), 146.0 (SO2ArC(4)), 168.8 (C(4)); 19F NMR (376 MHz, CDCl3) δF: −62.7 
(ArF); m/z (NSI+) 461 ([M+H]+, 40%); HMRS (NSI+) C23H19F3NSO4+ ([M+H]+) 
requires 462.0976; found 462.0981 (–1.2 ppm). 
Selected Data for the syn diastereoisomer 235: colourless oil, Chiral HPLC analysis, 
Chiralcel OD-H (90:10 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C) tR major 
(2S,5R): 15.9 min, tR minor (2R,5S): 35.9 min, 36% ee; 1H NMR (500 MHz, CDCl3) 
δH: 2.38 (3H, s, CH3), 5.48 (1H, s, C(5)H), 6.62 (1H, d, J 1.3, C(2)H), 7.15-7.17 (2H, 
m, SO2ArC(3)H), 7.31-7.35 (2H, m, ArCH), 7.35-7.40 (2H, m, ArH), 7.40-7.44 (2H, 
m, ArCH), 7.52-7.58 (2H, m, ArCH), 7.58-7.63 (2H, m, ArCH); 13C{1H} NMR (125 
MHz, CDCl3) δC: 21.9 (CH3), 78.1 (C(5)), 91.2 (C(2)), 125.6 (q, 3JCF 4.0, C(5)ArC(3)), 
126.4 (C(2)ArC(2)), 128.3 (C(5)ArC(2)), 128.8 (SO2ArC(2)), 129.7 (ArC), 130.7 
(ArC); 19F NMR (376 MHz, CDCl3) δF: −62.7 (ArF). 
 
(R)-1-Phenylethane-1,2-diol 237 
 
Following a modified procedure of Ye et al.16 to a solution of oxazolidin-4-one 214 
(39.3 mg, 0.1 mmol, 1 equiv.) in dry THF (1 mL, 0.1 M) at 0 °C, 1 M LiAlH4 in THF 
(0.2 mL, 0.2 mmol, 2 equiv.) was added and the reaction stirred at 0 °C allowing to 
warm to room temperature over 16 h. The reaction was quenched with 10% NaOH 
and stirred for 1 h, CH2Cl2 (1 mL) was added and the organic layer separated, dried 
237
Ph
Ph OH
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(MgSO4) and concentrated in vacuo to give the crude product as a colourless oil. 
Purification by column chromatography using silica gel (Petrol:Et2O 70:30) gave 237 
as a white solid (4.8 mg, 35%) with data in accordance with the literature.16 mp 46-50 
{lit.16 66-68 °C};  –50 (c, 0.1, CHCl3) {lit.16  −23.4 (c 1, CHCl3)}; Chiral 
HPLC analysis, Chiralcel OD-H (95:5 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 
30 °C) tR major (R): 23.4 min, tR minor (S): 26.8 min, 90% ee; 1H NMR (500 MHz, 
CDCl3) δH: 2.07 (1H, br. s, OH), 2.52 (1H, br. s, OH), 3.67 (1H, dd, J 11.3, 8.1, 
CHAHB), 3.76 (1H, t, J 2.1, CHAHB), 4.84 (1H, dd, J 8.1, 3.6, CH), 7.28-7.41 (5H, m, 
ArH). 
 
(R,E)-Pent-3-ene-1,2-diol 238 
 
Following a modified procedure of Ye et al. to a solution of oxazolidin-4-one 234 
(178.7 mg, 0.5 mmol, 1 equiv.) in dry THF (5 mL, 0.1 M) at 0 °C, 1 M LiAlH4 in THF 
(1 mL, 1 mmol, 2 equiv.) was added and the reaction stirred at 0 °C allowing to warm 
to room temperature over 16 h. The reaction was quenched with 10% NaOH, stirred 
for 1 h, CH2Cl2 (5 mL) was added and the organic layer separated, dried (MgSO4) and 
concentrated in vacuo to give the crude product as a colourless oil. Purification by 
column chromatography using silica gel (petrol:Et2O 70:30) gave 238 as a colourless 
oil (20.5 mg, 40%) with data in accordance with the literature17  –10.0 (c 0.1, 
CHCl3) {lit.17  −23.4 (c 1, CHCl3)}; Chiral GC analysis, Agilent Cyclosil B 
(length: 30 m, thickness: 0.250 mm, film thickness: 0.25 µm), carrier gas: He, linear 
velocity: 40 cm/sec, initial temperature: 100 °C (hold 2 min), ramp rate: 5 °C/min to 
140 °C (hold 2 min), total run time 12 min, tR minor (S) 7.7 min, tR major (R) 7.9 min, 
95% ee; 1H NMR (500 MHz, CDCl3) δH: 1.73 (3H, dd, J 6.4, 1.7, CH3), 2.38 (2H, br. 
s, 2 OH), 3.49 (1H, ddd, J 11.2, 7.6, 1.8, CHAHB), 3.64 (1H, dt, J 11.3, 2.6, CHAHB), 
4.20 (1H, td, J 7.1, 3.2, CHOH), 5.48 (1H, ddt, J 15.4, 6.7, 1.7, CHCH3), 5.69-5.92 
(1H, m,  CHCHCH3). 
22
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(2R,5R)-2,5-Diphenyloxazolidin-4-one 239 
 
Using a modified version of the procedure by Lectka et al.18 N-tosyloxazolidin-4-one 
214 (100 mg, 0.25 mmol, 1 equiv.) was stirred in degassed THF (1mL) at –78 °C and 
SmI2 (5 mL, 0.5 mmol, 2 equiv.) was added dropwise until the colour remained 
consistent. The reaction mixture was stirred for 5 min, quenched with NaHCO3 (5 
mL), extracted (3 × EtOAc), dried (MgSO4) and concentrated in vacuo to give the 
crude product. Following purification by column chromatography (Petrol:Et2O 50:50) 
oxazolidin-4-one 239 was isolated as a white solid (40.4 mg, 68%, anti:syn >95:5). 
mp 128-130 °C;  –71.8 (c 0.5, CHCl3); νmax (neat) 3207 (NH), 1725 (C=O), 1373 
(C-N); Chiral HPLC analysis, Chiralcel AD-H (90:10 hexane:IPA, flow rate 1.0 mL 
min-1, 211 nm, 30 °C) tR major (2R,5R): 11.5 min, tR minor (2S,3S): 15.5 min, 88% ee;  
1H NMR (500 MHz, CDCl3) δH: 5.42 (1H, d, J 2.2, C(5)H), 6.32 (1H, d, J 2.2, 
C(2)H), 7.31-7.47 (5H, m, ArCH), 7.47-7.60 (5H, m, ArCH), 7.77 (1H, s, NH); 
13C{1H} NMR (125 MHz, CDCl3) δC: 78.6 (C(5)), 88.0 (C(2)), 126.4 (C(5)ArC(2)), 
126.6 (C(2)ArC(2)), 128.8 (SO2ArC(2)), 128.9 (ArC), 129.1 (ArC), 130.1 (ArC), 
136.2 (C(5)ArC(1)), 138.4 (C(2)ArC(1)), 173.7 (C(4)); m/z (NSI+) 262 ([M+Na]+, 
100%); HMRS (NSI+) C15H13NO2Na+ ([M+Na]+) requires 262.0841; found 262.0838 
(+1.0 ppm).  
 
(R)-3-Phenyl-2-tosyl-1,2-oxaziridine 211 
 
Using the procedure by Jørgensen et al.19 a flask was charged with the N-tosylphenyl 
imine 
NH
O
O
Ph Ph
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 (0.52 g, 2.0 mmol), hydroquinidine (65.3 mg, 0.2 mmol) and toluene (20 mL). The 
mixture was stirred at room temperature until fully dissolved and then cooled to −40 
°C. m-CPBA (0.63 g, purity 70%, 2.8 mmol) was added and the reaction mixture 
stirred at −40 °C for 20 h. The crude mixture was loaded directly onto a column 
packed with silica gel and eluted with the toluene to give 211 as a white solid (0.21g, 
39%) with data in accordance with the literature.19 mp 86-89 °C {lit.19 90.4- 91.7 °C}; 
 –40.0 (c 0.5, CH2Cl2) {lit.19 −49.8 (c 0.58, CH2Cl2)}; Chiral HPLC analysis, 
Chiralcel OD-H (95:5 hexane:IPA, flow rate 1.0 mL min-1, 211 nm, 30 °C) tR major 
(R): 14.7 min, tR minor (S): 21.4 min, 70% ee; 1H NMR (500 MHz, CDCl3) δH: 2.49 
(3H, s, CH3), 5.46 (1H, s, CH), 7.42-7.50 (7H, m, ArH). 
 
6.4.5 Stereoselectivity Experiments 
6.4.5.1 Reaction of Homoanhydride with Enantioenriched Oxaziridine in 
Presence of Enantiomerically Pure Catalyst 
 
Following General Procedure C, homoanhydride 134 (76.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), enantioenriched oxaziridine 211 (55.1 mg, 0.2 
mmol, 70% ee) and (2S,3R)-HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 
°C to room temperature for 2 h to give the crude product (>95:5 anti:syn, 34% 
conversion). Purification yielded the remaining oxaziridine 211 as a white solid (46.1 
mg, 60%) and 214 as a white solid (20.7 mg, 26%) with all data in accordance with 
that previously reported. 
Chiral HPLC analysis of oxaziridine 211: Chiralcel OD-H (95:5 hexane:IPA, flow 
rate 1.0 mL min-1, 211 nm, 30 °C) tR major (R): 14.7 min, tR minor (S): 21.4 min, 52% 
ee  
22
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Chiral HPLC analysis of oxazolidin-4-one 214: Chiralcel AD-H (95:5 hexane:IPA, 
flow rate 1.5 mL min-1, 211 nm, 40 ˚C) tR major (2R,5R): 27.1 min, tR minor (2S,5S): 
53.9 min, >99%.   
6.4.5.2  Reaction of Homoanhydride with Enantioenriched Oxaziridine in 
Presence of Enantiomerically Pure Catalyst in a Mis-matched Case 
 
 
Following General Procedure C, homoanhydride 234 (76.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), enantioenriched oxaziridine 211 (55.1 mg, 0.2 
mmol, 70% ee) and (2R,3S)-HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 
°C to room temperature for 2 h to give the crude product 214 (45:55 anti:syn, 22% 
conversion). Purification yielded the remaining oxaziridine 211 as a white solid (31.3 
mg, 57%) and 214 as a white solid (22.4 mg, 28%) with all data in accordance with 
that previously reported. 
Chiral HPLC analysis of oxaziridine 211: Chiralcel OD-H (95:5 hexane:IPA, flow 
rate 1.0 mL min-1, 211 nm, 30 °C) tR major (R): 14.7 min, tR minor (S): 21.4 min, 76% 
ee.  
Chiral HPLC analysis of anti-oxazolidin-4-one 214: Chiralcel AD-H (95:5 
hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 40 ˚C) tR minor (2R,5R): 27.1 min, tR 
major (2S,5S): 53.9 min, 87%.   
Chiral HPLC analysis of the syn-oxazolidin-4-one 214: Chiralcel AD-H (95:5 
hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 40 ˚C) tR minor (2S,5R): 25.1 min, tR 
major (2R,5S): 30.4 min, 89% ee. 
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6.4.5.3 Reaction of Homoanhydride with Enantioenriched Oxaziridine in 
Presence of Achiral Catalyst 
Following General Procedure C, homoanhydride 134 (76.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), enantioenriched oxaziridine 211 (55.1 mg, 0.2 
mmol, 70% ee) and DHPB 101 (3.8 mg, 0.02 mmol) were stirred at –78 °C to room 
temperature for 2 h to give the crude product (62:38 anti:syn, 14% conversion). 
Purification yielded the remaining oxaziridine 211 as a white solid (34.9 mg, 63%) 
and 214 as a white solid (15.5 mg, 20%) with all data in accordance with that 
previously reported. 
Chiral HPLC analysis of oxaziridine 211: Chiralcel OD-H (95:5 hexane:IPA, flow 
rate 1.0 mL min-1, 211 nm, 30 °C) tR major (R): 14.7 min, tR minor (S): 21.4 min, 48% 
ee.  
Chiral HPLC analysis of anti-oxazolidin-4-one 214: Chiralcel AD-H (95:5 
hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 40 ˚C) tR major (2R,5R): 27.1 min, tR 
minor (2S,5S): 53.9 min, 78%.   
Chiral HPLC analysis of the syn-oxazolidin-4-one 214: Chiralcel AD-H (95:5 
hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 40 ˚C) tR minor (2S,5R): 25.1 min, tR 
major (2R,5S): 30.4 min, 71% ee. 
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6.4.5.4 Monitoring of Diastereoselectivity and Enantioselectivity Over Time 
 
 
Entry Time Conversion (%)a dr (anti:syn)a 
214 ee  
(%, anti/syn) b 211 ee (%)
b 
1 <1 min 15 70:30 ND ND 
2 5 min 15 72:28 ND ND 
3 15 min 27 68:32 >99/ND 10 
4 30 min 32 66:34 ND ND 
5 1 h 27 68:32 >99/>99 10 
6 2 h 33 68:32 ND ND 
7 4 h 74 57:43 >99/>99 ND 
8 16 h 100 53:47 >99/>99 N/A 
a Determined by inspection of crude1H NMR. b Obtained by chiral HPLC analysis following 
preparative tlc. 
 
Following General Procedure C, homoanhydride 134 (187 mg, 0.8 mmol), cesium 
carbonate (326 mg, 1.0 mmol), oxaziridine 211 (138 mg, 0.5 mmol) and (2S,3R)-
HBTM-2.1 26 (15.4 mg, 0.05 mmol) were stirred at –78 °C to room temperature for 
16 h with 0.2 mL samples taken at intervals to monitor conversion, dr and ee. 
Samples were purified for HPLC using preparative tlc (50:50 Petrol:Et2O). All data 
was in accordance to that already reported. 
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6.4.5.5 Repeat of “Matched” Case with Reaction Completed 
 
Following General Procedure C, homoanhydride 134 (76.3 mg, 0.3 mmol), cesium 
carbonate (131.5 mg, 0.4 mmol), enantioenriched oxaziridine 211 (55.1 mg, 0.2 
mmol, 70% ee) and (2S,3R)-HBTM-2.1 26 (6.2 mg, 0.02 mmol) were stirred at –78 
°C to room temperature for 16 h to give the crude product (85:15 anti:syn, 100% 
conversion). Purification yielded the product 214 as a white solid (17.1 mg, 20%) 
with all data in accordance with that previously reported. 
Chiral HPLC analysis of anti-oxazolidin-4-one 214: Chiralcel AD-H (95:5 
hexane:IPA flow rate 1.5 mL min-1, 211 nm, 40 ˚C) tR major (2R,5R): 27.1 min, tR 
minor (2S,5S): 53.9 min, 98%.   
Chiral HPLC analysis of the syn-oxazolidin-4-one 214: Chiralcel AD-H (95:5 
hexane:IPA, flow rate 1.5 mL min-1, 211 nm, 40 ˚C) tR major (2S,5R): 25.1 min, tR 
minor (2R,5S): 30.4 min, 98% ee. 
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